Imidazole-containing ALK2 kinase inhibitors

By designing an ALK2 kinase inhibitor containing imidazole groups, the problem of difficulty in effectively treating ALK2-related diseases in the prior art is solved, effective inhibition of ALK2 kinase is achieved, and the treatment of progressive ossified fibrous dysplasia and cancer is provided. New ways.

CN119060060APending Publication Date: 2024-12-03BIOCRYST PHARMACEUTICALS INC
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
CN202411166057.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-06-15
Filing Date
2018-06-14
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing ALK2 kinase inhibitors are difficult to effectively treat diseases that lead to progressive ossified fibrosis and a variety of cancers, especially gliomas.

Method used

A new compound structure is provided, including an ALK2 kinase inhibitor containing an imidazole group. Through specific aromatic rings, heteroaromatic rings, cycloalkyl rings or heterocycloalkyl structures, it can effectively inhibit the activity of ALK2 kinase, using In the treatment of ossified fibrous dysplasia and cancer.

Benefits of technology

These compounds are able to significantly reduce the activity of ALK2 kinases and provide potential solutions for treatment of progressive ossified fibrous dysplasia and cancer, especially gliomas.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060060A_ABST
    Figure CN119060060A_ABST
Patent Text Reader

Abstract

The invention relates to an ALK2 kinase inhibitor containing imidazole. Compounds of formulae (I), (II), (III) and (IV) and pharmaceutically acceptable salts thereof are disclosed. The compounds are inhibitors of ALK2 kinase. Also provided are pharmaceutical compositions comprising a compound of Formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, and methods relating to the treatment and prevention of various diseases and conditions, such as progressive osteodysplasia, using the compounds, or pharmaceutically acceptable salts and compositions thereof. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with application date of June 14, 2018, application number 201880052585.8, and invention name “ALK2 kinase inhibitors containing imidazole”.

[0002] Related applications

[0003] This application claims the benefit of priority to U.S. Provisional Patent Application Serial No. 62 / 520,150, filed on June 15, 2017. Background of the Invention

[0005] A single mutation (R206H) within the kinase domain of one of the four human bone morphogenetic protein (BMP) receptors (ACVR1 / ALK2) is associated with a catastrophic condition of secondary (ectopic) bone formation. As a result of the mutation, all children who present with the typical features of fibrodysplasia ossificans progressiva (FOP) are eventually surrounded by a second ectopic bone, and their movements are blocked by the second ectopic bone. The condition has long been associated with dysregulation of BMP signaling in soft tissues (skeletal muscle, tendons, ligaments, fascia), which are converted into bands, sheets, and plates of ectopic bone through the endochondral process. In addition to the common R206H mutation associated with the typical form of FOP, other dysregulatory mutations have been identified in ACVR1 / ALK2 that result in atypical and variant forms of FOP. Furthermore, compounds that effectively modulate BMP signaling based on their ability to inhibit ALK2 have also been shown to inhibit kinases from multiple signaling pathways.

[0006] Therefore, there remains a need for additional compounds that inhibit ALK2 kinase, which would be suitable for a variety of important therapeutic applications. SUMMARY OF THE INVENTION

[0008] In certain aspects, the present invention provides compounds of formula (I) or formula (II):

[0009]

[0010] or a pharmaceutically acceptable salt thereof;

[0011] in:

[0012] A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring or partially unsaturated heterocycloalkyl ring;

[0013] W is C or N;

[0014] R a represents H or alkyl;

[0015] R 1 represents a heteroarylene group;

[0016] R 1a represents H or optionally substituted –C(O)alkyl, –C(O)O(alkyl), –C(O)(heterocyclyl), –C(O)(aryl), –C(O)(heteroaryl), –C(O)NR x R y , alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0017] J represents H, halogen, -OR 2 、-NR 2 R 3 、-C(O)NR 2 R 3 , -C(O)O(alkyl), -C(O)OH, aryl or heteroaryl, wherein aryl or heteroaryl is optionally replaced by one or more occurrences of R 2a replace;

[0018] R 2 represents an optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl or hydroxyalkyl group;

[0019] R 3 represents H or an alkyl group; or

[0020] R 2 and R 3 together to form a heterocycloalkyl ring, which is optionally replaced by one or more occurrences of R 2a replace;

[0021] R 2a Each occurrence independently represents halogen, hydroxy, -C(O)H, oxo, -NH2, -C(O)NH2, -C(O)OH, -C(O)R 5 、-C(O)OR 5 、-C(O)NH(R 5 ), or optionally substituted alkyl, alkoxy, hydroxyalkyl, heteroaryl, aryl, or -N(alkyl)2;

[0022] or any two Rs in a germinal or adjacent position 2a together may form a spiro or fused cycloalkyl ring;

[0023] R 5 represents independently at each occurrence optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; and

[0024] R x and R yEach independently represents H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl or hydroxyalkyl.

[0025] In other aspects, the present invention provides compounds of formula (III) or formula (IV):

[0026]

[0027] or a pharmaceutically acceptable salt thereof;

[0028] in:

[0029] A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring or partially unsaturated heterocycloalkyl ring;

[0030] W is C or N;

[0031] B is CH or N;

[0032] D is CH or N;

[0033] The condition is that when B is CH, then D is N; or when D is CH, then B is N;

[0034] R a represents H or alkyl;

[0035] R 1 represents a heteroarylene group;

[0036] R 1a represents H or optionally substituted –C(O)alkyl, –C(O)aryl, –C(O)heteroaryl, –C(O)O(alkyl), –C(O)(heterocyclyl), –C(O)NR x R y , alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0037] J represents H, halogen, -OR 2 、-NR 2 R 3 、-C(O)NR 2 R 3 , -C(O)O(alkyl), -C(O)OH, aryl or heteroaryl, wherein aryl or heteroaryl is optionally replaced by one or more occurrences of R 2a replace;

[0038] R 2 represents an optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl or hydroxyalkyl group;

[0039] R 3 represents H or an alkyl group; or

[0040] R 2 and R 3 together to form a heterocycloalkyl ring, which is optionally replaced by one or more occurrences of R 2a replace;

[0041] R 2a Each occurrence independently represents halogen, hydroxy, -C(O)H, oxo, -NH2, -C(O)NH2, -C(O)OH, -C(O)R 5 、-C(O)OR 5 、-C(O)NH(R 5 ), or optionally substituted alkyl, alkoxy, hydroxyalkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, or -N(alkyl);

[0042] or any two Rs in a germinal or adjacent position 2a together may form a spiro or fused cycloalkyl ring;

[0043] R 5 represents independently at each occurrence optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; and

[0044] R x and R y Each independently represents H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl or hydroxyalkyl.

[0045] In still other aspects, the present invention provides a compound selected from the group consisting of:

[0046]

[0047] In certain aspects, the present invention provides a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

[0048] In certain aspects, the present invention provides a method of inhibiting ALK2 kinase, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.

[0049] The present invention also provides a method for treating fibrodysplasia ossificans progressiva, comprising administering to a subject in need thereof an effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.

[0050] In other aspects, the present invention provides a method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof. In certain embodiments, the cancer is glioma. Detailed Description of the Invention

[0052] Provided herein are compounds of Formulas (I), (II), (III), and (IV), and pharmaceutically acceptable salts thereof, which are useful for inhibiting ALK2 kinase and for treating or preventing diseases or conditions that would benefit from ALK2 kinase inhibition. For example, the disclosed ALK2 kinase inhibitors may be used in therapeutic methods and compositions suitable for treating cancer or fibrodysplasia ossificans progressiva.

[0053] definition

[0054] The articles "a" and "an" are used herein to refer to one or to more than one (ie, to at least one) of the grammatical object of the article. For example, "an element" means one element or more than one element.

[0055] The term "heteroatom" is art-recognized and refers to an atom of any element other than carbon or hydrogen. Exemplary heteroatoms include boron, nitrogen, oxygen, phosphorus, sulfur, and selenium, or oxygen, nitrogen, or sulfur.

[0056] The term "alkyl" as used herein is a term of art and refers to a saturated aliphatic group, including straight chain alkyl groups, branched chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups. In certain embodiments, a straight chain or branched chain alkyl group has about 30 or fewer carbon atoms in its backbone (e.g., for a straight chain C1-C1 30 , for the branched C3-C 30 ), or about 20 or less, or 10 or less. In certain embodiments, the term "alkyl" refers to a C1-C 10 In certain embodiments, the term "alkyl" refers to a C1-C6 alkyl group, such as a C1-C6 straight chain alkyl group. In certain embodiments, the term "alkyl" refers to a C3-C6 alkyl group. 12 Branched chain alkyl. In certain embodiments, the term "alkyl" refers to a C3-C8 branched chain alkyl. Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.

[0057] The term "cycloalkyl" refers to a monocyclic or bicyclic or bridged saturated carbocyclic ring, each having 3 to 12 carbon atoms. Some cycloalkyls have 5-12 carbon atoms in their ring structure and may have 6-10 carbons in the ring structure. Preferably, the cycloalkyl is a (C3-C7)cycloalkyl, which represents a monocyclic saturated carbocyclic ring with 3-7 carbon atoms. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl. Bicyclic cycloalkyl ring systems include bridged monocyclic and fused bicyclic rings. Bridged monocycles include monocyclic cycloalkyl rings in which two non-adjacent carbon atoms of the monocyclic ring are connected by an alkylene bridge (i.e., -(CH2)) of one to three additional carbon atoms. w -form bridging group, wherein w is 1, 2 or 3) connection. Representative examples of bicyclic ring systems include, but are not limited to, bicyclo [3.1.1] heptane, bicyclo [2.2.1] heptane, bicyclo [2.2.2] octane, bicyclo [3.2.2] nonane, bicyclo [3.3.1] nonane and bicyclo [4.2.1] nonane. Fused bicyclic cycloalkyl ring systems contain a monocyclic cycloalkyl ring fused to a phenyl, monocyclic cycloalkyl, monocyclic cycloalkenyl, monocyclic heterocyclic radical or monocyclic heteroaryl. The bridged or fused bicyclic cycloalkyl is connected to the parent molecular group through any carbon atom contained in the monocyclic cycloalkyl ring. Cycloalkyl is optionally substituted. In certain embodiments, the fused bicyclic cycloalkyl is a 5 or 6 membered monocyclic cycloalkyl ring fused to a benzene ring, a 5 or 6 membered monocyclic cycloalkyl, a 5 or 6 membered monocyclic cycloalkenyl, a 5 or 6 membered monocyclic heterocyclyl, or a 5 or 6 membered monocyclic heteroaryl, wherein the fused bicyclic cycloalkyl is optionally substituted.

[0058] As used herein, the term "(cycloalkyl)alkyl" refers to an alkyl group substituted with one or more cycloalkyl groups. An example of a (cycloalkyl)alkyl group is cyclohexylmethyl.

[0059] As used herein, the term "heterocycloalkyl" refers to a group of non-aromatic ring systems, including but not limited to monocyclic, bicyclic and tricyclic rings, which may be fully saturated or which may contain one or more unsaturated units (for the avoidance of doubt, unsaturation does not result in an aromatic ring system), and having from 3 to 12 atoms, including at least one heteroatom such as nitrogen, oxygen or sulfur. For the purpose of illustration, the following are examples of heterocycles, but they should not be construed as limiting the scope of the invention: aziridine, aziridine, oxiranyl, thiiridine, thiiridine, dioxirane, diazirinyl, diazepanyl, 1,3-dioxanyl, 1,3-dioxolane, 1,3-dithiolanyl, 1,3-dithianyl, imidazolidinyl, isothiazolinyl, isothiazolidinyl, isoxazolinyl, isoxazolidinyl, azetyl, oxadiazol ... oxetanyl, oxetyl, thietanyl, thietanyl, diazetidinyl, dioxetanyl, dioxetenyl, dithietanyl, dithietanyl, dithietyl, dioxalanyl, oxazolyl, thiazolyl, triazinyl, isothiazolyl, isoxazolyl, azepine Heterocycloalkyl is optionally substituted with one or more substituents as described below.

[0060] As used herein, the term "(heterocycloalkyl)alkyl" refers to an alkyl group substituted with one or more heterocycloalkyl groups (ie, heterocyclyl groups).

[0061] As used herein, term "alkenyl" means a straight or branched hydrocarbon radical containing 2 to 10 carbon atoms and containing at least one carbon-carbon double bond formed by removing two hydrogen atoms. Representative examples of alkenyl include, but are not limited to, vinyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, and 3-decenyl. The unsaturated bond of alkenyl can be located anywhere in the group and can have (Z) or (E) configuration about the double bond.

[0062] As used herein, the term "alkynyl" means a straight or branched chain hydrocarbon radical containing 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.

[0063] The term "alkylene" is art-recognized and, as used herein, is a divalent group obtained by removing two hydrogen atoms of an alkyl group as defined above. In one embodiment, alkylene refers to a disubstituted alkane, i.e., an alkane substituted at two positions with substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclic, aromatic or heteroaromatic groups, fluoroalkyl (e.g., trifluoromethyl), cyano, etc. That is, in one embodiment, "substituted alkyl" is an "alkylene".

[0064] The term "amino" is a term of art and as used herein refers to unsubstituted and substituted amines, for example, groups that can be represented by the following general formula:

[0065]

[0066] where R a 、R b and R c Each independently represents hydrogen, alkyl, alkenyl, -(CH2) x -R d , or R a and R b Together with the nitrogen atom to which they are attached, they form a heterocyclic ring having 4 to 8 atoms in the ring structure; R d represents an aryl group, a cycloalkyl group, a cycloalkenyl group, a heterocyclic group, or a polycyclic group; and x is zero or an integer ranging from 1 to 8. In certain embodiments, R a or R b Only one of them can be a carbonyl group, for example, R a 、R bIn other embodiments, R a and R b (and optionally R c ) each independently represents hydrogen, alkyl, alkenyl or -(CH2) x -R d In certain embodiments, the term "amino" refers to -NH2.

[0067] In certain embodiments, the term "alkylamino" refers to -NH(alkyl).

[0068] In certain embodiments, the term "dialkylamino" refers to -N(alkyl)2.

[0069] The term "amido" as used herein refers to -NHC(=O)-, wherein the amide group is attached to the parent molecular group through the nitrogen. Examples of amide groups include alkylamide groups such as CH3C(=O)N(H)- and CH3CH2C(=O)N(H)-.

[0070] The term "acyl" is a technical term and as used herein refers to any group of the form RCO-, where R is any organic group such as alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl. Representative acyl groups include acetyl, benzoyl, and malonyl.

[0071] As used herein, the term "aminoalkyl" refers to an alkyl group substituted with one or more amino groups. In one embodiment, the term "aminoalkyl" refers to an aminomethyl group.

[0072] The term "aminoacyl" is a term of art and as used herein refers to an acyl group substituted with one or more amino groups.

[0073] As used herein, the term "aminothionyl" refers to an analog of an aminoacyl group in which the O of RC(O)- is replaced by sulfur, thus the form RC(S)-.

[0074] The term "phosphoryl" is a term of art and as used herein can be generally represented by the formula:

[0075]

[0076] wherein Q50 represents S or O, and R59 represents hydrogen, lower alkyl or aryl; for example, -P(O)(OMe)- or -P(O)(OH)2. When used to replace, for example, an alkyl group, the phosphoryl group of the phosphorylalkyl group can be represented by the following general formula:

[0077]

[0078] wherein Q50 and R59 are each independently as defined above, and Q51 represents O, S or N; for example, -OP(O)(OH)OMe or -NH-P(O)(OH)2. When Q50 is S, the phosphoryl group is a "phosphorothioate".

[0079] As used herein, the term "aminophosphoryl" refers to a phosphoryl group substituted with at least one amino group as defined herein; for example, -P(O)(OH)NMe2.

[0080]

[0046] The term "azide" or "azido" as used herein refers to a -N3 group.

[0081] The term "carbonyl" as used herein refers to -C(=O)-.

[0082] The term "thiocarbonyl" as used herein refers to -C(=S)-.

[0083] The term "alkylphosphoryl" as used herein refers to a phosphoryl group substituted with at least one alkyl group as defined herein; for example -P(O)(OH)Me.

[0084] As used herein, the term "alkylthio" refers to an alkyl-S- group. The term "(alkylthio)alkyl" refers to an alkyl group substituted with an alkylthio group.

[0085] The term "carboxy" as used herein refers to a -CO2H group.

[0086] The term "aryl" is a technical term and as used herein refers to a group including monocyclic, bicyclic and polycyclic aromatic hydrocarbon groups, such as benzene, naphthalene, anthracene and pyrene. Aryl groups typically contain 6-10 carbon ring atoms (i.e., (C6-C 10 ) aryl). Aromatic ring can be substituted by one or more substituents at one or more ring positions, such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino, amide, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclic radical, aromatic or heteroaromatic group, fluoroalkyl (such as trifluoromethyl), cyano group etc.Term " aryl " also includes the polycyclic ring system with two or more rings, wherein two adjacent rings share two or more carbons (the ring is " fused ring "), wherein at least one ring is an aromatic hydrocarbon, for example, other rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclic radical.In certain embodiments, term " aryl " refers to phenyl.

[0087] The term "arylene" refers to a divalent group obtained by removing two hydrogen atoms of an aryl group as defined above. In certain embodiments, arylene refers to a disubstituted aromatic hydrocarbon, i.e., an aromatic hydrocarbon substituted at two positions by a substituent such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino, amide, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclic, aromatic or heteroaromatic group, fluoroalkyl (e.g., trifluoromethyl), cyano, etc. That is, in certain embodiments, "substituted aryl" is an "arylene".

[0088] The term "heteroaryl" is a term of art and as used herein refers to monocyclic, bicyclic and polycyclic aromatic groups having a total of 3 to 12 atoms in the ring structure, including one or more heteroatoms such as nitrogen, oxygen or sulfur. Exemplary heteroaryl groups include azaindolyl, benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoxadiazolyl, furanyl, imidazolyl, imidazolyl, indolyl, indolinyl, indazolyl, isoindolyl, isoxazolyl, isothiazolyl, isoquinolinyl, oxadiazolyl, oxazolyl, purinyl,

[0014] Examples of heteroaryl groups include pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimidinyl, pyrrolyl, pyrrolo[2,3-d]pyrimidinyl, pyrazolo[3,4-d]pyrimidinyl, quinolinyl, quinazolinyl, triazolyl, thiazolyl, thiophenyl, tetrahydroindolyl, tetrazolyl, thiadiazolyl, thiophenyl, thiomorpholinyl, triazolyl, or tropanyl. "Heteroaryl" may be substituted at one or more ring positions with one or more substituents, such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxy, alkoxy, amino, nitro, thiol, imino, amide, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamide, ketone, aldehyde, ester, heterocyclic group, aromatic or heteroaromatic group, fluoroalkyl (e.g., trifluoromethyl), cyano, and the like. The term "heteroaryl" also includes polycyclic ring systems having two or more rings in which two adjacent rings share two or more carbon atoms (the rings are "fused rings"), wherein at least one ring is an aromatic group having one or more heteroatoms in the ring structure, for example, the other rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl and / or heterocyclyl.

[0089] The term "heteroarylene" refers to a divalent group obtained by removing two hydrogen atoms of a heteroaryl as defined above. In certain embodiments, heteroarylene refers to a disubstituted heteroarene, i.e., a heteroarene substituted at two positions by substituents such as halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxy, amino, nitro, sulfhydryl, imino, amide, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclic, aromatic or heteroaromatic groups, fluoroalkyl (e.g., trifluoromethyl), cyano, etc. That is, in certain embodiments, "substituted heteroaryl" is a "heteroarylene".

[0090] The term "aralkyl" or "arylalkyl" is a term of art and as used herein refers to an alkyl group substituted with an aryl group, wherein the group is attached to the parent molecule through the alkyl group.

[0091] The term "heteroaralkyl" or "heteroarylalkyl" is a term of art and as used herein refers to an alkyl group substituted with a heteroaryl group attached to the parent molecular group through the alkyl group.

[0092] The term "alkoxy" as used herein means an alkyl group, as defined herein, attached to the parent molecular group through an oxygen atom. Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentoxy, and hexoxy.

[0093] The term "alkoxyalkyl" refers to an alkyl group substituted with an alkoxy group.

[0094] The term "alkoxycarbonyl" means an alkoxy group, as defined herein, appended to the parent molecular group through a carbonyl group, represented by -C(=O)-, as defined herein. Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.

[0095] The term "alkylcarbonyl" as used herein means an alkyl group, as defined herein, appended to the parent molecular group through a carbonyl group, as defined herein. Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl-1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.

[0096] The term "arylcarbonyl" as used herein means an aryl group, as defined herein, appended to the parent molecular group through a carbonyl group, as defined herein. Representative examples of arylcarbonyl include, but are not limited to, benzoyl and (2-pyridyl)carbonyl.

[0097] As used herein, the terms "alkylcarbonyloxy" and "arylcarbonyloxy" refer to an alkylcarbonyl or arylcarbonyl group, as defined herein, attached to the parent molecular group through an oxygen atom. Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy. Representative examples of arylcarbonyloxy include, but are not limited to, phenylcarbonyloxy.

[0098] The term "alkenoxy" or "alkenoxyl" means an alkenyl group, as defined herein, attached to the parent molecular group through an oxygen atom. Representative examples of alkenoxy include, but are not limited to, 2-propylene-1-oxy (i.e., CH2=CH-CH2-O-) and vinyloxy (i.e., CH2=CH-O-).

[0099] The term "aryloxy" as used herein means an aryl group, as defined herein, appended to the parent molecular group through an oxygen atom.

[0100] The term "heteroaryloxy" as used herein means a heteroaryl group, as defined herein, appended to the parent molecular group through an oxygen atom.

[0101] As used herein, the term "carbocyclyl" means a monocyclic or polycyclic (e.g., bicyclic, tricyclic, etc.) hydrocarbon radical containing from 3 to 12 carbon atoms, which is fully saturated or has one or more unsaturated bonds, and for the avoidance of doubt, the unsaturation does not result in an aromatic ring system (e.g., phenyl). Examples of carbocyclyl radicals include 1-cyclopropyl, 1-cyclobutyl, 2-cyclopentyl, 1-cyclopentenyl, 3-cyclohexyl, 1-cyclohexenyl, and 2-cyclopentenylmethyl.

[0102] The term "cyano" is a term of art and as used herein refers to -CN.

[0103] The term "halogen" is a term of art and as used herein refers to -F, -Cl, -Br, or -I.

[0104] The term "haloalkyl" as used herein refers to an alkyl group as defined herein wherein some or all of the hydrogens are replaced by halogen atoms.

[0105] The term "hydroxy" is a term of art and as used herein refers to -OH.

[0106] The term "hydroxyalkyl" as used herein means at least one hydroxy group, as defined herein, is attached to the parent molecular group through an alkyl group, as defined herein. Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl, 2,3-dihydroxypentyl, and 2-ethyl-4-hydroxyheptyl.

[0107] As used herein, the term "silyl" includes hydrocarbyl derivatives of silyl (H3Si-) (i.e., (hydrocarbyl)3Si-), wherein the hydrocarbyl is a monovalent group formed by removing a hydrogen atom from a hydrocarbon, such as ethyl, phenyl. The hydrocarbyl can be a combination of different groups, which can be varied to provide a variety of silyl groups, such as trimethylsilyl (TMS), tert-butyldiphenylsilyl (TBDPS), tert-butyldimethylsilyl (TBS / TBDMS), triisopropylsilyl (TIPS), and [2-(trimethylsilyl)ethoxy]methyl (SEM).

[0108] The term "silyloxy" as used herein, means a silyl group, as defined herein, appended to the parent molecular group through an oxygen atom.

[0109] Certain compounds contained in the compositions of the present invention can exist in specific geometric or stereoisomeric forms. In addition, the compounds of this invention can also have optical activity. The present invention encompasses all such compounds, including their cis and trans isomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, racemic mixtures and other mixtures thereof, which all fall within the scope of the present invention. Additional asymmetric carbon atoms may be present in substituents such as alkyl. All such isomers and mixtures thereof are intended to be included in the present invention.

[0110] For example, if a specific enantiomer of a compound of the invention is desired, it can be prepared by asymmetric synthesis or by derivatization with a chiral auxiliary, wherein the resulting diastereomeric mixture is separated and the auxiliary group is cleaved to provide the pure desired enantiomer. Alternatively, where the molecule contains a basic functional group such as an amino group or an acidic functional group such as a carboxyl group, diastereomeric salts are formed with an appropriate optically active acid or base, and the diastereomers thus formed are then resolved by fractional crystallization or chromatographic methods well known in the art, followed by recovery of the pure enantiomers.

[0111] It is understood that "substituted" or "substituted by" includes the implicit limitation that such substitution is consistent with the permitted valencies of the substituted atom and the substituent and that the substitution results in a stable compound, e.g., one that does not spontaneously undergo transformation by, for example, rearrangement, fragmentation, decomposition, cyclization, elimination, or other reactions.

[0112] The term "substituted" also contemplates all permissible substituents comprising organic compounds. In a broad aspect, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. Illustrative substituents include those substituents such as described above. For suitable organic compounds, permissible substituents can be one or more and can be identical or different. For purposes of the present invention, heteroatoms such as nitrogen can have any permissible substituent that satisfies the heteroatom valence state of a hydrogen substituent and / or an organic compound described herein. The present invention is not intended to be limited in any way to the permissible substituents of organic compounds.

[0113] In certain embodiments, optional substituents can include, for example, halogen, haloalkyl, hydroxy, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxy, alkenyloxy, alkynyloxy, phosphoryl, phosphate, phosphonate, phosphinate, amino (including alkyl- and dialkylamino), amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, silyl, silyloxy, heterocycloalkyl, cycloalkyl, alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, or heteroaralkyl.

[0114] As used herein, the phrase "protecting group" refers to a temporary substituent that protects a potentially reactive functional group from undesirable chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. The field of protecting group chemistry has been reviewed (Greene, TW; Wuts, PGM Protective Groups in Organic Synthesis, 2nd edition; Wiley: New York, 1991). Protected forms of the compounds of the present invention are included within the scope of the present invention.

[0115] For purposes of this invention, the chemical elements are identified according to the Periodic Table of the Elements, CAS edition, Handbook of Chemistry and Physics, 67th edition, 1986-87, inside front cover.

[0116] Other chemical terms herein are used according to conventional usage in the art, as exemplified by The McGraw-Hill Dictionary of Chemical Terms (Parker, S. ed., 1985, McGraw-Hill, San Francisco), which is incorporated herein by reference. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0117] As used herein, the term "pharmaceutically acceptable salt" includes salts derived from inorganic or organic acids, including, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, phosphoric acid, formic acid, acetic acid, lactic acid, maleic acid, fumaric acid, succinic acid, tartaric acid, glycolic acid, salicylic acid, citric acid, methanesulfonic acid, benzenesulfonic acid, benzoic acid, malonic acid, trifluoroacetic acid, trichloroacetic acid, naphthalene-2-sulfonic acid, and other acids. Pharmaceutically acceptable salt forms may include forms in which the ratio of salt-containing molecules is not 1:1. For example, a salt may include more than one inorganic or organic acid molecule per molecule of base, such as two hydrochloric acid molecules per molecule of Formula I, II, III, or IV compound. As another example, a salt may include less than one inorganic or organic acid molecule per molecule of base, such as two molecules of Formula I, II, III, or IV compound per molecule of tartaric acid.

[0118] As used herein, the terms "carrier" and "pharmaceutically acceptable carrier" refer to a diluent, adjuvant, excipient, or vehicle with which a compound is administered or formulated for administration. Non-limiting examples of such pharmaceutically acceptable carriers include liquids such as water, saline, and oils; and solids such as gum arabic, gelatin, starch paste, talc, keratin, colloidal silicon dioxide, urea, and the like. In addition, adjuvants, stabilizers, thickeners, lubricants, flavorings, and coloring agents may be used. Other examples of suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences by EW Martin, which is incorporated herein by reference in its entirety.

[0119] As used herein, the term "treating" means preventing, halting, or slowing the progression of a disease or condition in a subject, or eliminating the disease or condition. In one embodiment, "treating" means halting or slowing the progression of a disease or condition in a subject, or eliminating the disease or condition. In one embodiment, "treating" means reducing at least one objective manifestation of a disease or condition in a subject.

[0120] As used herein, the term "effective amount" refers to an amount sufficient to produce a desired biological effect.

[0121] As used herein, the term "therapeutically effective amount" refers to an amount sufficient to produce the desired therapeutic effect.

[0122] As used herein, the term "inhibit" means to reduce an objectively measurable amount or degree. In various embodiments, "inhibit" means to reduce by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 95% compared to a relevant control. In one embodiment, "inhibit" means to reduce by 100%, i.e., to stop or eliminate.

[0123] As used herein, the term "subject" refers to a mammal. In various embodiments, the subject is a mouse, rat, rabbit, cat, dog, pig, sheep, horse, cow, or non-human primate. In one embodiment, the subject is a human.

[0124] Compound

[0125] The present invention provides compounds of formula (I) or (II):

[0126]

[0127] or a pharmaceutically acceptable salt thereof;

[0128] in:

[0129] A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring or partially unsaturated heterocycloalkyl ring;

[0130] W is C or N;

[0131] R a represents H or alkyl;

[0132] R 1 represents a heteroarylene group;

[0133] R 1a represents H or optionally substituted –C(O)alkyl, –C(O)aryl, –C(O)heteroaryl, –C(O)O(alkyl), –C(O)(heterocyclyl), –C(O)NR x R y , alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0134] J represents H, halogen, -OR 2 、-NR 2 R 3 、-C(O)NR 2 R 3 , -C(O)O(alkyl), -C(O)OH, aryl or heteroaryl, wherein aryl or heteroaryl is optionally replaced by one or more occurrences of R 2a replace;

[0135] R 2 represents an optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl or hydroxyalkyl group;

[0136] R 3 represents H or an alkyl group; or

[0137] R 2 and R 3 together to form a heterocycloalkyl ring, which is optionally replaced by one or more occurrences of R 2a replace;

[0138] R 2a Each occurrence independently represents halogen, hydroxy, -C(O)H, oxo, -NH2, -C(O)NH2, -C(O)OH, -C(O)R 5 、-C(O)OR 5 、-C(O)NH(R 5 ), or optionally substituted alkyl, alkoxy, hydroxyalkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, or -N(alkyl);

[0139] or any two Rs in a germinal or adjacent position 2a together may form a spiro or fused cycloalkyl ring;

[0140] R 5 represents independently at each occurrence optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; and

[0141] R x and R y Each independently represents H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl or hydroxyalkyl.

[0142] In certain embodiments, the compounds of the present invention are represented by Formula (Ia) or Formula (IIa):

[0143]

[0144] in:

[0145] If valence permits, Q, T, U and V each independently represent CH, CH2, N, NH, O or SO2, wherein any hydrogen of a CH, CH2 or NH group is optionally replaced by an R 4 Replacement;

[0146] R 4Each occurrence independently represents halogen, cyano, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(O)NH2, -C(O)R 5 、-C(O)OR 5 or –S(O)2R 5 ;

[0147] m is an integer from 0 to 4, as permitted by valence.

[0148] In certain embodiments, the compounds of the present invention are represented by Formula (Ib) or Formula (IIb):

[0149]

[0150] wherein Q represents CH or N; and V represents CH or N. In certain embodiments, Q is N and V is CH. In alternative embodiments, Q is CH and V is N.

[0151] In certain embodiments, the compounds of the present invention are represented by Formula (Ic) or Formula (IIc):

[0152]

[0153] In certain embodiments, the compounds of the present invention are represented by Formula (Id) or Formula (IId):

[0154]

[0155] wherein T represents CH2, NH, O, or SO2; and U represents CH2, NH, O, or SO2. In certain embodiments, T is NH; and U is CH2. In other embodiments, T is CH2 and U is NH.

[0156] In certain embodiments, the compounds of the present invention are represented by Formula (Ie) or Formula (IIe):

[0157]

[0158] In any of Formulas (Ia), (IIa), (Ib), (IIb), (Ic), (IIc), (Id), (IId), (Ie), and (IIe), in certain embodiments, m is 0 or 1.

[0159] In certain embodiments, the compounds of the present invention are represented by formula (Ij) or (IIj):

[0160]

[0161] in:

[0162] W is C or N;

[0163] If valence permits, X, Y and Z each independently represent CH, CH2, CO, N, NH, O, S or SO2, wherein any hydrogen in a CH, CH2 or NH group is optionally replaced by an R 4 Replacement;

[0164] R 4 Each occurrence independently represents cyano, halogen, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(O)NH2, -C(O)R 5 、-C(O)OR 5 or –S(O)2R 5 ;

[0165] n is an integer from 0 to 4, as allowed by valence.

[0166] In certain embodiments, R 4 Each occurrence independently represents halogen, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, -CH2C(O)NH2, -C(O)R 5 、-C(O)OR 5 or –S(O)2R 5 .

[0167] In certain embodiments, R 4 Each occurrence independently represents halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, or heteroarylalkyloxy.

[0168] In certain embodiments, one of X, Y, or Z is NR 4 .

[0169] In certain such embodiments, R 4 Selected from:

[0170]

[0171] In certain embodiments, the compounds of the present invention are represented by formula (Ik) or (IIk):

[0172]

[0173] wherein X, Y and Z each independently represent CH, N, NH, O, S or SO2.

[0174] In certain embodiments, the compounds of the present invention are represented by formula (Ik') or (IIk'):

[0175]

[0176] Alternatively, in certain embodiments, the compounds of the present invention are represented by formula (Ik") or (IIk"):

[0177]

[0178] wherein at least one of X and Z is selected from O, N, NH and S.

[0179] In certain embodiments of compounds of Formula (Ik") and (IIk"), one of X and Z is selected from O, NH, and S; and the other of X and Z is CH. For example, X can be selected from O, NH, and S. Alternatively, Z can be selected from O, NH, and S.

[0180] In other embodiments of the compounds of Formula (Ik") and (IIk"), X and Z are each selected from O, N, NH, and S. For example, one of X and Z can be N and the other of X and Z can be NH.

[0181] In certain embodiments, the compounds of the present invention are represented by formula (In) or (IIn):

[0182]

[0183] wherein Y and Z are independently selected from O, N, NH and S.

[0184] In certain such embodiments, Y is N and Z is NH.

[0185] In certain embodiments, the compounds of the present invention are represented by Formula (Im) or (IIm):

[0186]

[0187] wherein X, Y and Z each independently represent CH2, CO, NH, O, S or SO2.

[0188] In certain embodiments of the compound of Formula (Im) or (IIm), X, Y, and Z are each CH 2 . In alternative embodiments, one of X, Y, and Z is N or O.

[0189] In any of Formulas (Ij), (IIj), (Ik), (IIk), (Ik′), (IIk′), (Ik″), (IIk″), (Im), and (IIm), in certain embodiments, n is 0 or 1.

[0190] In any of the preceding embodiments, R 4 , if present, may be selected from optionally substituted alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl and (heterocycloalkyl)alkyl.

[0191] In any of the preceding embodiments, R a It can be H.

[0192] In certain embodiments, R 1 is a nitrogen-containing heteroarylene group, such as a 5-membered nitrogen-containing heteroarylene group. In certain embodiments, R 1 It is an imidazolyl group.

[0193] In some embodiments, -R 1 -R 1a express

[0194] In certain embodiments, R 1a It’s H.

[0195] Or, R 1a It can be an optionally substituted phenyl group. Specifically, R 1a R may be phenyl substituted with one or more occurrences of halogen, hydroxy, cyano, -C(O)NH2, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, -C(O)alkyl, -C(O)O-alkyl, heterocycloalkyl, -C(O)NH(alkyl), -C(O)N(alkyl), -C(O)heterocycloalkyl, -C(O)(prolinol), -C(O)NH((cycloalkyl)alkyl), or -C(O)NH(cycloalkyl). In certain embodiments, R 1a is phenyl, which is substituted with two or more occurrences of alkoxy. 1a It is 3,4,5-trimethoxyphenyl.

[0196] In certain embodiments, R 1a is a substituted phenyl group, wherein two adjacent substituents on the phenyl group, together with the intervening atoms, form an optionally substituted cycloalkyl or heterocycloalkyl ring. For example, R 1aIt may be phenyl, wherein two adjacent substituents form a fused optionally substituted heterocyclic ring, for example 1,4-dioxane or 1,3-dioxolane.

[0197] In certain embodiments, R 1a is optionally substituted heteroaryl, for example quinoline.

[0198] In certain embodiments, J is aryl, which is optionally replaced by one or more occurrences of R 2a replace.

[0199] In alternative embodiments, J is -NR 2 R 3 .

[0200] In certain such embodiments, R 2 and R 3 together to form a heterocycloalkyl ring, for example a pyrrolidine ring, which is optionally replaced by one or more occurrences of R 2a replace.

[0201] In certain such embodiments, R 2a Each occurrence independently represents -C(O)NH2, -C(O)R 5 , hydroxyalkyl, heteroaryl or aryl; preferably -C(O)NH2 or hydroxyalkyl.

[0202] In certain embodiments, A represents a fused optionally substituted cycloalkyl ring, such as an optionally substituted cyclohexane or cycloheptane ring.

[0203] In certain embodiments, A represents a fused optionally substituted heterocycloalkyl ring, such as an optionally substituted tetrahydrofuran or pyrrolidine ring.

[0204] In certain embodiments, the compounds of the present invention are selected from the compounds described in the following table, or pharmaceutically acceptable salts thereof:

[0205]

[0206]

[0207]

[0208]

[0209]

[0210]

[0211]

[0212]

[0213]

[0214]

[0215]

[0216]

[0217]

[0218]

[0219]

[0220]

[0221]

[0222]

[0223]

[0224]

[0225]

[0226]

[0227]

[0228]

[0229]

[0230]

[0231]

[0232]

[0233]

[0234]

[0235]

[0236]

[0237]

[0238]

[0239]

[0240]

[0241]

[0242]

[0243]

[0244]

[0245]

[0246]

[0247]

[0248]

[0249]

[0250]

[0251]

[0252]

[0253] In other aspects, the present invention provides compounds represented by formula (III) or formula (IV):

[0254]

[0255] or a pharmaceutically acceptable salt thereof;

[0256] in:

[0257] A is a fused optionally substituted aromatic ring, heteroaromatic ring, partially unsaturated cycloalkyl ring or partially unsaturated heterocycloalkyl ring;

[0258] W is C or N;

[0259] B is CH or N;

[0260] D is CH or N;

[0261] The condition is that when B is CH, then D is N; or when D is CH, then B is N;

[0262] R a represents H or alkyl;

[0263] R 1 represents a heteroarylene group;

[0264] R 1a represents H or optionally substituted –C(O)alkyl, –C(O)aryl, –C(O)heteroaryl, –C(O)O(alkyl), –C(O)(heterocyclyl), –C(O)NR x R y , alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl;

[0265] J represents H, halogen, -OR 2 、-NR 2 R 3 、-C(O)NR 2 R 3 , -C(O)O(alkyl), -C(O)OH, aryl or heteroaryl, wherein aryl or heteroaryl is optionally replaced by one or more occurrences of R 2a replace;

[0266] R 2 represents an optionally substituted alkyl, aralkyl, heteroaralkyl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl or hydroxyalkyl group;

[0267] R 3 represents H or an alkyl group; or

[0268] R 2 and R 3 together to form a heterocycloalkyl ring, which is optionally replaced by one or more occurrences of R 2a replace;

[0269] R 2a Each occurrence independently represents halogen, hydroxy, -C(O)H, oxo, -NH2, -C(O)NH2, -C(O)OH, -C(O)R 5 、-C(O)OR 5 、-C(O)NH(R 5 ), or optionally substituted alkyl, alkoxy, hydroxyalkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, or -N(alkyl);

[0270] or any two Rs in geminal or vicinal positions 2a together may form a spiro or fused cycloalkyl ring;

[0271] R 5 represents independently at each occurrence optionally substituted alkyl, aralkyl, aryl, heteroaralkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, or (heterocycloalkyl)alkyl; and

[0272] Rx and R y Each independently represents H, alkyl, aralkyl, heteroaralkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)alkyl, (heterocycloalkyl)alkyl or hydroxyalkyl.

[0273] In certain embodiments, the compound is represented by Formula (IIIa) or Formula (IVa):

[0274]

[0275] in:

[0276] If valence permits, Q, T, U and V each independently represent CH, CH2, N, NH, O or SO2, wherein any hydrogen in a CH, CH2 or NH group is optionally replaced by an R 4 Replacement;

[0277] R 4 Each occurrence independently represents halogen, cyano, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(O)NH2, -C(O)R 5 、-C(O)OR 5 or –S(O)2R 5 ;

[0278] m is an integer from 0 to 4, as permitted by valence.

[0279] In certain embodiments, the compound is represented by Formula (IIIb) or Formula (IVb):

[0280]

[0281] wherein Q represents CH or N; and V represents CH or N. In certain embodiments, Q is N and V is CH. In alternative embodiments, Q is CH and V is N.

[0282] In certain embodiments, the compound is represented by Formula (IIIc) or Formula (IVc):

[0283]

[0284] In certain embodiments, the compound is represented by Formula (IIId) or Formula (IVd):

[0285]

[0286] wherein T represents CH2, NH, O, or SO2; and U represents CH2, NH, O, or SO2. In certain embodiments, T is NH; and U is CH2. In other embodiments, T is CH2 and U is NH.

[0287] In certain embodiments, the compound is represented by Formula (IIIe) or Formula (IVe):

[0288]

[0289] In any of Formulas (IIIa), (IVa), (IIIb), (IVb), (IIIc), (IVc), (IIId), (IVd), (IIIe), and (IVe), in certain embodiments, m is 0 or 1.

[0290] In certain embodiments, the compound is represented by Formula (IIIj) or Formula (IVj):

[0291]

[0292] in:

[0293] W is C or N;

[0294] If valence permits, X, Y and Z each independently represent CH, CH2, CO, N, NH, O, S or SO2, wherein any hydrogen in a CH, CH2 or NH group is optionally replaced by an R 4 Replacement;

[0295] R 4 Each occurrence independently represents halogen, cyano, or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, heteroarylalkyloxy, -CH2C(O)NH2, -C(O)R 5 、-C(O)OR 5 or –S(O)2R 5 ;

[0296] n is an integer from 0 to 4, as allowed by valence.

[0297] In certain embodiments, R 4Each occurrence independently represents halogen or optionally substituted alkyl, alkenyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)alkyl, cycloalkyl, (cycloalkyl)alkyl, -CH2C(O)NH2, -C(O)R 5 、-C(O)OR 5 or –S(O)2R 5 .

[0298] In certain embodiments, R 4 Each occurrence independently represents halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, arylalkyloxy, or heteroarylalkyloxy.

[0299] In certain embodiments, one of X, Y, or Z is NR 4 .

[0300] In certain such embodiments, R 4 Selected from:

[0301]

[0302] In certain embodiments, the compound is represented by Formula (IIIk) or (IVk):

[0303]

[0304] wherein X, Y and Z each independently represent CH, N, NH, O, S or SO2.

[0305] In other embodiments, the compound is represented by formula (IIIk') or (IVk'):

[0306]

[0307] In certain embodiments, the compound is represented by formula (IIIk") or (IVk"):

[0308]

[0309] wherein at least one of X and Z is selected from O, N, NH and S.

[0310] In certain embodiments of the compounds of Formula (IIIk") and (IVk"), one of X and Z is selected from O, NH, and S; and the other of X and Z is CH. For example, X can be selected from O, NH, and S. Alternatively, Z can be selected from O, NH, and S.

[0311] In other embodiments of the compounds of Formula (IIIk") and (IVk"), X and Z are each selected from O, N, NH, and S. For example, one of X and Z is N and the other of X and Z is NH.

[0312] In certain embodiments, the compounds of the present invention are represented by the following: wherein the compound is represented by formula (IIIn) or (IVn):

[0313]

[0314] wherein Y and Z are independently selected from O, N, NH and S.

[0315] In certain embodiments, Y is N and Z is NH.

[0316] In certain embodiments, the compounds of the present invention are represented by Formula (IIIm) or (IVm):

[0317]

[0318] wherein X, Y and Z each independently represent CH2, CO, NH, O, S or SO2.

[0319] In certain embodiments of the compound of Formula (IIIm) or (IVm), X, Y, and Z are each CH. In alternative embodiments, one of X, Y, and Z is N or O.

[0320] In any of Formulas (IIIj), (IVj), (IIIk), (IVk), (IIIk′), (IVk′), (IIIk″), (IVk″), (IIIm), and (IVm), in certain embodiments, n is 0 or 1.

[0321] In any of the preceding embodiments, R 4 , if present, may be selected from optionally substituted alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, aralkyl and (heterocycloalkyl)alkyl.

[0322] In any of the preceding embodiments, R a It can be H.

[0323] In certain embodiments, R 1 is a nitrogen-containing heteroarylene group, such as a 5-membered nitrogen-containing heteroarylene group. 1 It is an imidazolyl group.

[0324] In some embodiments, -R 1 -R 1a express

[0325] In certain embodiments, R1a It’s H.

[0326] Or, R 1a It can be an optionally substituted phenyl group. Specifically, R 1a R may be phenyl substituted with one or more occurrences of halogen, hydroxy, cyano, -C(O)NH2, hydroxyalkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, -C(O)alkyl, -C(O)O-alkyl, heterocycloalkyl, -C(O)NH(alkyl), -C(O)N(alkyl), -C(O)heterocycloalkyl, -C(O)(prolinol), -C(O)NH((cycloalkyl)alkyl), or -C(O)NH(cycloalkyl). In certain embodiments, R 1a is phenyl, which is substituted with two or more occurrences of alkoxy. 1a It is 3,4,5-trimethoxyphenyl.

[0327] In certain embodiments, R 1a is a substituted phenyl group, wherein two adjacent substituents on the phenyl group, together with the intervening atoms, form an optionally substituted cycloalkyl or heterocycloalkyl ring. For example, R 1a It may be phenyl, wherein two adjacent substituents form a fused optionally substituted heterocyclic ring, for example 1,4-dioxane or 1,3-dioxolane.

[0328] In certain embodiments, R 1a is optionally substituted heteroaryl, for example quinoline.

[0329] In certain embodiments, J is aryl, which is optionally replaced by one or more occurrences of R 2a replace.

[0330] In alternative embodiments, J is -NR 2 R 3 .

[0331] In certain such embodiments, R 2 and R 3 together to form a heterocycloalkyl ring, for example a pyrrolidine ring, which is optionally replaced by one or more occurrences of R 2a replace.

[0332] In certain such embodiments, R 2a Each occurrence independently represents -C(O)NH2, -C(O)R 5 , hydroxyalkyl, heteroaryl or aryl; preferably -C(O)NH2 or hydroxyalkyl.

[0333] In certain embodiments, the compounds of the present invention are selected from the compounds described in the following table:

[0334]

[0335] Pharmaceutical composition

[0336] The present invention provides pharmaceutical compositions, each of which comprises one or more compounds of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition comprises a compound of the present invention and a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition comprises a plurality of compounds of the present invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0337] In certain embodiments, the pharmaceutical compositions of the present invention further comprise at least one additional pharmaceutically active agent in addition to the compounds of the present invention. The at least one additional pharmaceutically active agent can be an agent useful in treating a disease or condition that would benefit from inhibition of ALK2 kinase.

[0338] The pharmaceutical compositions of the present invention can be prepared by combining one or more compounds of the present invention, or pharmaceutically acceptable salts thereof, with a pharmaceutically acceptable carrier and, optionally, one or more additional pharmaceutically active agents.

[0339] How to use

[0340] The present invention provides compounds and pharmaceutically acceptable salts thereof that are useful in treating or preventing diseases or conditions that would benefit from ALK2 kinase inhibition.

[0341] In certain aspects, the present invention provides a method of inhibiting ALK2 kinase, comprising administering to a subject in need thereof an effective amount of a compound of the present invention (e.g., a compound of Formula (I), (II), (III) or (IV)) or a pharmaceutically acceptable salt thereof.

[0342] In certain aspects, the present invention provides a compound of the present invention, or a pharmaceutically acceptable salt thereof, for use as a medicament.

[0343] In certain aspects, the present invention provides a method for treating fibrodysplasia ossificans progressiva, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof.

[0344] The present invention also provides a method for treating cancer, comprising the step of administering a therapeutically effective amount of a compound of the present invention or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[0345] In certain embodiments, the cancer comprises a central nervous system tumor, breast cancer, prostate cancer, skin cancer (including basal cell carcinoma, squamous cell carcinoma, and melanoma), cervical cancer, uterine cancer, lung cancer, ovarian cancer, testicular cancer, thyroid cancer, astrocytoma, glioma, pancreatic cancer, stomach cancer, liver cancer, colon cancer, kidney cancer, bladder cancer, esophageal cancer, laryngeal cancer, parotid gland cancer, biliary tract cancer, rectal cancer, endometrial cancer, adenocarcinoma, small cell carcinoma, neuroblastoma, mesothelioma, adrenocortical carcinoma, epithelial carcinoma, desmoid tumor, desmoid small round cell tumor, endocrine tumor, Ewing sarcoma family of tumors, germ cell tumors, hepatoblastoma, hepatocellular carcinoma, non-rhabdomyosarcoma, soft tissue sarcoma, osteosarcoma, peripheral primitive neuroectodermal tumor, retinoblastoma, rhabdomyosarcoma, and Wilms' tumor.

[0346] In certain embodiments, the cancer is a glioma, such as diffuse intrinsic pontine glioma.

[0347] The compounds of the present invention can be used to treat any disease or condition whose treatment would benefit from inhibition of ALK2 kinase, meaning that in such a disease or condition, it is desirable to reduce ALK2 kinase activity. For example, in cases of inappropriate activation or hyperactivation of ALK2 kinase, it may be desirable to reduce ALK2 kinase activity.

[0348] Formulation, route of administration and dosing

[0349] The compounds of the present invention and pharmaceutically acceptable salts thereof can be formulated into pharmaceutical compositions and administered to mammalian hosts, such as human patients, in various forms suitable for the selected route of administration, such as oral or parenteral, by intravenous, intraperitoneal, intramuscular, topical or subcutaneous routes. Additional routes of administration are also contemplated by the present invention.

[0350] Therefore, the compounds of the present invention or its pharmaceutically acceptable salt can be combined with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier for systemic administration, such as oral administration. They can be encapsulated in hard or soft shell gelatin capsules, can be compressed into tablets, or can be directly combined with the food of the patient's diet. For oral treatment, the active compound (that is, the compounds of the present invention or its pharmaceutically acceptable salt) can be combined with one or more excipients and used in the form of tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups, wafers, etc. that can be taken. Such compositions and preparations should contain at least 0.1% active compound. Of course, the percentage of the composition and preparation can vary and can be conveniently between about 2% to about 60% of the weight of a given unit dosage form. The amount of the active compound in such a therapeutically useful composition makes it possible to obtain an effective dosage level.

[0351] Tablets, lozenges, pills, capsules, etc. may also contain the following diluents and carriers: binders such as gum tragacanth, gum arabic, corn starch, or gelatin; excipients such as dicalcium phosphate; disintegrants such as corn starch, potato starch, alginic acid, etc.; lubricants such as magnesium stearate; and sweeteners such as sucrose, fructose, lactose, or aspartame; or flavorings such as peppermint, wintergreen oil, or cherry flavoring may be added. When the unit dosage form is a capsule, in addition to the above types of materials, it may also contain a liquid carrier such as a vegetable oil or polyethylene glycol. Various other materials may exist as a coating or otherwise change the physical form of the solid unit dosage form. For example, tablets, pills, or capsules may be coated with gelatin, wax, shellac, or sugar. Syrups or elixirs may contain the active compound, sucrose or fructose as a sweetener, methylparaben and propylparaben as preservatives, dyes, and flavorings such as cherry or orange flavoring. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. Additionally, the active compound can be incorporated into sustained-release preparations and devices.

[0352] The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound may be prepared in water or physiologically acceptable aqueous solutions, optionally mixed with a nontoxic surfactant. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof, and in oils. Under typical conditions of storage and use, these preparations contain a preservative to prevent microbial growth.

[0353] The pharmaceutical dosage form suitable for injection or infusion can include sterile aqueous solution or dispersion or the sterile powder that comprises active compound and is applicable to temporary preparation aseptic injectable or infusible solution or dispersion, optionally encapsulated in liposome.In all cases, final dosage form should be sterile fluid and stable under manufacturing and storage conditions.Liquid carrier or vehicle can be solvent or liquid dispersion medium, comprise for example water, ethanol, polyol (for example glycerol, propylene glycol, liquid polyethylene glycol etc.), vegetable oil, non-toxic glyceride and suitable mixture thereof.Suitable fluidity can be for example by forming liposome, by maintaining required particle size or by using surfactant to maintain in the case of dispersion.The prevention of microbial activity can be realized by various antibacterial and antifungal agents, for example parahydroxybenzoate, chlorobutanol, phenol, sorbic acid, thimerosal etc. In many cases, preferably include isotonic agent, for example sugar, buffer or sodium chloride.The extended absorption of injectable composition can be realized by using the medicament of delayed absorption in composition, for example aluminum monostearate and gelatin.

[0354] Sterile injectable solutions are prepared by incorporating the active compound in the required amount in an appropriate solvent with various of the other ingredients enumerated above, optionally followed by filtered sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation may include vacuum drying and freeze-drying techniques which yield a powder of the active compound plus any additional desired ingredient present in a previously sterile-filtered solution.

[0355] For topical administration, the compounds of the present invention or their pharmaceutically acceptable salts can be applied in pure form, that is, when they are liquid. However, it is generally desirable to combine them with a dermatologically acceptable carrier, which can be a solid or liquid, and apply them to the skin in the form of a composition or formulation.

[0356] Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silicon dioxide, aluminum oxide, and the like. Useful liquid carriers include water, alcohols, or glycols or water-alcohol / glycol blends in which the compounds of the invention or pharmaceutically acceptable salts thereof can be dissolved or dispersed at effective levels (optionally with the aid of non-toxic surfactants). Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize properties for a given use. The resulting liquid composition can be applied from an absorbent pad for impregnating bandages and other dressings, or sprayed onto the affected area using a pump-type or aerosol sprayer.

[0357] Thickening agents such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses, or modified mineral materials may also be employed with the liquid carrier to form spreadable pastes, gels, ointments, soaps, etc., for application directly to the user's skin.

[0358] Examples of useful dermatological compositions that can be used to deliver the compounds of the present invention, or pharmaceutically acceptable salts thereof, to the skin are known in the art; see, for example, Jacquet et al. (U.S. Pat. No. 4,608,392; incorporated herein by reference), Geria (U.S. Pat. No. 4,992,478; incorporated herein by reference), Smith et al. (U.S. Pat. No. 4,559,157; ​​incorporated herein by reference), and Wortzman (U.S. Pat. No. 4,820,508; incorporated herein by reference).

[0359] The useful dosage of the compounds of the present invention or their pharmaceutically acceptable salts can be determined at least first by comparing their in vitro activity and in vivo activity in animal models. Methods for extrapolating effective dosages in mice and other animals to humans are known in the art; for example, see U.S. Patent No. 4,938,949 (incorporated herein by reference).

[0360] The amount of the compound or pharmaceutically acceptable salt thereof required for therapeutic use will vary not only with the particular compound or salt selected, but will also vary with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be determined by the attending physician or clinician.

[0361] In general, however, suitable dosages are in the range of about 0.5 to about 100 mg per kilogram body weight of the recipient per day, for example, about 3 to about 90 mg per kilogram body weight per day, about 6 to about 75 mg per kilogram body weight per day, about 10 to about 60 mg per kilogram body weight per day, or about 15 to about 50 mg per kilogram body weight per day.

[0362] The compounds of the present invention or pharmaceutically acceptable salts thereof can be conveniently formulated in unit dosage forms; for example, each unit dosage form contains 5 to 1000 mg, 10 to 750 mg, or 50 to 500 mg of active compound. In one embodiment, the present invention provides a composition comprising a compound of the present invention or pharmaceutically acceptable salt thereof formulated in such a unit dosage form. The desired dose can be conveniently presented as a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four, or more sub-doses per day. The sub-doses themselves can be further divided into, for example, multiple discrete, loosely spaced administrations.

[0363] The compounds of the invention, or pharmaceutically acceptable salts thereof, may also be administered in combination with other therapeutic agents, such as other agents useful in the treatment or prevention of diseases or conditions whose treatment would benefit from inhibition of ALK2 kinase.

[0364] Other delivery systems can include timed release (time-release), delayed release or sustained release delivery systems, such as those well-known in the art. Such systems can avoid repeated administration of the active compound, increasing convenience for the object and the doctor. There are many types of release delivery systems that can be obtained and are known to those of ordinary skill in the art. It may be desirable to use an implant of long-term sustained release. As used herein, long-term release means that a delivery system or implant is constructed and arranged to continue at least 30 days and preferably 60 days to deliver the active compound for treatment levels.

[0365] In certain embodiments, the compounds of the present invention, or pharmaceutically acceptable salts thereof, are formulated for intraocular administration, such as by direct injection or insertion or in combination with an intraocular medical device.

[0366] The compounds of the present invention, or pharmaceutically acceptable salts thereof, can be formulated for deposition into medical devices, which can include any of a variety of conventional grafts, stents, including stent grafts, catheters, balloons, baskets, or other devices that can be deployed or permanently implanted within a body lumen. As a specific example, it would be desirable to have devices and methods capable of delivering the compounds of the present invention, or pharmaceutically acceptable salts thereof, to areas of the body that have been treated with interventional techniques.

[0367] In an exemplary embodiment, a compound of the invention or a pharmaceutically acceptable salt thereof can be deposited within a medical device such as a stent and delivered to a treatment site to treat a part of the body.

[0368] Stents have been used as delivery vehicles for therapeutic agents (i.e., drugs). Intravascular stents are generally permanently implanted in coronary or peripheral blood vessels. Stent designs include those of U.S. Patent No. 4,733,655 (Palmaz), U.S. Patent No. 4,800,882 (Gianturco), or U.S. Patent No. 4,886,062 (Wiktor). Such designs include metal stents and polymer stents, as well as self-expanding stents and balloon expandable stents. Stents can also be used to deliver drugs to sites in contact with the vascular system, as disclosed in, for example, U.S. Patent No. 5,102,417 (Palmaz), U.S. Patent No. 5,419,760 (Narciso, Jr.), U.S. Patent No. 5,429,634 (Narciso, Jr.), and International Patent Application No. WO 91 / 12779 (Medtronic, Inc.) and WO 90 / 13332 (Cedars-Sanai Medical Center).

[0369] The term "deposition" means coating, adsorption, placement or otherwise incorporation of the active compound into the device by methods known in the art. For example, the active compound can be embedded in and released from a polymer material that coats or covers the medical device ("matrix type"), or surrounded by and released from the polymer material ("reservoir type"). In the latter example, the active compound can be embedded in or coupled to the polymer material using one or more techniques known in the art for producing such materials. In other formulations, the active compound can be attached to the surface of the medical device without coating, for example, by means of a detachable adhesive, and released over time, or can be removed by an effective mechanical or chemical process. In other formulations, the active compound can be in a permanently fixed form that provides the active compound at the implant site.

[0370] In certain embodiments, the active compound can be incorporated into the polymer composition during the formation of a biocompatible coating for a medical device such as a stent. The coating produced from these components is generally homogeneous and can be used to coat a variety of devices designed for implantation.

[0371] Depending on the desired release rate or the desired degree of polymer stability, the polymer can be a biostable or bioresorbable polymer, but generally bioresorbable polymers are suitable for this embodiment because, unlike biostable polymers, bioresorbable polymers generally do not persist for a long time after implantation to cause any adverse chronic local reactions. Bioresorbable polymers that can be used include, but are not limited to, poly(L-lactic acid), polycaprolactone, polyglycolide (PGA), poly(lactide-co-glycolide) (PLLA / PGA), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoesters, polyanhydrides, poly(glycolic acid), poly(D-lactic acid), poly(L-lactic acid), poly(D,L-lactic acid), poly(D,L-lactide) (PLA), poly(L-lactide) (PLLA), poly(glycolic acid-co-trimethylene carbonate) (PGA / PTMC), polyethylene oxide ( oxide, PEO), polydioxanone (PDS), polyphosphates, polyphosphate polyurethanes, poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(imidocarbonates), copoly(ether-esters) such as PEO / PLA, polyalkylene oxalates, polyphosphazenes, and biomolecules such as fibrin, fibrinogen, cellulose, starch, collagen, and hyaluronic acid, poly-ε-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates, cross-linked or amphiphilic block copolymers of hydrogels, and other suitable bioresorbable polymers known in the art.In addition, biostable polymers with relatively low chronic tissue reactions may be used, such as polyurethanes, silicones, and polyesters, and other polymers may be used if they can be dissolved and cured or polymerized on the medical device, such as polyolefins, polyisobutylene, and ethylene-alpha-olefin copolymers; acrylic polymers and copolymers, vinyl halide polymers and copolymers, such as polyvinyl chloride; polyvinyl pyrrolidone; polyvinyl ethers, such as polyvinyl methyl ether; polyvinylidene halide; and polyvinyl chloride.

[0014] The present invention also includes but is not limited to vinyl chloride, vinyl acrylate, vinyl styrene, ethylene methyl methacrylate, acrylonitrile, styrene, ABS resin, and ethylene vinyl acetate copolymers; pyran copolymers; polyhydroxypropyl-methacrylamide-phenol; polyhydroxyethyl-aspartamide-phenol; polyethylene oxide-polylysine substituted with palmitoyl residues; polyamides such as nylon 66 and polycaprolactam; alkyd resins, polycarbonates; polyoxymethylene; polyimides; polyethers; epoxy resins, polyurethanes; rayon; triacetate rayon; cellulose, cellulose acetate, cellulose butyrate; cellulose acetate butyrate; cellophane; cellulose nitrate; cellulose propionate; cellulose ethers; and carboxymethyl cellulose.

[0372] Polymers and semipermeable polymer matrices can be formed into shaped articles, such as valves, stents, tubes, prostheses, and the like.

[0373] In certain embodiments of the present invention, a compound of the present invention, or a pharmaceutically acceptable salt thereof, is coupled to a polymer or semipermeable polymer matrix formed into a stent or stent-graft device.

[0374] The polymer is typically applied to the surface of the implantable device by spin coating, dipping, or spraying. Other methods known in the art may also be used for this purpose. Spray coating methods include traditional methods as well as microdeposition techniques using inkjet-type dispensers. In addition, photopatterning can be used to deposit the polymer on the implantable device by placing the polymer only on specific portions of the implantable device. This coating provides a uniform layer around the device, which improves the diffusion of various analytes through the device coating.

[0375] In certain embodiments of the present invention, the compounds of the present invention or pharmaceutically acceptable salts thereof are formulated to be released from a polymer coating into the environment in which the medical device is placed. Preferably, at least one of several well-known techniques involving a polymer carrier or layer to control elution is used to release the active compound in a controlled manner over an extended period of time (e.g., several months). Some of these techniques are described in U.S. Patent Application 2004 / 0243225A1, the entire disclosure of which is incorporated herein in its entirety.

[0376] In addition, as described in, for example, U.S. Patent No. 6,770,729, which is incorporated herein in its entirety, the reagents and reaction conditions of the polymer composition can be manipulated to control the release of the active compound from the polymer coating. For example, the diffusion coefficient of one or more polymer coatings can be adjusted to control the release of the active compound from the polymer coating. In a variation of this theme, the diffusion coefficient of one or more polymer coatings can be controlled to adjust the ability (and for example, to adjust the release of the active compound from the polymer coating) of the analyte (such as an analyte that contributes to the decomposition or hydrolysis of a certain part of the polymer) present in the environment where the medical device is placed to approach one or more components in the polymer composition. Another embodiment of the present invention includes a device with a plurality of polymer coatings, each of which has a plurality of diffusion coefficients. In this type of embodiment of the present invention, the release of the active compound from the polymer coating can be adjusted by these various polymer coatings.

[0377] In another embodiment of the invention, the release of the active compound from the polymer coating is controlled by adjusting one or more properties of the polymer composition, such as the presence of one or more endogenous or exogenous compounds, or the pH of the polymer composition. For example, certain polymer compositions can be designed to release the active compound in response to a decrease in the pH of the polymer composition.

[0378] Reagent test kit

[0379] The present invention also provides a kit comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, at least one other therapeutic agent, packaging materials, and instructions for administering the compound of the present invention or a pharmaceutically acceptable salt thereof and one or more other therapeutic agents to a mammal to treat or prevent a disease or condition that would benefit from ALK2 inhibition. In one embodiment, the mammal is a human.

[0380] It will be appreciated by those skilled in the relevant art that, in view of the information known to those skilled in the art, other suitable modifications and adaptations of the compositions and methods described herein will be apparent from the description of the invention contained herein and may be made without departing from the scope of the invention or any embodiment thereof. Example

[0381] Now that the present invention has been described in detail, the invention will be more clearly understood by reference to the following examples, which are included herein for illustrative purposes only and are not intended to limit the invention. Section 1 shows the synthesis of exemplary compounds of the invention. Section 2 shows the preparation of various exemplary 3-substituted-(4-amino-1H-imidazol-1-yl) reagents. Section 3 provides biological assay data for exemplary compounds of the invention.

[0382] For purposes of the present invention, the numerical descriptors "pyrrolo[2,1-f][1,2,4]triazine" and "pyrrolo[1,2-f][1,2,4]triazine" and the like are to be understood as synonyms in the context of the chemical names provided for the compounds disclosed herein, and thus may be, and are sometimes, used interchangeably. As a non-limiting example, the chemical names "2,4-dichloropyrrolo[2,1-f][1,2,4]triazine" and "2,4-dichloropyrrolo[1,2-f][1,2,4]triazine" are both understood to refer to the compound having the following structure:

[0383]

[0384] As another non-limiting example, the chemical names "2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine" and "2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine" are both understood to refer to the compound having the following structure:

[0385]

[0386] Part 1: Synthesis of Imidazole-Containing ALK2 Kinase Inhibitors

[0387] Solution 1

[0388]

[0389] Preparation of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b)

[0390] To a solution of 2,4-dichlorofuro[3,2-d]pyrimidine (1a) (0.71 g, 3.74 mmol; CAS# 956034-07-4) in 2-propanol (20 mL) was added DIPEA (1.63 mL, 9.36 mmol), 1-methyl-1H-imidazol-4-amine hydrochloride (0.5 g, 3.74 mmol) and heated under reflux for 24 h. The reaction mixture was concentrated to dryness in vacuo and the obtained residue was triturated with water. The obtained solid was collected by filtration and dried in vacuo to give 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (550 mg, 59% yield) as a brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.89 (s, 1H, D2O exchangeable), 8.35 (d, J = 2.1 Hz, 1H), 7.52 (d, J = 1.6 Hz, 1H), 7.39 (d, J = 1.3 Hz, 1H), 7.03 (d, J = 2.1 Hz, 1H), 3.71 (s, 3H); MS (ES+): 250.3 (M+1), 272.3, 274.3 (M+Na), (ES-): 248.2 (M-1).

[0391] Option 2

[0392]

[0393] Preparation of (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a)

[0394] A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-methyl-2-pyrrolidone (1 mL) was subjected to microwave irradiation at 150 ° C for 2 hours. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2×20 mL), dried, filtered and concentrated in vacuo. The crude residue was purified by combiflash (silica gel, 12 g, eluted with chloroform / CMA-80) to give (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34% yield) as a light yellow solid; 1H NMR (300 MHz, DMSO-d6) δ 9.90 (s, 1H, D2O exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83–3.69 (m, 1H), 3.64 (s, 3H), 3.62–3.49 (m, 1H), 3.48–3.23 (m, 2H), 2.07–1.83 (m, 4H); MS (ES+): 315.4 (M+1), 337.5 (M+Na), (ES-): 313.4 (M-1). HPLC purity: 98.70%.

[0395] Option 3

[0396]

[0397] Preparation of (R)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (3a)

[0398] According to the procedure reported in Scheme 2, 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol) was reacted with (R)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in NMP (1 mL) to give (R)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (3a) (65 mg, 52% yield) as a light yellow solid after workup and purification; 1 H NMR (300 MHz, DMSO-d6) δ9.91 (s, 1H, D2O exchangeable), 8.00 (d, J = 2.2 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.93 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.82–3.69 (m, 1H), 3.64 (s, 3H), 3.61–3.48 (m, 1H), 3.48–3.23 (m, 2H), 2.06–1.80 (m, 4H); MS (ES+): 315.4 (M+1), 337.4 (M+Na), (ES-): 313.3 (M-1).

[0399] Option 4

[0400]

[0401] Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (4c)

[0402] Step-1: 2-Chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (4b) was prepared from compound 4a according to the procedure reported by Mastalerz, Harold et al. in PCT Int. Appl., WO 2008 / 005956, January 10, 2008 (incorporated by reference). This gave 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (4b) as a pale off-white solid; 1 H NMR (300MHz, DMSO-d6) δ11.15(s,1H),7.75-7.67(m,1H),7.54(s,1H),7.44(s,1H),7.35(dd,J=4.5,1.5Hz , 1H), 6.68 (dd, J=4.4, 2.6Hz, 1H), 3.70 (s, 3H); MS (ES+): 249.3 (M+1), 271.3 (M+Na); MS (ES-): 247.2 (M-1).

[0403] Step-2: Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (4c)

[0404] Compound 4c was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (4b) (100 mg, 0.40 mmol), 2-(pyrrolidin-2-yl)pyridine (179 mg, 1.21 mmol) and DIPEA (0.21 mL, 1.21 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica gel (24 g), eluted with CMA80 / CHCl3 from 0 to 20%], N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (4c) (50 mg, 35% yield) was obtained as a yellow solid; 1H NMR(300MHz,DMSO-d6)δ10.24(s,1H),8.67-8.56(m,1H),7.67(td,J=7.7,1.8Hz,1H),7.4 4-7.32(m,2H),7.28-7.15(m,2H),7.06(dd,J=4.4,1.7Hz,1H),6.86-6.67(m,1H),6.36(dd ,J=4.4,2.5Hz,1H),5.29(d,J=8.3Hz,1H),3.81(t,J=9.0Hz,1H),3.67-3.54(m,1H),3.53 (s,3H),2.46-2.24(m,1H),2.09-1.75(m,3H);MS(ES+):361.5(M+1);MS(ES-)359.4(M-1).

[0405] Option 5

[0406]

[0407] Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (5a)

[0408] Compound 5a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), DIPEA (155 mg, 1.20 mmol) and 2-(pyrrolidin-2-yl)pyridine hydrochloride (148 mg, 0.8 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica gel (12 g), eluted with CMA80 / CHCl3 from 0 to 20%], N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (5a) (22 mg, 15% yield) was obtained as an off-white solid; 1HNMR (300 MHz, DMSO-d6) δ9.83 (s, 1H, D2O exchangeable), 8.61 (s, 1H), 8.00 (s, 1H), 7.66 (td, J = 7.6, 1.8 Hz, 1H), 7.38-7.27 (m, 1H), 7.26-7.18 (m, 1H), 7.15 (d, J = 7.8 Hz, 1H), 6.84-6.67 ( m,1H),6.67-6.44(m,1H),5.29(d,J=8.2Hz,1H),3.99-3.81(m,1H),3.78-3.60(m,1H), 3.52(s,3H),2.46-2.27(m,1H),2.06-1.74(m,3H); MS(ES+):362.4(M+1),384.5(M+Na).

[0409] Option 6

[0410]

[0411] Preparation of (S)-(1-(4-(1-methyl-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (6a)

[0412] Compound 6a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (4b) (50 mg, 0.2 mmol), (S)-pyrrolidin-2-ylmethanol (61 mg, 0.6 mmol) and DIPEA (0.11 mL, 0.6 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica gel (24 g), eluted with CMA80 / CHCl3 from 0 to 40%], (S)-(1-(4-(1-methyl-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (6a) (34 mg, 54% yield) was obtained; 1HNMR(300MHz,DMSO-d6)δ10.32(s,1H),7.47(s,2H),7.35(dd,J=2.4,1.7Hz, 1H),7.08(d,J=3.5Hz,1H),6.36(dd,J=4.4,2.4Hz,1H),4.81(t,J=5.0Hz,1H) ,4.16–4.07(m,1H),3.82–3.70(m,1H),3.65(s,3H),3.54–3.42(m,1H),3.36– 3.25(m,2H),2.12–1.79(m,4H); MS(ES+):314.4(M+1); MS(ES-):312.4(M-1).

[0413] Option 7

[0414]

[0415] Preparation of (R)-(1-(4-(1-methyl-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (7a)

[0416] Compound 7a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (4b) (50 mg, 0.2 mmol), (R)-pyrrolidin-2-ylmethanol (61 mg, 0.6 mmol) and DIPEA (0.11 mL, 0.6 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica gel (24 g), eluted with CMA-80 / CHCl3 from 0 to 40%], (R)-(1-(4-(1-methyl-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (7a) (27 mg, 43% yield) was obtained; 1 HNMR(300MHz,DMSO-d6)δ10.32(s,1H),7.47(s,2H),7.35(dd,J=2.5,1.7Hz, 1H),7.08(dd,J=4.5,1.7Hz,1H),6.36(dd,J=4.4,2.4Hz,1H),4.81(t,J=5.0 Hz,1H),4.20–4.04(m,1H),3.82–3.69(m,1H),3.65(s,3H),3.54–3.42(m,1H ),3.35–3.24(m,2H),2.11–1.78(m,4H); MS(ES+):314.5(M+1),336.5(M+Na).

[0417] Option 8

[0418]

[0419] Preparation of (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (8c)

[0420] Step-1: Preparation of 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (8b)

[0421] Compound 8b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (240 mg, 1.28 mmol; CAS# 918538-05-3) in 2-propanol (5 mL) using DIPEA (0.67 mL, 3.83 mmol) and 1-phenyl-1H-imidazol-4-amine, HCl (8a) (250 mg, 1.28 mmol; prepared according to the procedure reported by Sakamoto, Toshihiro et al. in Bioorganic & Medicinal Chemistry, 17(14), 5015-5026; 2009 and Francini, Cinzia Maria et al. in Chem. Med. Chem, 10(12), 2027-2041) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (8b) (302 mg, 76% yield); 1 HNMR(300MHz,DMSO-d6)δ11.35(s,1H),8.35-8.18(m,1H),7.95-7.87(m,1H),7.81-7.73(m,1H),7.65(d,J=7.9H z, 2H), 7.56 (t, J = 7.7Hz, 2H), 7.46-7.35 (m, 2H), 6.80-6.66 (m, 1H); MS (ES+): 311.3 (M+1); MS (ES-): 309.3 (M-1).

[0422] Step-2: Preparation of (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (8c)

[0423] Compound 8c was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (8b) (100 mg, 0.32 mmol), (S)-pyrrolidin-2-ylmethanol (98 mg, 0.97 mmol) and DIPEA (0.17 mL, 0.97 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica gel (24 g), eluting with CMA-80 / CHCl3 from 0 to 40%], (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (8c) (29 mg, 24% yield) TFA salt was obtained as a light off-white solid (obtained by reverse phase column purification of the final compound using acetonitrile / water containing 0.1% TFA as the mobile phase); 1 HNMR(300MHz,DMSO-d6)δ10.58(s,1H),8.32(s,1H),7.98(s,1H),7.76(d, J=7.8Hz,2H),7.51(t,J=7.7Hz,2H),7.43–7.37(m,1H),7.37–7.31(m,1H) ,7.23–7.09(m,2H),7.00(s,1H),6.48–6.31(m,1H),4.26–4.09(m,1H),3. 84–3.68(m,1H),3.59–3.44(m,1H),3.44–3.28(m,2H),2.15–1.78(m,4H); 19 F NMR (282MHz, DMSO-d6)) δ-74.29; MS (ES+): 376.5 (M+1); MS (ES-): 374.4 (M-1), 410.4 (M+Cl).

[0424] Option 9

[0425]

[0426] Preparation of N-(1-phenyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (9a)

[0427] Compound 9a was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (8b) (100 mg, 0.32 mmol), 2-(pyrrolidin-2-yl)pyridine hydrochloride (149 mg, 0.81 mmol) and DIPEA (0.28 mL, 1.61 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica gel (24 g), eluting with CMA-80 / CHCl3 from 0 to 40%], N-(1-phenyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (9a) (27 mg, 20% yield) was obtained as a light brown solid; 1 HNMR(300MHz,DMSO-d6)δ10.55(s,1H),8.43(s,1H),8.26–8.08(m,1H),8.04–7.76(m,1H),7.67–7.52(m,6H),7.49–7.34(m,3H),7.20–7. 10(m,1H),6.42(dd,J=4.4,2.5Hz,1H),5.47(d,J=8.3Hz,1H),3.91–3.78(m,1H),3.70–3.62(m,1H),2.53–2.36(m,1H),2.14–1.73(m,3H); 19 F NMR (282MHz, DMSO-d6) δ-74.26; MS (ES+): 423.5 (M+1), 445.5 (M+Na); MS (ES-): 421.4 (M-1).

[0428] Plan 10

[0429]

[0430] Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (10a)

[0431] Compound 10a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (4b) (80 mg, 0.32 mmol), 2-phenylpyrrolidine (142 mg, 0.97 mmol) and DIPEA (0.17 mL, 0.97 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica gel (24 g), eluted with CMA-80 / CHCl3 from 0 to 40%], N-(1-methyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (10a) (31 mg, 27% yield) was obtained as a light off-white solid; 1 H NMR(300MHz,DMSO-d6)δ10.20(s,1H),7.41-7.25(m,6H),7.24-7.15(m,1H),7.05(dd,J= 4.4,1.7Hz,1H),6.78-6.66(m,1H),6.35(dd,J=4.4,2.4Hz,1H),5.32(d,J=8.0Hz,1H),3. 84-3.70(m,1H),3.64-3.54(m,1H),3.49(s,3H),2.41-2.30(m,1H),2.01-1.76(m,3H);M S(ES+): 360.5(M+1), 382.5(M+Na); MS(ES-): 358.4(M-1), 394.5(M+Cl); HPLC purity: 95.75%.

[0432] Plan 11

[0433]

[0434] Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-3-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (11a)

[0435] Compound 11a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.4 mmol), 3-(pyrrolidin-2-yl)pyridine (119 mg, 0.8 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA 0-100%,] N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-3-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (11a) (23 mg, 16% yield) was obtained as an off-white solid; 1 H NMR (300 MHz, DMSO-d6) δ9.83 (s, 1H, D2O exchangeable), 8.54 (s, 1H), 8.41 (dd, J = 4.8, 1.6 Hz, 1H), 8.01 (d, J = 2.2 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.32 (dd, J = 7.8, 4.7 Hz, 2H), 6.72 (s, 1H), 6.70-6.30 (m, 1H),5.35(d,J=7.9Hz,1H),3.98-3.81(m,1H),3.77-3.60(m,1H),3.51(s,3H),2.47-2.33(m,1 H), 2.02-1.73 (m, 3H); MS (ES+): 362.5 (M+1), 384.5 (M+Na), 745.8 (2M+Na), (ES-): 360.4 (M-1).

[0436] Plan 12

[0437]

[0438] Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)thieno[3,2-d]pyrimidin-4-amine (12c)

[0439] Step-1: Preparation of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (12b)

[0440] Compound 12b was prepared from 2,4-dichlorothieno[3,2-d]pyrimidine (12a) (0.31 g, 1.5 mmol; CAS# 16234-14-3) in 2-propanol (10 mL) using 1-methyl-1H-imidazol-4-amine hydrochloride (0.2 g, 1.5 mmol) and DIPEA (0.65 mL, 3.74 mmol) according to the procedure reported in Scheme 1. After workup and purification by flash column chromatography [silica gel, 24 g, eluted with CMA-80 / chloroform], 2-chloro-N-(1-methyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (12b) (165 mg, 42% yield) was obtained as a yellow solid; 1 H NMR (300MHz, DMSO-d6) δ10.82(s,1H),8.21(d,J=5.4Hz,1H),7.55(s,1H),7.41(s,1H),7. 36 (d, J=5.4Hz, 1H), 3.71 (s, 3H); MS (ES+): 266.3 (M+1), 288.3 (M+Na), (ES-): 264.2 (M-1).

[0441] Step-2: Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)thieno[3,2-d]pyrimidin-4-amine (12c)

[0442] Compound 12c was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (12b) (100 mg, 0.38 mmol) and 2-(pyrrolidin-2-yl)pyridine (167 mg, 1.13 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica C-18, 30 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)thieno[3,2-d]pyrimidin-4-amine (12c) (86 mg, 61% yield) was obtained as an off-white solid; 1H NMR (300 MHz, DMSO-d6) δ9.81 (s, 1H, D2O exchangeable), 8.62 (s, 1H), 8.02-7.80 (m, 1H), 7.66 (td, J = 7.6, 1.8 Hz, 1H), 7.31 (s, 1H), 7.27-7.05 (m, 3H), 6.62 (s, 1H), 5.34 (d, J = 8.2 Hz, 1H), 4.01-3.84 (m, 1H), 3.79-3.64 (m, 1H), 3.64-3.43 (m, 3H), 2.44 (s, 1H), 2.08-1.77 (m, 3H); MS (ES+): 378.5 (M+1), 400.5 (M+Na), (ES-): 376.4 (M-1).

[0443] Plan 13

[0444]

[0445] Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (13a)

[0446] Compound 13a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.4 mmol), 2-phenylpyrrolidine (147 mg, 1.0 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-methyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (13a) (8 mg, 6% yield) was obtained as a colorless solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.50 (s, 1H, D2O exchangeable), 8.33 (s, 1H), 7.68 (s, 1H), 7.36 (d, J = 5.6 Hz, 4H), 7.32-7.20 (m, 1H), 6.97 (s, 1H), 6.58 (s, 1H), 5.47 (d, J = 7.2 Hz, 1H), 3.96 (s, 1H), 3.74-3.63 (m, 1H), 3.54 (s, 3H), 2.49-2.34 (m, 1H), 2.08 (s, 1H), 2.01-1.83 (m, 2H); MS (ES+): 361.5 (M+1).

[0447] Plan 14

[0448]

[0449] Preparation of (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (14b)

[0450] Step-1: Preparation of 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (14a)

[0451] Compound 14a was prepared from 2,4-dichlorofuro[3,2-d]pyrimidine (1a) (400 mg, 2.12 mmol) in 2-propanol (30 mL) using DIPEA (0.92 mL, 5.29 mmol) and 1-phenyl-1H-imidazol-4-amine, HCl (8a) (414 mg, 2.12 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (14a) (267 mg, 41% yield) as a light brown solid; 1 HNMR (300MHz, DMSO-d6) δ11.01(s,1H),8.38(d,J=2.2Hz,1H),8.23(d,J=1.6Hz,1H),7.88(d,J=1.7Hz,1H),7.70-7.63 (m,2H),7.63-7.50(m,2H),7.45-7.35(m,1H),7.06(d,J=2.2Hz,1H); MS(ES+):312.3(M+1),334.3(M+Na),310.3(M-1).

[0452] Step-2: Preparation of (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (14b)

[0453] Compound 14b was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (14a) (100 mg, 0.32 mmol), (S)-pyrrolidin-2-ylmethanol (81 mg, 0.8 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (14b) (65 mg, 54% yield) was obtained as a brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.13 (s, 1H, D2O exchangeable), 8.18 (d, J = 1.6 Hz, 1H), 8.04 (d, J = 2.1 Hz, 1H), 7.95 (d, J = 1.7 Hz, 1H), 7.80-7.64 (m, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H) ,6.74(d,J=2.1Hz,1H),5.00(s,1H,D2O exchangeable),4.20(s,1H),3.85-3.69(m,1H),3.66-3.54(m,1H),3.55-3.41(m,2H),2.09-1.83(m,4H);MS(ES+):377.5(M+1),(ES-):375.4(M-1).

[0454] Plan 15

[0455]

[0456] Preparation of (S)-N-(1-methyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (15a)

[0457] Compound 15a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (4b) (80 mg, 0.32 mmol), (S)-2-phenylpyrrolidine (142 mg, 0.97 mmol), DIPEA (0.17 mL, 0.97 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-N-(1-methyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (15a) (42 mg, 36% yield) was obtained as an off-white solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.20 (s, 1H, D2O exchangeable), 7.40-7.34 (m, 2H), 7.34-7.26 (m, 4H), 7.25-7.15 (m, 1H), 7.05 (dd, J = 4.3, 1.7 Hz, 1H), 6.73 (s, 1H), 6.36 (dd, J = 4.4, 2 .4Hz,1H),5.33(d,J=8.0Hz,1H),3.86-3.70(m,1H),3.66-3.50(m,1H),3.49(s,3H ),2.42-2.28(m,1H),2.02-1.71(m,3H); MS(ES+):360.5(M+1),(ES-):358.5(M-1).

[0458] Plan 16

[0459]

[0460] Preparation of (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (16b)

[0461] Step-1: Preparation of 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (16a)

[0462] Compound 16a was prepared from 2,4-dichlorothieno[3,2-d]pyrimidine (12a) (500 mg, 2.44 mmol) in 2-propanol (30 mL) using DIPEA (1.07 mL, 6.1 mmol) and 1-phenyl-1H-imidazol-4-amine, HCl (8a) (477 mg, 2.45 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (16a) (340 mg, 43% yield) as a light pink solid; 1 HNMR (300 MHz, DMSO-d6) δ10.97 (s, 1H, D2O exchangeable), 8.27 (s, 1H), 8.24 (d, J = 5.4 Hz, 1H), 7.96 (d, J = 1.7 Hz, 1H), 7.73-7.65 (m, 2H), 7.62-7.52 (m, 2H), 7.46-7.36 (m, 2H); MS (ES+): 328.3 (M+1) (ES-): 326.3 (M-1).

[0463] Step-2: Preparation of (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (16b)

[0464] Compound 16b was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (16a) (100 mg, 0.31 mmol), (S)-pyrrolidin-2-ylmethanol (77 mg, 0.76 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (16b) (95 mg, 79% yield) was obtained as a brown solid; 1H NMR (300 MHz, DMSO-d6) δ 10.14 (s, 1H, D2O exchangeable), 8.20 (d, J = 1.6 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 7.93 (d, J = 5.4 Hz, 1H), 7.72 (s, 2H), 7.51 (t, J = 7.8 Hz, 2H), 7.35 (t, J = 7.4 Hz, 1H), 7.10 (d, J=5.4 Hz, 1H), 5.03 (s, 1H, D2O exchangeable), 4.24 (s, 1H), 3.87-3.70 (m, 1H), 3.70-3.45 (m, 1H), 3.43-3.36 (m, 2H), 2.12-1.78 (m, 4H); MS (ES+): 393.5 (M+1), 415.5 (M+Na), (ES-): 391.4 (M-1).

[0465] Plan 17

[0466]

[0467] Preparation of (S)-N4-(1-phenyl-1H-imidazol-4-yl)-N2-(1-phenylethyl)thieno[3,2-d]pyrimidine-2,4-diamine (17a)

[0468] Compound 17a was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (16a) (100 mg, 0.31 mmol), (S)-1-phenylethylamine (111 mg, 0.92 mmol) and DIPEA (0.2 mL, 1.2 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-N4-(1-phenyl-1H-imidazol-4-yl)-N2-(1-phenylethyl)thieno[3,2-d]pyrimidine-2,4-diamine (17a) (65 mg, 52% yield) was obtained as an off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 10.10 (s, 1H, D2O exchangeable), 8.33-8.16 (m, 1H), 8.14 (s, 1H), 7.97-7.87 (m, 1H), 7.76-7.63 (m, 2H), 7.57 (t, J = 7.8 Hz, 2H), 7.48-7.30 (m, 3H), 7.33-7.19 (m, 3H), 7.22-7.07 (m, 1H), 7.04 (d, J = 5.4 Hz, 1H), 5.32-5.16 (m, 1H), 1.50 (d, J = 7.0 Hz, 3H); MS (ES+): 413.5 (M+1), (ES-): 411.5 (M-1); HPLC purity: 91.57%.

[0469] Plan 18

[0470]

[0471] Preparation of (S)-N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (18a)

[0472] Compound 18a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), (S)-2-(pyrrolidin-2-yl)pyridine dihydrochloride (98 mg, 0.44 mmol) and DIPEA (0.17 mL, 0.97 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (18a) (11 mg, 8% yield) was obtained as a light yellow solid; 1H NMR (300 MHz, DMSO-d6) δ 10.24 (s, 1H, D2O exchangeable), 8.66-8.56 (m, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.43-7.31 (m, 2H), 7.27-7.16 (m, 2H), 7.06 (dd, J = 4.5, 1.7 Hz, 1H), 6.75 (bs, 1H), 6.36(dd,J=4.4,2.4Hz,1H),5.29(d,J=8.2Hz,1H),3.87-3.74(m,1H),3.66-3.56(m,1H) ,3.53(s,3H),2.44-2.31(m,1H),2.05-1.79(m,3H); MS(ES+):361.5(M+1),383.5(M+Na).

[0473] Plan 19

[0474]

[0475] Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-3-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (19a)

[0476] Compound 19a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 3-(pyrrolidin-2-yl)pyridine (119 mg, 0.804 mmol) and DIPEA (0.21 mL, 1.21 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-3-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (19a) (11 mg, 8% yield) was obtained as a light yellow solid; 1H NMR (300 MHz, DMSO-d6) δ 10.24 (s, 1H, D2O exchangeable), 8.66-8.56 (m, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.43-7.31 (m, 2H), 7.27-7.16 (m, 2H), 7.06 (dd, J = 4.5, 1.7 Hz, 1H), 6.75 (bs, 1H), 6.36(dd,J=4.4,2.4Hz,1H),5.29(d,J=8.2Hz,1H),3.87-3.74(m,1H),3.66-3.56(m,1H) ,3.53(s,3H),2.44-2.31(m,1H),2.05-1.79(m,3H); MS(ES+):361.5(M+1),383.5(M+Na).

[0477] Plan 20

[0478]

[0479] Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-4-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (20a)

[0480] Compound 20a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 4-(pyrrolidin-2-yl)pyridine (119 mg, 0.8 mmol) and DIPEA (0.21 mL, 1.21 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-methyl-1H-imidazol-4-yl)-2-(2-(pyridin-4-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (20a) (23 mg, 16% yield) was obtained as a light brown solid; 1H NMR (300 MHz, DMSO-d6) δ 10.26 (s, 1H, D2O exchangeable), 8.55-8.42 (m, 2H), 7.37 (s, 2H), 7.34-7.30 (m, 2H), 7.07 (dd, J = 4.4, 1.7 Hz, 1H), 6.74 (s, 1H), 6.36 (dd, J = 4.5, 2.4 Hz, 1H), 5.30(d,J=8.3Hz,1H),3.86-3.73(m,1H),3.68-3.58(m,1H),3.52(s,3H),2.47-2.30 (m,1H),2.01-1.73(m,3H); MS(ES+):361.5(M+1),383.5(M+Na),(ES-):359.4(M-1).

[0481] Plan 21

[0482]

[0483] Preparation of (S)-N4-(1-methyl-1H-imidazol-4-yl)-N2-(1-phenylethyl)quinazoline-2,4-diamine (21c)

[0484] Step-1: Preparation of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)quinazolin-4-amine (21b)

[0485] Compound 21b was prepared according to the procedure reported by Su, Qibin et al. in Journal of Medicinal Chemistry, 57(1), 144-158; 2014. This gave 2-chloro-N-(1-methyl-1H-imidazol-4-yl)quinazolin-4-amine (21b) as a light brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.97 (s, 1H, D2O exchangeable), 8.72 (dd, J = 8.3, 1.3 Hz, 1H), 7.84 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.68 (dd, J = 8.4, 1.2 Hz, 1H), 7.62-7.50 (m, 3H), 3.73 (s, 3H); MS (ES+): 260.3 (M+1), 282.3 (M+Na), (ES-): 258.3 (M-1).

[0486] Step-2: Preparation of (S)-N4-(1-methyl-1H-imidazol-4-yl)-N2-(1-phenylethyl)quinazoline-2,4-diamine (21c)

[0487] Compound 21c was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)quinazolin-4-amine (21b) (100 mg, 0.39 mmol), (S)-1-phenylethylamine (140 mg, 1.16 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-N4-(1-methyl-1H-imidazol-4-yl)-N2-(1-phenylethyl)quinazoline-2,4-diamine (21c) (24 mg, 18% yield) was obtained as a light brown solid; 1 H NMR (300 MHz, DMSO-d6) δ9.96 (s, 1H, D2O exchangeable), 8.36 (d, J = 8.2 Hz, 1H), 7.96 (s, 1H), 7.55-7.39 (m, 4H), 7.37-7.3 (m, 5H), 7.08-6.93 (m, 1H), 5.29 (s, 1H), 3.69 (s, 3H), 1.50 (d, J = 7.0 Hz, 3H); MS (ES+): 345.5 (M+1), 367.5 (M+Na), (ES-): 343.4 (M-1), 379.5 (M+Cl).

[0488] Plan 22

[0489]

[0490] Preparation of (S)-(1-(6-methyl-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (22c)

[0491] Step-1: Preparation of 2-chloro-6-methyl-N-(1-phenyl-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (22b)

[0492] Compound 22b was prepared from 2,4-dichloro-6-methylthieno[2,3-d]pyrimidine (22a) (500 mg, 2.28 mmol, CAS# 76872-23-6) in 2-propanol (30 mL) using DIPEA (1.0 mL, 5.71 mmol) and 1-phenyl-1H-imidazol-4-amine, HCl (8a) (363 mg, 2.28 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-6-methyl-N-(1-phenyl-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (22b) (340 mg, 44% yield) as a light pink solid; 1HNMR (300 MHz, DMSO-d6) δ10.88 (s, 1H, D2O exchangeable), 8.25 (d, J = 1.7 Hz, 1H), 7.91 (d, J = 1.7 Hz, 1H), 7.72 (s, 1H), 7.70-7.63 (m, 2H), 7.57 (dd, J = 8.7, 7.1 Hz, 2H), 7.46-7.36 (m, 1H), 2.56 (d, J = 1.2 Hz, 3H); MS (ES+): 364.3 (M+Na), (ES-): 340.3 (M-1).

[0493] Step-2: Preparation of (S)-(1-(6-methyl-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (22c)

[0494] Compound 22c was prepared from 2-chloro-6-methyl-N-(1-phenyl-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (22b) (100 mg, 0.29 mmol), (S)-pyrrolidin-2-ylmethanol (89 mg, 0.88 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(6-methyl-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (22c) (65 mg, 55% yield) was obtained as a light brown solid; 1 H NMR (300 MHz, DMSO-d6) δ9.98 (s, 1H, D2O exchangeable), 8.20 (s, 1H), 7.96 (d, J = 1.6 Hz, 1H), 7.84-7.60 (m, 2H), 7.57-7.42 (m, 3H), 7.40-7.29 (m, 1H), 4.94 (s, 1H, D2O exchangeable), 4.42-4.02 (m, 1H), 3.87-3.39 (m, 2H), 2.63-2.51 (m, 1H), 2.49-2.35 (m, 4H), 2.13-1.76 (m, 4H); MS (ES+): 407.5 (M+1), 429.5 (M+Na), (ES-): 405.4.

[0495] Plan 23

[0496]

[0497] Preparation of (S)-(1-(6-methyl-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (23c)

[0498] Step-1: Preparation of 2-chloro-6-methyl-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (23b)

[0499] Compound 23b was prepared from 2,4-dichloro-6-methylthieno[3,2-d]pyrimidine (23a) (500 mg, 2.28 mmol, CAS# 35265-82-8) in 2-propanol (30 mL) using DIPEA (1.00 mL, 5.71 mmol) and 1-phenyl-1H-imidazol-4-amine, HCl (8a) (363 mg, 2.28 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-6-methyl-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (23b) (340 mg, 44% yield) as a light pink solid; 1 HNMR (300 MHz, DMSO-d6) δ10.75 (s, 1H, D2O exchangeable), 8.27 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.68 (dd, J = 7.9, 1.6 Hz, 2H), 7.57 (dd, J = 8.6, 7.1 Hz, 2H), 7.45-7.36 (m, 1H), 7.17-7.08 (m, 1H), 2.60 (s, 3H); MS (ES+): 342.3 (M+1), 364.3 (M+Na), (ES-): 340.3 (M-1).

[0500] Step-2: Preparation of (S)-(1-(6-methyl-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (23c)

[0501] Compound 23c was prepared from 2-chloro-6-methyl-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (23b) (100 mg, 0.29 mmol) and (S)-pyrrolidin-2-ylmethanol (89 mg, 0.88 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography (silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA), followed by conversion to the free base using NaHCO3, (S)-(1-(6-methyl-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (23c) (65 mg, 55% yield) was obtained as an off-white solid. 1 H NMR (300 MHz, DMSO-d6) δ9.95 (s, 1H, D2O exchangeable), 8.19 (d, J = 1.6 Hz, 1H), 7.96 (d, J = 1.6 Hz, 1H), 7.72 (s, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H), 6.83 (d, J = 1.5 Hz, 1H), 5 .37-4.71(m,1H,D2O exchangeable),4.36-4.05(m,1H),3.85-3.69(m,1H),3.70-3.38(m,3H),2.52(s,3H),2.10-1.80(m,4H);MS(ES+):407.5(M+1),429.5(M+Na),(ES-):405.5(M-1).

[0502] Plan 24

[0503]

[0504] Preparation of (S)-N4-(1-phenyl-1H-imidazol-4-yl)-N2-(1-phenylethyl)quinazoline-2,4-diamine (24b)

[0505] Step-1: Preparation of 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)quinazolin-4-amine (24a)

[0506] Compound 24a was prepared from 2,4-dichloroquinazoline (21a) (180 mg, 0.9 mmol; CAS# 607-68-1) in 2-propanol (5 mL) using DIPEA (0.51 mL, 2.92 mmol) and 1-phenyl-1H-imidazol-4-amine, HCl (8a) (177 mg, 0.9 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)quinazolin-4-amine (24a) (125 mg, 43% yield) as an off-white solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.18 (s, 1H, D2O exchangeable), 8.77 (d, J = 8.2 Hz, 1H), 8.29 (d, J = 1.7 Hz, 1H), 8.04 (d, J = 1.7 Hz, 1H), 7.87 (ddd, J = 8.3, 7.0, 1.3 Hz, 1H), 7.73 (dd, J = 8.4, 1.2 Hz, 1H), 7.70-7.65 (m, 2H), 7.60 (tdd, J = 8.5, 6.9, 1.5 Hz, 3H), 7.46-7.37 (m, 1H); MS (ES+): 322.4 (M+1), 344.4 (M+Na), (ES-): 320.3 (M-1).

[0507] Step-2: Preparation of (S)-N4-(1-phenyl-1H-imidazol-4-yl)-N2-(1-phenylethyl)quinazoline-2,4-diamine (24b)

[0508] Compound 24b was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)quinazolin-4-amine (24a) (100 mg, 0.31 mmol) and (S)-1-phenylethylamine (113 mg, 0.93 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-N4-(1-phenyl-1H-imidazol-4-yl)-N2-(1-phenylethyl)quinazoline-2,4-diamine (24b) (86 mg, 68% yield) was obtained as an off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 11.47-10.14 (m, 1H, D2O exchangeable), 8.66-8.36 (m, 2H), 8.22 (d, J = 1.7 Hz, 1H), 7.82-7.63 (m, 1H), 7.59 (t, J = 7.6 Hz, 2H), 7.51-7.28 (m, 9H), 7.26-7.15 (m, 2H), 5.35 (q, J = 7.2 Hz, 1H), 1.57 (d, J = 6.9 Hz, 3H); MS (ES+): 407.5 (M+1), (ES-): 405.6 (M-1).

[0509] Plan 25

[0510]

[0511] Preparation of (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (25c)

[0512] Step-1: Preparation of 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (25b)

[0513] Compound 25b was prepared according to the procedure reported in Scheme 1 from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (323 mg, 1.72 mmol) in 2-propanol (20 mL) using DIPEA (0.9 mL, 5.15 mmol) and 1-(4-fluorophenyl)-1H-imidazol-4-amine (25a) (440 mg, 2.06 mmol; prepared according to the procedures reported by Sakamoto, Toshihiro et al., Bioorganic & Medicinal Chemistry, 17(14), 5015-5026; 2009 and Francini, Cinzia Maria et al., Chem. Med. Chem, 10(12), 2027-2041). This afforded 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (25b) (381 mg, 68% yield) as a light off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 11.35 (s, 1H, D2O exchangeable), 8.21 (d, J = 1.6 Hz, 1H), 7.87 (d, J = 1.6 Hz, 1H), 7.77 (dd, J = 2.6, 1.5 Hz, 1H), 7.74–7.65 (m, 2H), 7.49–7.35 (m, 3H), 6.72 (dd, J = 4.5, 2.6 Hz, 1H); 19 F NMR (282MHz, DMSO) δ-114.97; MS (ES+): 329.3 (M+1); MS (ES-): 327.3 (M-1).

[0514] Step-2: Preparation of (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (25c)

[0515] Compound 25c was prepared from 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (25b) (100 mg, 0.32 mmol), (S)-pyrrolidin-2-ylmethanol (154 mg, 1.52 mmol) and DIPEA (0.16 mL, 0.91 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica (24 g), eluting with CMA-80 / CHCl3 from 0 to 40%], (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (25c) (40 mg, 33% yield) was obtained as a white solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.53 (s, 1H, D2O exchangeable), 8.20 (d, J = 1.6 Hz, 1H), 7.93 (d, J = 1.6 Hz, 1H), 7.86-7.74 (m, 2H), 7.39 (dd, J = 2.4, 1.6 Hz, 1H), 7.38-7.29 (m, 2H), 7.15 (dd, J = 4.5,1.7 Hz,1H),6.39 (dd, J=4.4,2.4 Hz,1H),4.91 (t, J=5.0 Hz,1H,D2O exchangeable),4.26-4.12 (m,1H),3.83-3.69 (m,1H),3.55-3.44 (m,1H),3.39-3.25 (m,2H),2.12-1.81 (m,4H); 19F NMR (282MHz, DMSO-d6) δ-115.67; MS (ES+): 394.5 (M+1), 416.5 (M+Na); MS (ES-): 392.5 (M-1).

[0516] Plan 26

[0517]

[0518] Preparation of (S)-(1-(4-((1-cyclopropyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (26c)

[0519] Step-1: Preparation of 2-chloro-N-(1-cyclopropyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (26b)

[0520] Compound 26b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (268 mg, 1.43 mmol) in 2-propanol (5 mL) using DIPEA (1.25 mL, 7.14 mmol) and 1-cyclopropyl-1H-imidazol-4-amine hydrochloride (26a) (1.4 g, 7.14 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-N-(1-cyclopropyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (26b) (225 mg, 57% yield) as a brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.19 (s, 1H, D2O exchangeable), 7.73 (dd, J = 2.6, 1.5 Hz, 1H), 7.65 (d, J = 1.5 Hz, 1H), 7.50 (d, J = 1.5 Hz, 1H), 7.35 (dd, J = 4.5, 1.6 Hz, 1H), 6.68 (dd, J = 4.5, 2.6 Hz, 1H), 3.62–3.46 (m, 1H), 1.14–0.89 (m, 4H); MS (ES-): 273.3 (M-1).

[0521] Step-2: Preparation of (S)-(1-(4-((1-cyclopropyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (26c)

[0522] Compound 26c was prepared from 2-chloro-N-(1-cyclopropyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (26b) (70 mg, 0.26 mmol), (S)-pyrrolidin-2-ylmethanol (129 mg, 1.27 mmol) and DIPEA (0.13 mL, 0.76 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica (24 g), eluting with CMA-80 / CHCl3 from 0 to 40%], (S)-(1-(4-((1-cyclopropyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (26c) (22 mg, 25% yield) was obtained as a white solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.31 (s, 1H, D2O exchangeable), 7.60 (d, J = 1.4 Hz, 1H), 7.49 (d, J = 1.6 Hz, 1H), 7.35 (dd, J = 2.4, 1.6 Hz, 1H), 7.09 (dd, J = 4.5, 1.7 Hz, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H) ,4.77(t,J=5.1Hz,1H,D2O exchangeable),4.21–4.01(m,1H),3.80–3.64(m,1H),3.59–3.38(m,2H),3.39(s,2H),2.13–1.77(m,4H),1.07–0.83(m,4H); MS(ES+):340.5(M+1),362.5(M+Na).

[0523] Plan 27

[0524]

[0525] Preparation of N-(1-cyclopropyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (27a)

[0526] Compound 27a was prepared from 2-chloro-N-(1-cyclopropyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (26b) (70 mg, 0.26 mmol), 2-(pyrrolidin-2-yl)pyridine (113 mg, 0.76 mmol) and DIPEA (0.13 mL, 0.76 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-cyclopropyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (27a) (48 mg, 51% yield) was obtained as a white solid; 1H NMR (300 MHz, DMSO-d6) δ10.19 (s, 1H, D2O exchangeable), 8.59 (s, 1H), 7.78–7.60 (m, 1H), 7.52–7.43 (m, 1H), 7.41–7.32 (m, 1H), 7.29–7.11 (m, 2H), 7.09–6.99 (m, 1H), 6.93–6.70 (m, 1H), 6.46–6.26 (m ,1H),5.43–5.21(m,1H),3.89–3.70(m,1H),3.42(s,1H),3.37–3.21(m,1H),2.47–2.29(m,1H) ,2.12–1.68(m,3H),1.09–0.87(m,3H),0.88–0.71(m,1H); MS(ES+):387.5(M+1),409.5(M+Na).

[0527] Plan 28

[0528]

[0529] Preparation of (S)-(1-(4-((1-cyclohexyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (28c)

[0530] Step-1: Preparation of 2-chloro-N-(1-cyclohexyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (28b)

[0531] Compound 28b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (376 mg, 2.0 mmol) in 2-propanol (10 mL) using DIPEA (1.05 mL, 6.0 mmol) and 1-cyclohexyl-1H-imidazol-4-amine hydrochloride (28a) (572 mg, 2.4 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-cyclohexyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (28b) (381 mg, 60% yield) as a light off-white solid; 1 H NMR (300MHz, DMSO-d6) δ11.68(s,1H),8.76(s,1H),7.86(dd,J=2.6,1.5Hz,1H),7. 78(d,J=1.7Hz,1H),7.36(s,1H),6.79(dd,J=4.5,2.6Hz,1H),4.28(ddd,J=11.7,7 .9,3.8Hz,1H),2.10(d,J=11.9Hz,2H),1.85(d,J=13.3Hz,2H),1.72(dt,J=14.9,1 1.6Hz, 3H), 1.40 (q, J = 12.7Hz, 2H), 1.24 (t, J = 12.5Hz, 1H); MS (ES+): 317.3 (M+1).

[0532] Step-2: Preparation of (S)-(1-(4-((1-cyclohexyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (28c)

[0533] Compound 28c was prepared from 2-chloro-N-(1-cyclohexyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (28b) (100 mg, 0.32 mmol), (S)-pyrrolidin-2-ylmethanol (160 mg, 1.56 mmol) and DIPEA (0.17 mL, 0.95 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-cyclohexyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (28c) (25 mg, 21% yield) was obtained as a light off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 10.31 (s, 1H, D2O exchangeable), 7.66–7.51 (m, 2H), 7.43–7.28 (m, 1H), 7.18–7.01 (m, 1H), 6.45–6.22 (m, 1H), 4.93–4.76 (m, 1H, D2O exchangeable), 4.20–4.07 (m, 1H), 4.07–3.92 (m,1H),3.83–3.65(m,1H),3.54–3.20(m,3H),2.13–1.84(m,6H),1.89–1.70(m,4H),1.72– 1.54(m,1H),1.47–1.12(m,3H); MS(ES+):382.5(M+1),404.5(M+Na); MS(ES-):380.4(M-1).

[0534] Plan 29

[0535]

[0536] Preparation of N-(1-cyclohexyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (29a)

[0537] Compound 29a was prepared from 2-chloro-N-(1-cyclohexyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (28b) (100 mg, 0.32 mmol), 2-(pyrrolidin-2-yl)pyridine (140 mg, 0.95 mmol) and DIPEA (0.17 mL, 0.95 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-cyclohexyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (29a) (47 mg, 35% yield) was obtained as a white solid; 1H NMR (300 MHz, DMSO-d6) δ 10.25 (s, 1H, D2O exchangeable), 8.64–8.52 (m, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.49 (d, J = 1.5 Hz, 1H), 7.38 (s, 1H), 7.26–7.21 (m, 1H), 7.19 (d, J = 7.9 Hz, 1H), 7.08 (dd, J = 4.4, 1.7 Hz, 1H), 6.91–6.83 (m, 1H), 6 .36(dd,J=4.4,2.5Hz,1H),5.33(d,J=8.1Hz,1H),3.87–3.70(m,2H),3.66–3.50(m,1H),2.42–2.28(m,1H),2.1 5–2.03(m,1H),2.03–1.78(m,6H),1.81–1.64(m,2H),1.67–1.51(m,1H),1.51–1.37(m,2H),1.37–1.15(m,1H). MS(ES+):429.6(M+1),451.6(M+Na).

[0538] Plan 30

[0539]

[0540] Preparation of N-(1-cyclopropyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (30a)

[0541] Compound 30a was prepared from 2-chloro-N-(1-cyclopropyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (26b) (100 mg, 0.36 mmol), 2-phenylpyrrolidine (161 mg, 1.09 mmol) and DIPEA (0.19 mL, 1.09 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-cyclopropyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (30a) (74 mg, 53% yield) was obtained as a light off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 10.36 (s, 1H, D2O exchangeable), 7.89 (s, 1H), 7.50–7.39 (m, 1H), 7.36–7.27 (m, 2H), 7.26 (d, J = 7.5 Hz, 2H), 7.23–7.16 (m, 1H), 7.08–6.90 (m, 2H), 6.40 (dd, J = 4.4, 2.4 Hz, 1H), 5.33 (d, J = 7.9 Hz, 1H), 4.00–3.29 (m, 3H), 2.41–2.21 (m, 1H), 2.05–1.73 (m, 3H), 1.11–0.76 (m, 4H). MS (ES+): 386.5 (M+1), 408.5 (M+Na).

[0542] Plan 31

[0543]

[0544] Preparation of (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (31c)

[0545] Step-1: Preparation of 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (31b)

[0546] Compound 31b was prepared from 2,4-dichlorothieno[2,3-d]pyrimidine (31a) (500 mg, 2.44 mmol; CAS# 18740-39-1) in 2-propanol (10 mL) using DIPEA (1.70 mL, 9.75 mmol) and 1-phenyl-1H-imidazol-4-amine, HCl (8a) (716 mg, 3.66 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (31b) (640 mg, 80% yield) as a light pink solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.06 (s, 1H, D2O exchangeable), 8.26 (d, J = 1.7 Hz, 1H), 8.04 (d, J = 5.6 Hz, 1H), 7.94 (d, J = 1.6 Hz, 1H), 7.71 (d, J = 5.9 Hz, 1H), 7.69-7.63 (m, 2H), 7.62–7.54 (m, 2H), 7.46-7.36 (m, 1H); MS (ES+): 328.2 (M+1), 350.2 (M+Na), (ES-): 326.2 (M-1).

[0547] Step-2: Preparation of (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (31c)

[0548] Compound 31c was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (31b) (100 mg, 0.31 mmol), (S)-pyrrolidin-2-ylmethanol (93 mg, 0.92 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (31c) (95 mg, 79% yield) was obtained as a light brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.16 (s, 1H, D2O exchangeable), 8.22 (s, 1H), 7.99 (d, J = 1.7 Hz, 1H), 7.89-7.59 (m, 2H), 7.60-7.42 (m, 3H), 7.35 (t, J = 7.3 Hz, 1H), 7.03 (d, J = 6.0 Hz, 1H), 4.96 (s, 1H, D2O exchangeable), 4.46-4.00 (m, 1H), 3.95-3.36 (m, 4H), 2.17-1.82 (m, 4H); MS (ES+): 393.5 (M+1), 415.5 (M+Na), (ES-): 391.4 (M-1).

[0549] Plan 32

[0550]

[0551] Preparation of (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)quinazolin-2-yl)pyrrolidin-2-yl)methanol (32a)

[0552] Compound 32a was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)quinazolin-4-amine (24a) (100 mg, 0.31 mmol), (S)-pyrrolidin-2-ylmethanol (94 mg, 0.93 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-phenyl-1H-imidazol-4-yl)amino)quinazolin-2-yl)pyrrolidin-2-yl)methanol (32a) (75 mg, 62% yield) was obtained as a light brown solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.49-10.15 (m, 1H, D2O exchangeable), 8.48 (d, J = 8.2 Hz, 1H), 8.25 (s, 1H), 8.07 (s, 1H), 7.93-7.63 (m, 3H), 7.61-7.43 (m, 2H), 7.43-7.24 (m, 2H), 7.0 9 (t, J = 7.5 Hz, 1H), 5.16-4.88 (m, 1H, D2O exchangeable), 4.49-4.14 (m, 1H), 3.93-3.56 (m, 3H), 3.54-3.36 (m, 1H), 2.19-1.79 (m, 4H); MS (ES+): 387.4 (M+1), (ES-): 385.3 (M-1).

[0553] Plan 33

[0554]

[0555] Preparation of N-(1-phenyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (33a)

[0556] Compound 33a was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (14a) (100 mg, 0.32 mmol), 2-(pyrrolidin-2-yl)pyridine hydrochloride (148 mg, 0.8 mmol) and DIPEA (0.22 mL, 1.28 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-phenyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (33a) (61 mg, 45% yield) was obtained as a light brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.03 (s, 1H, D2O exchangeable), 8.26 (s, 1H), 8.17-7.90 (m, 2H), 7.80-7.45 (m, 5H), 7.39 (p, J = 8.5, 4.2 Hz, 1H), 7.35-7.18 (m, 1H), 7.11 (d, J = 7.7 Hz, 2H),6.77(s,1H),5.39(s,1H),4.01-3.82(m,1H),3.79-3.54(m,1H),2.45-2.28( m,1H),2.11-1.88(m,2H),1.88-1.71(m,1H); MS(ES+):424.5(M+1),446.5(M+Na).

[0557] Plan 34

[0558]

[0559] Preparation of N-(1-methyl-1H-imidazol-4-yl)-2-(4-methylpiperazin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (34a)

[0560] Compound 34a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 1-methylpiperazine (0.13 mL, 1.21 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-methyl-1H-imidazol-4-yl)-2-(4-methylpiperazin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (34a) (37 mg, 30% yield) was obtained as an off-white solid; 1 HNMR (300 MHz, DMSO-d6) δ10.32 (s, 1H, D2O exchangeable), 7.49 (d, J = 1.4 Hz, 1H), 7.37 (t, J = 2.1 Hz, 1H), 7.30 (d, J = 1.6 Hz, 1H), 7.11 (s, 1H), 6.41 (dd, J = 4.5, 2.5 Hz, 1H), 3.69 (s, 3H), 3.55 (t, J = 4.9 Hz, 4H), 2.41 (q, J = 5.0 Hz, 4H), 2.22 (s, 3H); MS (ES+): 313.4 (M+1), 325.4 (M+Na).

[0561] Plan 35

[0562]

[0563] Preparation of 2-(4-methylpiperazin-1-yl)-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (35a)

[0564] Compound 35a was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (8b) (100 mg, 0.32 mmol), 1-methylpiperazine (0.11 mL, 0.97 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, 2-(4-methylpiperazin-1-yl)-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (35a) (16 mg, 13% yield) was obtained as a brown solid; 1HNMR (300 MHz, DMSO-d6) δ 10.59 (s, 1H, D2O exchangeable), 8.23 ​​(d, J = 1.6 Hz, 1H), 7.83 (d, J = 1.6 Hz, 1H), 7.63 (dd, J = 8.5, 1.5 Hz, 2H), 7.56 (dd, J = 8.7, 7.1 Hz, 2H), 7.45-7.39 (m, 1H), 7.39-7.34 (m, 1H), 7.16 (d, J = 4.3 Hz, 1H), 6.45 (dd, J = 4.4, 2.5 Hz, 1H), 3.66-3.52 (m, 4H), 2.50-2.36 (m, 4H), 2.23 (s, 3H); MS (ES+): 375.5 (M+1).

[0565] Plan 36

[0566]

[0567] Preparation of (S)-(1-(4-((1-(2-fluorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (36c)

[0568] Step-1: Preparation of 2-chloro-N-(1-(2-fluorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (36b)

[0569] Compound 36b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (260 mg, 1.38 mmol) in 2-propanol (20 mL) using DIPEA (0.73 mL, 4.15 mmol) and 1-(2-fluorophenyl)-1H-imidazol-4-amine hydrochloride (36a) (450 mg, 1.8 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(2-fluorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (36b) (125 mg, 28% yield) as a light off-white solid; 1 HNMR (300 MHz, DMSO-d6) δ 11.40 (s, 1H, D2O exchangeable), 8.08 (t, J = 1.5 Hz, 1H), 7.83 (t, J = 1.9 Hz, 1H), 7.77 (dd, J = 2.6, 1.5 Hz, 2H), 7.73 (td, J = 7.9, 1.6 Hz, 1H), 7.59–7.46 (m, 2H), 7.40 (ddd, J = 9.1, 6.0, 2.0 Hz, 2H); 19F NMR (282MHz, DMSO-d6) δ-125.09; MS (ES+): 329.3 (M+1); MS (ES-): 363.4 (M+Cl).

[0570] Step-2: Preparation of (S)-(1-(4-((1-(2-fluorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (36c)

[0571] Compound 36c was prepared from 2-chloro-N-(1-(2-fluorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (36b) (70 mg, 0.21 mmol), (S)-pyrrolidin-2-ylmethanol (108 mg, 1.07 mmol) and DIPEA (0.11 mL, 0.64 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(2-fluorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (36c) (45 mg, 54% yield) was obtained as a light yellow solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.56 (s, 1H, D2O exchangeable), 8.02 (t, J = 1.8 Hz, 1H), 7.87 (t, J = 1.7 Hz, 1H), 7.76 (td, J = 7.9, 1.7 Hz, 1H), 7.55–7.41 (m, 2H), 7.40–7.31 (m, 2H), 7.15 (dd, J = 4.5,1.7 Hz,1H),6.39(dd,J=4.4,2.4 Hz,1H),4.74(t,J=5.2 Hz,1H,D2O exchangeable),4.20–4.04(m,1H),3.72–3.62(m,1H),3.54–3.44(m,1H),3.46–3.26(m,2H),2.08–1.79(m,4H); 19 F NMR (282MHz, DMSO-d6) δ-125.10; MS (ES+): 394.5 (M+1); 416.5 (M+Na); MS (ES-): 392.5 (M-1), 428.5 (M+Cl).

[0572] Plan 37

[0573]

[0574] Preparation of N-(1-cyclobutyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (37c)

[0575] Step-1: Preparation of 2-chloro-N-(1-cyclobutyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (37b)

[0576] Compound 37b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (350 mg, 1.86 mmol) in 2-propanol (20 mL) using DIPEA (0.98 mL, 5.58 mmol) and 1-cyclobutyl-1H-imidazol-4-amine hydrochloride (37a) (420 mg, 2.42 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-cyclobutyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (37b) (348 mg, 65% yield) as a slightly yellow solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.16 (s, 1H, D2O exchangeable), 7.83–7.62 (m, 2H), 7.53 (d, J = 1.6 Hz, 1H), 7.35 (dd, J = 4.5, 1.6 Hz, 1H), 6.68 (dd, J = 4.4, 2.6 Hz, 1H), 4.88–4.61 (m, 1H), 2.55–2.19 (m, 4H), 1.96–1.64 (m, 2H); MS (ES+): 289.3 (M+1), 311.3 (M+Na); MS (ES-): 287.3 (M-1).

[0577] Step-2: Preparation of N-(1-cyclobutyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (37c)

[0578] Compound 37c was prepared from 2-chloro-N-(1-cyclobutyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (37b) (70 mg, 0.24 mmol), 2-(pyrrolidin-2-yl)pyridine (108 mg, 0.73 mmol) and DIPEA (0.13 mL, 0.73 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-cyclobutyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (37c) (65 mg, 67% yield) was obtained as a light yellow solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.27 (s, 1H, D2O exchangeable), 8.59 (d, J = 4.8 Hz, 1H), 7.67 (t, J = 7.7 Hz, 1H), 7.56 (s, 1H), 7.38 (s, 1H), 7.29–7.12 (m, 2H), 7.08 (d, J = 4.4 Hz, 1H), 7.05–6.93 (m, 1H), 6.42–6. 30(m,1H),5.35(d,J=8.2Hz,1H),4.55(q,J=8.6Hz,1H),3.90–3.75(m,1H),3.71–3.54(m,1H), 2.45–2.26(m,4H),2.26–2.09(m,1H),2.12–1.99(m,1H),2.02–1.88(m,1H),1.89–1.69(m,3H). MS(ES+): 401.5(M+1); 423.5(M+Na).

[0579] Plan 38

[0580]

[0581] Preparation of (S)-(1-(4-((1-(quinolin-3-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (38c)

[0582] Step-1: Preparation of 2-chloro-N-(1-(quinolin-3-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (38b)

[0583] Compound 38b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (384 mg, 2.04 mmol) in 2-propanol (20 mL) using DIPEA (1.07 mL, 6.12 mmol) and 11-(quinolin-3-yl)-1H-imidazol-4-amine hydrochloride (38a) (730 mg, 2.96 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(quinolin-3-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (38b) (264 mg, 36% yield) as a light off-white solid; 1 HNMR (300MHz, DMSO-d6) δ11.41(s,1H),9.30(d,J=2.7Hz,1H),8.68(d,J=2.6Hz,1H),8.47(d,J=1.6Hz,1H),8. 16-8.06(m,3H),7.88-7.76(m,2H),7.71(t,J=7.4Hz,1H),7.42(d,J=4.3Hz,1H),6.74(dd,J=4.5,2.6Hz,1H); 1 H NMR (300MHz, DMSO-d6 / D2O) δ9.24(d,J=2.5Hz,1H),8.63(d,J=2.6Hz,1H),8.41(s,1H),8.16-8.00(m,3H),7.80(t,J=7.7Hz,1H),7.75(d, J=2.0Hz, 1H), 7.69 (t, J=7.5Hz, 1H), 7.36 (s, 1H), 6.72 (dd, J=4.4, 2.5Hz, 1H); MS (ES+): 362.3 (M+1), 384.3 (M+Na); MS (ES-): 360.2 (M-1).

[0584] Step-2: Preparation of (S)-(1-(4-((1-(quinolin-3-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (38c)

[0585] Compound 38c was prepared from 2-chloro-N-(1-(quinolin-3-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (38b) (100 mg, 0.28 mmol), (S)-pyrrolidin-2-ylmethanol (140 mg, 1.38 mmol) and DIPEA (0.15 mL, 0.83 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(quinolin-3-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (38c) (66 mg, 56% yield) was obtained as a yellow solid; 1 HNMR (300 MHz, DMSO-d6) δ10.63 (s, 1H, D2O exchangeable), 9.42 (d, J = 2.7 Hz, 1H), 8.81 (d, J = 2.6 Hz, 1H), 8.53 (d, J = 1.5 Hz, 1H), 8.15 (d, J = 1.6 Hz, 1H), 8.12–8.00 (m, 2H), 7.79 (ddd, J = 8.4, 6.9, 1.6 Hz, 1H), 7.69 (td, J = 7.5, 6.9, 1.3 Hz, 1H), 7.41 (dd, J = 2.4, 1.7 Hz, 1H), 7.18 (dd, J = 4.4, 1.7 Hz, 1H), 6.41 (dd, J = 4.5, 2.4 Hz, 1H), 5.28–5.16 (m, 1H, D2O exchangeable), 4.37–4.18 (m, 1H), 3.93–3.79 (m, 1H), 3.56–3.40 (m, 1H), 3.45–3.20 (m, 2H), 2.21–1.72 (m, 4H). MS (ES+): 427.5 (M+1); 449.5 (M+Na).

[0586] Plan 39

[0587]

[0588] Preparation of (S)-(1-(4-((1-(pyridin-3-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (39c)

[0589] Step-1: Preparation of 2-chloro-N-(1-(pyridin-3-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (39b)

[0590] Compound 39b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (500 mg, 2.66 mmol) in 2-propanol (20 mL) using DIPEA (1.39 mL, 7.98 mmol) and 1-(pyridin-3-yl)-1H-imidazol-4-amine (39a) (511 mg, 3.19 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(pyridin-3-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (39b) (728 mg, 88% yield) as a brown solid; 1 HNMR (300 MHz, DMSO-d6) δ 11.38 (s, 1H, D2O exchangeable), 8.96 (d, J = 2.7 Hz, 1H), 8.61 (dd, J = 4.7, 1.4 Hz, 1H), 8.35 (d, J = 1.6 Hz, 1H), 8.13 (ddd, J = 8.3, 2.8, 1.4 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.78 (dd, J = 2.6, 1.5 Hz, 1H), 7.61 (dd, J = 8.3, 4.7 Hz, 1H), 7.47–7.35 (m, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H); MS (ES+): 312.3 (M+1); MS (ES-): 310.4 (M-1).

[0591] Step-2: Preparation of (S)-(1-(4-((1-(pyridin-3-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (39c)

[0592] Compound 39c was prepared from 2-chloro-N-(1-(pyridin-3-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (39b) (100 mg, 0.32 mmol), (S)-pyrrolidin-2-ylmethanol (162 mg, 1.60 mmol) and DIPEA (0.17 mL, 0.96 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(pyridin-3-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (39c) (60 mg, 50% yield) was obtained as a brown solid;1 HNMR (300 MHz, DMSO-d6) δ 10.59 (s, 1H, D2O exchangeable), 9.04 (d, J = 2.7 Hz, 1H), 8.55 (dd, J = 4.7, 1.3 Hz, 1H), 8.35 (d, J = 1.5 Hz, 1H), 8.25–8.14 (m, 1H), 8.01 (d, J = 1.6 Hz, 1H), 7.54 (dd, J = 8.3, 4.7 Hz, 1H), 7.40 (t, J = 2.1 Hz, 1H), 7.16 (dd, J = 4.4, 1.7 Hz, 1H), 6.40 (dd, J = 4.4, 2.5 Hz, 1H), 5.13–4.74 (m, 1H, D2O exchangeable), 4.28–4.13 (m, 1H), 3.77 (dd, J = 10.1, 3.4 Hz, 1H), 3.55–3.44 (m, 1H), 3.46–3.25 (m, 2H), 2.18–1.77 (m, 4H). MS (ES+): 377.5 (M+1); 399.5 (M+Na).

[0593] Plan 40

[0594]

[0595] Preparation of N-(1-phenyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (40a)

[0596] Compound 40a was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (14a) (100 mg, 0.32 mmol), 2-phenylpyrrolidine (118 mg, 0.8 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-phenyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)furo[3,2-d]pyrimidin-4-amine (40a) (18 mg, 13% yield) was obtained as a light yellow solid; 1HNMR (300 MHz, DMSO-d6) δ 10.04 (s, 1H, D2O exchangeable), 8.19-7.83 (m, 2H), 7.66-7.50 (m, 2H), 7.54-7.25 (m, 2H), 7.26-7.14 (m, 3H), 7.16-7.00 (m, 4H), 6.74 (s, 1H), 5.41 (s, 1H), 3.99-3.57 (m, 2H), 2.40-2.24 (m, 1H), 1.98-1.63 (m, 3H); MS (ES+) 423.5 (M+1), 445.5 (M+Na).

[0597] Plan 41

[0598]

[0599] Preparation of (S)-(1-(7-methyl-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (41c)

[0600] Step-1: Preparation of 2-chloro-7-methyl-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (41b)

[0601] Compound 41b was prepared from 2,4-dichloro-7-methylthieno[3,2-d]pyrimidine (41a) (500 mg, 2.28 mmol; CAS# 35265-83-9) and DIPEA (1.59 mL, 9.13 mmol) in 2-propanol (10 mL) using 1-phenyl-1H-imidazol-4-amine, HCl (8a) (558 mg, 2.85 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-7-methyl-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (41b) (350 mg, 45% yield) as an off-white solid; 1 HNMR (300 MHz, DMSO-d6) δ10.72 (s, 1H, D2O exchangeable), 8.27 (d, J = 1.6 Hz, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.89 (s, 1H), 7.72-7.63 (m, 2H), 7.57 (dd, J = 8.6, 7.1 Hz, 2H), 7.46-7.36 (m, 1H), 2.31 (d, J = 1.2 Hz, 3H); MS (ES+): 342.3 (M+1), 364.3 (M+Na), (ES-): 340.3 (M-1).

[0602] Step-2: Preparation of (S)-(1-(7-methyl-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (41c)

[0603] Compound 41c was prepared from 2-chloro-7-methyl-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (41b) (100 mg, 0.29 mmol) and (S)-pyrrolidin-2-ylmethanol (89 mg, 0.88 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(7-methyl-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (41c) (82 mg, 69% yield) was obtained as an off-white solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.08 (s, 1H, D2O exchangeable), 8.20 (d, J = 1.5 Hz, 1H), 7.99 (d, J = 1.6 Hz, 1H), 7.71 (s, 2H), 7.57 (d, J = 1.3 Hz, 1H), 7.51 (t, J = 7.7 Hz, 2H), 7.35 (t, J = 7.4 Hz, 1H), 5. 65-4.81 (m, 1H, D2O exchangeable), 4.26 (s, 1H), 3.86-3.52 (m, 2H), 3.51-3.24 (m, 2H), 2.22 (d, J = 1.2 Hz, 3H), 2.11-1.81 (m, 4H); MS (ES+): 407.5 (M+1), 429.5 (M+Na), (ES-): 405.5 (M-1).

[0604] Plan 42

[0605]

[0606] Preparation of (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)-6-methylthieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (42b)

[0607] Step-1: Preparation of 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)-6-methylthieno[3,2-d]pyrimidin-4-amine (42a)

[0608] Compound 42a was prepared from 2,4-dichloro-6-methylthieno[3,2-d]pyrimidine (23a) (302 mg, 1.38 mmol) in 2-propanol (10 mL) using DIPEA (0.96 mL, 5.51 mmol) and 1-(4-fluorophenyl)-1H-imidazol-4-amine hydrochloride (25a) (368 mg, 1.72 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)-6-methylthieno[3,2-d]pyrimidin-4-amine (42a) (100 mg, 21% yield) as a dark brown solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.74 (s, 1H, D2O exchangeable), 8.22 (d, J = 1.6 Hz, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.76-7.67 (m, 2H), 7.48-7.37 (m, 2H), 7.13 (d, J = 1.3 Hz, 1H), 2.60 (s, 3H); 19 F NMR (282MHz, DMSO-d6) δ-115.30; MS (ES+): 382.4 (M+Na), (ES-): 358.3 (M-1).

[0609] Step-2: Preparation of (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)-6-methylthieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (42b)

[0610] Compound 42b was prepared from 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)-6-methylthieno[3,2-d]pyrimidin-4-amine (42a) (90 mg, 0.25 mmol) and (S)-pyrrolidin-2-ylmethanol (89 mg, 0.88 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)-6-methylthieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (42b) (27 mg, 25% yield) was obtained as a brown solid; 1HNMR (300 MHz, DMSO-d6) δ 9.95 (s, 1H, D2O exchangeable), 8.14 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.7 Hz, 1H), 7.86-7.62 (m, 2H), 7.35 (t, J = 8.6 Hz, 2H), 6.83 (d, J = 1.3 Hz, 1H), 5.06 (s, 1H, D2O exchangeable), 4.37-4.01 (m, 1H), 3.89-3.68 (m, 1H), 3.68-3.44 (m, 3H), 2.52 (d, J = 1.1 Hz, 3H), 2.16-1.72 (m, 4H); 19 F NMR (282MHz, DMSO-d6) δ-73.43; MS (ES+): 425.4 (M+1), 447.4 (M+Na), (ES-): 423.4 (M-1).

[0611] Plan 43

[0612]

[0613] Preparation of (S)-(1-(4-((1-cyclobutyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (43a)

[0614] Compound 43a was prepared from 2-chloro-N-(1-cyclobutyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (37b) (100 mg, 0.35 mmol) and (S)-pyrrolidin-2-ylmethanol (175 mg, 1.73 mmol) and DIPEA (0.18 mL, 1.04 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography (silica gel 24 g, eluting with CMA-80 / chloroform 0-40%), (S)-(1-(4-((1-cyclobutyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (43a) (67 mg, 55% yield) was obtained as a yellow solid; 1HNMR (300 MHz, DMSO-d6) δ10.33 (s, 1H, D2O exchangeable), 7.67–7.56 (m, 2H), 7.42–7.29 (m, 1H), 7.09 (dd, J = 4.4, 1.7 Hz, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H), 4.97–4.76 (m, 1H, D2 O exchangeable), 4.69 (p, J = 8.5 Hz, 1H), 4.29–4.05 (m, 1H), 3.84–3.67 (m, 1H), 3.55–3.42 (m, 1H), 3.41–3.19 (m, 2H), 2.52–2.28 (m, 4H), 2.12–1.83 (m, 4H), 1.83–1.62 (m, 2H); 19 F NMR (282MHz, DMSO) δ-73.48; MS (ES+): 354.5 (M+1); 376.5 (M+Na); MS (ES-): 352.4 (M-1).

[0615] Plan 44

[0616]

[0617] Preparation of (S)-(1-(4-((1-(3-fluorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (44c)

[0618] Step-1: Preparation of 2-chloro-N-(1-(3-fluorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (44b)

[0619] Compound 44b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (254 mg, 1.35 mmol) in 2-propanol (20 mL) using DIPEA (0.71 mL, 4.06 mmol) and 1-(3-fluorophenyl)-1H-imidazol-4-amine hydrochloride (44a) (440 mg, 1.76 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(3-fluorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (44b) (343 mg, 77% yield) as a light off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 11.35 (s, 1H, D2O exchangeable), 8.33 (d, J = 1.6 Hz, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.78 (dd, J = 2.6, 1.5 Hz, 1H), 7.67 (dt, J = 10.1, 2.1 Hz, 1H), 7.63-7.57 (m, 1H), 7.55-7.49 (m, 1H), 7.44-7.37 (m, 1H), 7.30-7.20 (m, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H); MS (ES+): 329.3 (M+1), 351.3 (M+Na); MS (ES-): 327.3 (M-1).

[0620] Step-2: Preparation of (S)-(1-(4-((1-(3-fluorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (44c)

[0621] Compound 44c was prepared from 2-chloro-N-(1-(3-fluorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (44b) (100 mg, 0.3 mmol), (S)-pyrrolidin-2-ylmethanol (154 mg, 1.52 mmol) and DIPEA (0.16 mL, 0.91 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with 0.1% TFA in acetonitrile and 0.1% TFA in water], followed by conversion to the free base using NaHCO3, and then by flash chromatography [silica gel (24 g), eluting with CMA-80 / chloroform, 0-40%], (S)-(1-(4-((1-(3-fluorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (44c) (30 mg, 25% yield) was obtained as a white solid; 1H NMR (300 MHz, DMSO-d6) δ 10.54 (s, 1H, D2O exchangeable), 8.33 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.81–7.70 (m, 1H), 7.69–7.60 (m, 1H), 7.58–7.46 (m, 1H), 7.40 (dd, J = 2.4, 1.7 Hz, 1 H), 7.23–7.13 (m, 2H), 6.39 (dd, J = 4.4, 2.5 Hz, 1H), 5.07–4.90 (m, 1H, D2O exchangeable), 4.26–4.12 (m, 1H), 3.85–3.67 (m, 1H), 3.56–3.43 (m, 1H), 3.44–3.22 (m, 2H), 2.22–1.75 (m, 4H); 19 F NMR (282MHz, DMSO) δ-110.92; MS (ES+): 394.5 (M+1); 416.5 (M+Na); MS (ES-): 392.4 (M-1).

[0622] Plan 45

[0623]

[0624] Preparation of 2-(2,6-difluoro-4-methoxyphenyl)-1-(4-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl)ethanone (45d)

[0625] Step-1: Preparation of tert-butyl 4-(2-(2,6-difluoro-4-methoxyphenyl)acetyl)piperazine-1-carboxylate (45b)

[0626] To a stirred suspension of tert-butyl piperazine-1-carboxylate (1 g, 5.37 mmol), 2-(2,6-difluoro-4-methoxyphenyl)acetic acid (45a) (1.09 g, 5.37 mmol; CAS# 886498-98-2), EDC (1.24 g, 6.44 mmol) in acetonitrile (15 mL) and DMF (1 mL) were added TEA (2.25 mL, 16.11 mmol) and DMAP (33 mg, 0.27 mmol) and stirred at room temperature for 16 h. The reaction was concentrated to remove acetonitrile and diluted with ethyl acetate (100 mL), washed with 1N KHSO4 (2 x 20 mL), saturated sodium bicarbonate (2 x 20 mL), water (20 mL), brine (20 mL), dried and concentrated to afford tert-butyl 4-(2-(2,6-difluoro-4-methoxyphenyl)acetyl)piperazine-1-carboxylate (45b) (1.00 g, 50% yield) as a colorless solid; 1H NMR(300MHz,DMSO-d6)δ6.72(s,1H),6.69(d,J=1.4Hz,1H),3.77(s,3H),3.66(s,2H),3.57 (t, J=5.3Hz, 2H), 3.49-3.24 (m, 6H), 1.41 (s, 9H); MS (ES+): 393.5 (+Na) (ES-): 369.3 (M-1).

[0627] Step-2: Preparation of 2-(2,6-difluoro-4-methoxyphenyl)-1-(piperazin-1-yl)ethanone 2,2,2-trifluoroacetate (45c)

[0628] To a stirred solution of tert-butyl 4-(2-(2,6-difluoro-4-methoxyphenyl)acetyl)piperazine-1-carboxylate (45b) (0.95 g, 2.56 mmol) in dichloromethane (20 mL) was added TFA (1.98 mL, 25.6 mmol) and stirred at room temperature overnight. The reaction was concentrated in vacuo to afford 2-(2,6-difluoro-4-methoxyphenyl)-1-(piperazin-1-yl)ethanone 2,2,2-trifluoroacetate (45c) (800 mg, 81% yield) as an oil. 1 H NMR (300MHz, DMSO-d6) δ8.94 (s, 2H), 6.88-6.43 (m, 2H), 3.77 (s, 5H), 3.72 (s, 2H), 3.63 (d, J = 5.6Hz, 2H), 3.14 (d, J = 27.6Hz, 4H); 19 F NMR(282MHz, DMSO-d6)δ-74.66,-112.12--120.42(m); MS(ES+)271.3(M+1),293.3(M+Na),541.6(2M+1),563.5(2M+Na).

[0629] Step-3: Preparation of 2-(2,6-difluoro-4-methoxyphenyl)-1-(4-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl)ethanone (45d)

[0630] Compound 45d was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (31b) (100 mg, 0.31 mmol), 2-(2,6-difluoro-4-methoxyphenyl)-1-(piperazin-1-yl)ethanone 2,2,2-trifluoroacetate (45c) (371 mg, 0.97 mmol) and DIPEA (0.28 mL, 1.61 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] followed by conversion to the free base using NaHCO3, 2-(2,6-difluoro-4-methoxyphenyl)-1-(4-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl)ethanone (45d) (43 mg, 24% yield) was obtained as an off-white solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.30 (s, 1H, D2O exchangeable), 8.29 (d, J = 1.7 Hz, 1H), 7.87 (d, J = 1.7 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.70–7.64 (m, 2H), 7.57 (t, J = 7.9 Hz, 2H), 7.43–7.34 (m, 1H), 7.15 (d, J = 6.0 Hz, 1H), 6.71 (d, J = 9.5 Hz, 2H), 3.93–3.85 (m, 2H), 3.85–3.78 (m, 4H), 3.77 (s, 3H), 3.76–3.70 (m, 2H), 3.65–3.56 (m, 2H); 19 F NMR (282MHz, DMSO-d6) δ-113.98; MS (ES+): 562.6 (M+1), 584.6 (M+Na).

[0631] Plan 46

[0632]

[0633] Preparation of (S)-N-(1-cyclohexyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (46a)

[0634] Compound 46a was prepared from 2-chloro-N-(1-cyclohexyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (28b) (72 mg, 0.23 mmol), (S)-2-phenylpyrrolidine hydrochloride (50 mg, 0.27 mmol) and DIPEA (0.12 mL, 0.68 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-N-(1-cyclohexyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (46a) (13 mg, 13% yield) was obtained as a light off-white solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.42 (s, 1H, D2O exchangeable), 8.06 (s, 1H), 7.44 (s, 1H), 7.38–7.13 (m, 6H), 6.98 (dd, J = 4.5, 1.6 Hz, 1H), 6.42 (dd, J = 4.4, 2.5 Hz, 1H), 5.34 (d, J = 7.8 Hz,1H),3.99–3.81(m,1H),3.80–3.68(m,1H),3.66–3.49(m,1H),2.42–2.22(m,1H ),2.05–1.64(m,9H),1.62–1.32(m,3H),1.32–1.14(m,1H); MS(ES+):428.6(M+1).

[0635] Plan 47

[0636]

[0637] Preparation of (S)-1-(3-(4-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenyl)ethanone (47c)

[0638] Step-1: Preparation of 1-(3-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenyl)ethanone (47b)

[0639] Compound 47b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (185 mg, 1.0 mmol) in 2-propanol (20 mL) using DIPEA (0.52 mL, 2.96 mmol) and 1-(3-(4-amino-1H-imidazol-1-yl)phenyl)ethanone (47a) (238 mg, 1.18 mmol) according to the procedure reported in Scheme 1. This afforded 1-(3-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenyl)ethanone (47b) (282 mg, 81% yield) as a light off-white solid; 1 HNMR (300 MHz, DMSO-d6) δ11.37 (s, 1H, D2O exchangeable), 8.38 (d, J = 1.6 Hz, 1H), 8.14 (t, J = 1.9 Hz, 1H), 8.01–7.97 (m, 1H), 7.97–7.89 (m, 2H), 7.78 (dd, J = 2.6, 1.5 Hz, 1H), 7.72 (t, J = 7.9 Hz, 1H), 7.40 (d, J = 4.3 Hz, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H), 2.68 (s, 3H); MS (ES+): 353.3 (M+1); MS (ES-): 351.4 (M-1).

[0640] Step-2: Preparation of (S)-1-(3-(4-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenyl)ethanone (47c)

[0641] Compound 47c was prepared from 1-(3-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenyl)ethanone (47b) (100 mg, 0.28 mmol), (S)-pyrrolidin-2-ylmethanol (143 mg, 1.42 mmol) and DIPEA (0.15 mL, 0.85 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-1-(3-(4-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenyl)ethanone (47c) (39 mg, 33% yield) was obtained as a white solid; 1H NMR (300 MHz, DMSO-d6) δ 10.58 (s, 1H, D2O exchangeable), 8.38 (d, J = 1.5 Hz, 1H), 8.24–8.16 (m, 1H), 8.07 (d, J = 1.6 Hz, 1H), 8.06–7.98 (m, 1H), 7.98–7.84 (m, 1H), 7.65 (t, J = 7.9 Hz, 1H), 7.40 (dd, J = 2.4, 1.6 Hz, 1H), 7.15 (dd, J=4.5,1.6 Hz,1H),6.40(dd,J=4.4,2.5 Hz,1H),4.87(t,J=5.0 Hz,1H,D2O exchangeable),4.29–4.03(m,1H),3.84–3.70(m,1H),3.63–3.46(m,1H),3.47–3.22(m,2H),2.68(s,3H),2.10–1.85(m,4H); MS(ES+):418.5(M+1).

[0642] Plan 48

[0643]

[0644] Preparation of (S)-4-(4-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenol (48c)

[0645] Step-1: Preparation of 4-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenol (48b)

[0646] Compound 48b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (410 mg, 2.18 mmol) in 2-propanol (20 mL) using DIPEA (1.14 mL, 6.54 mmol) and 4-(4-amino-1H-imidazol-1-yl)phenol (458 mg, 2.61 mmol) (48a) (238 mg, 1.18 mmol) according to the procedure reported in Scheme 1. This gave 4-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenol (48b) (264 mg, 37% yield) as a slightly pink solid; 1H NMR (300MHz, DMSO-d6) δ11.34(s,1H),9.78(s,1H),8.04(d,J=1.6Hz,1H),7.77(d,J=1.6Hz,1H),7.77-7.74(m,1H),7.47 -7.35 (m, 3H), 6.94-6.86 (m, 2H), 6.71 (dd, J=4.5, 2.6Hz, 1H); MS (ES+): 327.3 (M+1); MS (ES-): 325.2 (M-1), 361.2 (M+Cl).

[0647] Step-2: Preparation of (S)-4-(4-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenol (48c)

[0648] Compound 48c was prepared from 4-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenol (48b) (100 mg, 0.31 mmol), (S)-pyrrolidin-2-ylmethanol (155 mg, 1.53 mmol) and DIPEA (0.16 mL, 0.92 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-4-(4-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)phenol (48c) (60 mg, 50% yield) was obtained as a white solid; 1HNMR (300 MHz, DMSO-d6) δ 10.46 (s, 1H, D2O exchangeable), 9.69 (s, 1H, D2O exchangeable), 8.02 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 1.6 Hz, 1H), 7.51 (d, J = 8.8 Hz, 2H), 7.38 (dd, J = 2.4, 1.6 Hz, 1H), 7.14 (dd, J = 4.4, 1.7 Hz, 1H), 6.85 (d, J =8.8Hz,2H),6.38(dd,J=4.4,2.4Hz,1H),4.85(t,J=5.0Hz,1H,D2O exchangeable),4.26–4.06(m,1H),3.81–3.65(m,1H),3.55–3.42(m,1H),3.45–3.23(m,2H),2.11–1.81(m,4H); MS(ES+):392.5(M+1);414.5(M+Na); C 20 H 21 Analytical calculated values ​​for N7O2: C, 61.37; H, 5.41; N, 25.05; found values: C, 60.88; H, 5.54; N, 24.96.

[0649] Plan 49

[0650]

[0651] Preparation of (S)-(1-(4-((1-(4-chlorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (49c)

[0652] Step-1: Preparation of 2-chloro-N-(1-(4-chlorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (49b)

[0653] Compound 49b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (375 mg, 2.0 mmol) in 2-propanol (20 mL) using DIPEA (1.05 mL, 5.99 mmol) and 1-(4-chlorophenyl)-1H-imidazol-4-amine (49a) (464 mg, 2.396 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(4-chlorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (49b) (264 mg, 38% yield) as a light off-white solid; 1H NMR (300MHz, DMSO-d6) δ11.36(s,1H),8.29(d,J=1.6Hz,1H),7.91(d,J=1.7Hz,1H),7.78(dd,J=2.6,1 .5Hz,1H),7.74-7.68(m,2H),7.66-7.60(m,2H),7.40(d,J=4.5Hz,1H),6.72(dd,J=4.5,2.6Hz,1H); 1H NMR (300MHz, DMSO-d6 / D2O) δ8.19(d,J=1.7Hz,1H),7.87(d,J=1.6Hz,1H),7.73(dd,J=2.6,1.5Hz,1H),7.70-7. 64(m,2H),7.62-7.56(m,2H),7.32(d,J=4.3Hz,1H),6.71(dd,J=4.5,2.6Hz,1H); MS(ES+):345.3,347.3(M+1).

[0654] Step-2: Preparation of (S)-(1-(4-((1-(4-chlorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (49c)

[0655] Compound 49c was prepared from 2-chloro-N-(1-(4-chlorophenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (49b) (100 mg, 0.29 mmol), (S)-pyrrolidin-2-ylmethanol (147 mg, 1.45 mmol) and DIPEA (0.15 mL, 0.87 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(4-chlorophenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (49c) (55 mg, 46% yield) was obtained as a white solid; 1HNMR (300 MHz, DMSO-d6) δ10.55 (s, 1H, D2O exchangeable), 8.27 (d, J = 1.5 Hz, 1H), 7.96 (d, J = 1.6 Hz, 1H), 7.86–7.77 (m, 2H), 7.63–7.50 (m, 2H), 7.39 (dd, J = 2.4, 1.6 Hz, 1H), 7.15 (dd, J = 4.5, 1.7 Hz, 1H), 6.39 (dd, J = 4.4, 2.5 Hz, 1H), 5.03–4.80 (m, 1H, D2O exchangeable), 4.31–4.07 (m, 1H), 3.87–3.67 (m, 1H), 3.53–3.35 (m, 1H), 3.42–3.23 (m, 2H), 2.11–1.83 (m, 4H). MS (ES+): 410.4 (M+1).

[0656] Plan 50

[0657]

[0658] Preparation of (S)-(1-(4-((1-cyclopentyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (50c)

[0659] Step-1: Preparation of 2-chloro-N-(1-cyclopentyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (50b)

[0660] Compound 50b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (392 mg, 2.08 mmol) in 2-propanol (20 mL) using DIPEA (1.09 mL, 6.25 mmol) and 1-cyclopentyl-1H-imidazol-4-amine hydrochloride (50a) (469 mg, 2.499 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-N-(1-cyclopentyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (50b) (397 mg, 63% yield) as a light yellow solid; 1H NMR (300 MHz, DMSO-d6) δ 11.17 (s, 1H, D2O exchangeable), 7.72 (dd, J = 2.6, 1.5 Hz, 1H), 7.68 (d, J = 1.5 Hz, 1H), 7.50 (d, J = 1.6 Hz, 1H), 7.35 (dd, J = 4.5, 1.5 Hz, 1H), 6.68 (dd, J = 4.5, 2.6 Hz, 1H), 4.69–4.50 (m, 1H), 2.24–2.05 (m, 2H), 1.92–1.57 (m, 6H). MS (ES+): 303.3 (M+1), 325.3 (M+Na); MS (ES-): 301.3 (M-1)

[0661] Step-2: Preparation of (S)-(1-(4-((1-cyclopentyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (50c)

[0662] Compound 50c was prepared from 2-chloro-N-(1-cyclopentyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (50b) (100 mg, 0.33 mmol), (S)-pyrrolidin-2-ylmethanol (33 mg, 0.33 mmol) and DIPEA (0.17 mL, 0.99 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-cyclopentyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (50c) (80 mg, 66% yield) was obtained; 1HNMR (300 MHz, DMSO-d6) δ 10.32 (s, 1H, D2O exchangeable), 7.59 (d, J = 1.5 Hz, 1H), 7.54 (d, J = 1.6 Hz, 1H), 7.35 (dd, J = 2.4, 1.7 Hz, 1H), 7.09 (dd, J = 4.6, 1.7 Hz, 1H), 6.35 (dd, J = 4.4, 2.4 Hz, 1H), 4.7 8 (t, J = 5.1 Hz, 1H, D2O exchangeable), 4.52 (p, J = 7.3 Hz, 1H), 4.20–4.04 (m, 1H), 3.77–3.64 (m, 1H), 3.55–3.44 (m, 1H), 3.44–3.28 (m, 2H), 2.22–1.97 (m, 2H), 1.99–1.70 (m, 9H), 1.73–1.52 (m, 1H). MS (ES+): 368.5 (M+1); 370.5 (M+Na).

[0663] Plan 51

[0664]

[0665] Preparation of 2-(2,6-difluoro-4-methoxyphenyl)-1-(4-(4-((1-methyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)piperazin-1-yl)ethanone (51a)

[0666] Compound 51a was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 2-(2,6-difluoro-4-methoxyphenyl)-1-(piperazin-1-yl)ethanone 2,2,2-trifluoroacetate (45c) (170 mg, 0.44 mmol) and DIPEA (0.21 mL, 1.21 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, 2-(2,6-difluoro-4-methoxyphenyl)-1-(4-(4-((1-methyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)piperazin-1-yl)ethanone (51a) (25 mg, 13% yield) was obtained as a light brown solid; 1H NMR (300 MHz, DMSO-d6) δ 10.54 (s, 1H, D2O exchangeable), 8.10 (s, 1H), 7.54-7.40 (m, 2H), 7.11-6.97 (m, 1H), 6.72 (d, J = 9.4 Hz, 2H), 6.49 (dd, J = 4.5, 2.4 Hz, 1H), 3.79 (s, 3H), 3.77 (s, 4H), 3.71 (s, 3H), 3.64 (d, J = 4.6 Hz, 2H), 3.57 (s, 4H); 19 F NMR (282MHz, DMSO-d6) δ-114.02; MS (ES+): 483.5 (M+1), 505.5 (M+Na).

[0667] Plan 52

[0668]

[0669] Preparation of 2-(2,6-difluoro-4-methoxyphenyl)-1-(4-(4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)piperazin-1-yl)ethanone (52a)

[0670] Compound 52a was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (8b) (100 mg, 0.32 mmol), 2-(2,6-difluoro-4-methoxyphenyl)-1-(piperazin-1-yl)ethanone 2,2,2-trifluoroacetate (45c) (247 mg, 0.64 mmol) and DIPEA (0.22 mL, 1.28 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, 2-(2,6-difluoro-4-methoxyphenyl)-1-(4-(4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)piperazin-1-yl)ethanone (52a) (25 mg, 14% yield) was obtained as a light brown solid; 1H NMR (300 MHz, DMSO-d6) δ 10.63 (s, 1H, D2O exchangeable), 8.24 (d, J = 1.6 Hz, 1H), 7.85 (d, J = 1.6 Hz, 1H), 7.72-7.64 (m, 2H), 7.57 (dd, J = 8.6, 7.2 Hz, 2H), 7.47 (dd, J = 2.5, 1.7 Hz, 1H), 7.43-7.34 (m, 1H), 7.19 (s, 1H), 6.72 (d, J = 9.5 Hz, 2H), 6.47 (dd, J = 4.5, 2.5 Hz, 1H), 3.77 (s, 3H), 3.76-3.65 (m, 6H), 3.64-3.58 (m, 4H); 19 F NMR (282MHz, DMSO-d6) δ-114.00 (d, J=9.4Hz); MS (ES+): 545.6 (M+1), 567.6 (M+Na), (ES-): 543.5 (M-1).

[0671] Plan 53

[0672]

[0673] Preparation of 1-(4-(4-((1-methyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)piperazin-1-yl)-2-phenylethanone (53b)

[0674] Compound 53b was prepared from 2-chloro-N-(1-methyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (4b) (100 mg, 0.4 mmol), 2-phenyl-1-(piperazin-1-yl)ethanone, 2,2-trifluoroacetate (53a) (256 mg, 0.80 mmol; prepared according to the procedure reported by Levy, Daniel E. et al., PCT Int. Appl., 2003 / 022214, March 20, 2003) and DIPEA (0.28 mL, 1.61 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, 1-(4-(4-(1-methyl-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)piperazin-1-yl)-2-phenylethanone (11 mg, 7% yield) was obtained as a brown solid; 1HNMR (300 MHz, DMSO-d6) δ 10.38 (s, 1H, D2O exchangeable), 7.50 (d, J = 1.4 Hz, 1H), 7.45-7.36 (m, 2H), 7.36-7.29 (m, 2H), 7.29-7.19 (m, 3H), 7.18-7.09 (m, 1H), 6.42 (dd, J = 4.4, 2.5 Hz, 1H), 3.78 (s, 2H), 3.70 (s, 3H), 3.67-3.59 (m, 4H), 3.60-3.43 (m, 4H); MS (ES+): 417.6 (M+1), 439.5 (M+Na), (ES-): 415.5 (M-1).

[0675] Plan 54

[0676]

[0677] Preparation of tert-butyl 4-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)piperazine-1-carboxylate (54a)

[0678] Compound 54a was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (16a) (100 mg, 0.31 mmol), tert-butyl piperazine-1-carboxylate (170 mg, 0.92 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, tert-butyl 4-(4-(1-phenyl-1H-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-2-yl)piperazine-1-carboxylate (54a) (92 mg, 63% yield) was obtained as an off-white solid; 1 HNMR (300MHz, DMSO-d6) δ10.10 (s, 1H), D2O exchangeable, 8.22 (d, J=1.5Hz, 1H), 7.97 (d, J= 5.4Hz,1H),7.85(d,J=1.7Hz,1H),7.68(d,J=1.4Hz,1H),7.65(dd,J=1.9,0.9Hz, 1H),7.55(dd,J=8.7,7.1Hz,2H),7.43-7.35(m,1H),7.12(d,J=5.4Hz,1H),3.85- 3.71(m,4H),3.50-3.38(m,4H),1.43(s,9H); MS(ES+):478.6(M+1),500.5(M+Na).

[0679] Plan 55

[0680]

[0681] Preparation of (S)-(1-(4-((1-(4-methoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (55c)

[0682] Step-1: Preparation of 2-chloro-N-(1-(4-methoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (55b)

[0683] Compound 55b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (423 mg, 2.25 mmol) in 2-propanol (20 mL) using DIPEA (1.18 mL, 6.75 mmol) and 1-(4-methoxyphenyl)-1H-imidazol-4-amine (55a) (511 mg, 2.70 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-N-(1-(4-methoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (55b) (635 mg, 83% yield) as a yellow solid; 1 HNMR (300MHz, DMSO-d6) δ11.33(s,1H),8.11(d,J=1.6Hz,1H),7.82(d,J=1.6Hz,1H),7.76(dd,J=2.6,1.5Hz,1H ),7.63-7.49(m,2H),7.40(dd,J=4.6,1.5Hz,1H),7.19-7.06(m,2H),6.71(dd,J=4.5,2.6Hz,1H),3.81(s,3H); 1 H NMR(300MHz,DMSO-d6-D2O)δ8.02(d,J=1.2Hz,1H),7.77(dd,J=1.6,0.8Hz,1H),7.74-7.67(m,1H),7 .56-7.47(m,2H),7.30(d,J=4.4Hz,1H),7.12-7.00(m,2H),6.70(dd,J=4.6,2.7Hz,1H),3.80(s,3H). MS(ES+): 341.3(M+1), 363.4(M+Na); MS(ES-): 339.3(M-1).

[0684] Step-2: Preparation of (S)-(1-(4-((1-(4-methoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (55c)

[0685] Compound 55c was prepared from 2-chloro-N-(1-(4-methoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (55b) (100 mg, 0.29 mmol), (S)-pyrrolidin-2-ylmethanol (148 mg, 1.47 mmol) and DIPEA (0.15 mL, 0.87 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(4-methoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (55c) (83 mg, 70% yield) was obtained as a white solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.49 (s, 1H, D2O exchangeable), 8.11 (d, J = 1.5 Hz, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.65 (d, J = 9.0 Hz, 2H), 7.38 (t, J = 2.0 Hz, 1H), 7.15 (dd, J = 4.5, 1.7 Hz, 1H), 7.04 (d, J = 9.0 Hz, 2H) ,6.39(dd,J=4.4,2.5Hz,1H),4.94–4.81(m,1H,D2O exchangeable),4.27–4.08(m,1H),3.80(s,3H),3.80–3.70(m,1H),3.56–3.43(m,1H),3.44–3.30(m,2H),2.13–1.79(m,4H); MS(ES+):406.5(M+1).

[0686] Plan 56

[0687]

[0688] Preparation of (S)-(1-(4-((1-(3-methoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (56c)

[0689] Step-1: Preparation of 2-chloro-N-(1-(3-methoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (56b)

[0690] Compound 56b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (373 mg, 1.99 mmol) in 2-propanol (20 mL) using DIPEA (1.04 mL, 5.96 mmol) and 1-(3-methoxyphenyl)-1H-imidazol-4-amine (56a) (451 mg, 2.38 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(3-methoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazine-4-amine (56b) (556 mg, 82% yield) as a light yellow solid; 1 HNMR (300MHz, DMSO-d6) δ11.34(s,1H),8.29(d,J=1.6Hz,1H),7.91(d,J=1.6Hz,1H),7.77(dd,J=2.6,1.5Hz,1H),7.47(t,J=8.1Hz ,1H),7.40(d,J=4.3Hz,1H),7.23(t,J=2.2Hz,1H),7.22-7.16(m,1H),7.03-6.93(m,1H),6.72(dd,J=4.5,2.6Hz,1H),3.85(s,3H); 1 H NMR (300MHz, DMSO-d6-D2O) δ8.22(d,J=1.6Hz,1H),7.88(d,J=1.6Hz,1H),7.74(dd,J=2.6,1.5Hz,1H),7.53-7.41(m,1H),7.34(d,J=4. 4Hz, 1H), 7.21-7.14 (m, 2H), 7.03-6.93 (m, 1H), 6.71 (dd, J = 4.5, 2.6Hz, 1H), 3.82 (s, 3H); MS (ES+): 341.4 (M+1); MS (ES-): 339.3 (M-1).

[0691] Step-2: Preparation of (S)-(1-(4-((1-(3-methoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (56c)

[0692] Compound 56c was prepared from 2-chloro-N-(1-(3-methoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (56b) (100 mg, 0.29 mmol), (S)-pyrrolidin-2-ylmethanol (148 mg, 1.47 mmol) and DIPEA (0.15 mL, 0.87 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(3-methoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (56c) (58 mg, 49% yield) was obtained as a white solid; 1 HNMR (300 MHz, DMSO-d6) δ10.53 (s, 1H, D2O exchangeable), 8.27 (d, J = 1.5 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.45–7.34 (m, 2H), 7.35–7.23 (m, 2H), 7.15 (dd, J = 4.4, 1.7 Hz, 1H), 6.97–6.86 (m, 1H), 6.39 (dd ,J=4.5,2.4Hz,1H),5.02–4.68(m,1H,D2O exchangeable),4.30–4.11(m,1H),3.85(s,3H),3.74(dd,J=9.9,3.5Hz,1H),3.61–3.46(m,1H),3.47–3.26(m,2H),2.17–1.77(m,4H); MS(ES+):406.5(M+1).

[0693] Plan 57

[0694]

[0695] Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (57c)

[0696] Step-1: Preparation of 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (57b)

[0697] Compound 57b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (226 mg, 1.2 mmol) in 2-propanol (20 mL) using DIPEA (0.63 mL, 3.61 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine (57a) (300 mg, 1.02 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (57b) (410 mg, 85% yield) as a white solid; 1 HNMR (300MHz, DMSO-d6) δ11.31(s,1H),8.21(d,J=1.6Hz,1H),7.89(d,J=1.6Hz,1H),7.77(dd,J=2.6, 1.6Hz,1H),7.39(d,J=4.4Hz,1H),6.93(s,2H),6.72(dd,J=4.4,2.6Hz,1H),3.87(s,6H),3.69(s,3H); 1 H NMR (300MHz, DMSO-d6-D2O) δ8.14(d,J=1.6Hz,1H),7.86(d,J=1.6Hz,1H),7.72(dd,J=2.6,1.6Hz,1H),7.35-7.28(m, 1H), 6.88 (s, 2H), 6.71 (dd, J = 4.5, 2.6Hz, 1H), 3.84 (s, 6H), 3.67 (s, 3H); MS (ES+): 401.4 (M+1); MS (ES-): 399.3 (M-1).

[0698] Step-2: Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (57c)

[0699] Compound 57c was prepared from 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (57b) (100 mg, 0.25 mmol), (S)-pyrrolidin-2-ylmethanol (126 mg, 1.25 mmol) and DIPEA (0.13 mL, 0.74 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (57c) (18 mg, 16% yield) was obtained as a white solid; 1 HNMR (300 MHz, DMSO-d6) δ10.54 (s, 1H, D2O exchangeable), 8.24 (d, J = 1.5 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.39 (dd, J = 2.4, 1.6 Hz, 1H), 7.14 (dd, J = 4.4, 1.7 Hz, 1H), 6.96 (s, 2H), 6.39 (dd, J = 4.4, 2.4 Hz, 1H), 4.84 (t, J = 5.1 Hz, 1H, D2O exchangeable), 4.29–4.15 ( m, 1H), 3.88 (s, 6H), 3.79–3.68 (m, 1H), 3.68 (s, 3H), 3.61–3.47 (m, 1H), 3.49–3.24 (m, 2H), 2.12–1.75 (m, 4H); MS (ES+): 466.5 (M+1), 488.5 (M+Na); The crude reaction mixture from the above step-2 was purified by reverse phase flash chromatography [(silica gel C-18, 24 g), eluted with acetonitrile and water containing 0.1% HCl], followed by lyophilization to obtain the hydrochloride salt of compound 57c; 1 HNMR (300MHz, DMSO-d6): δ10.78(s,1H),8.59(s,1H),8.03(s,1H),7.44(s,1H),7.12(d,J=4.5Hz,1H),7.02 (s,2H),6.43(dd,J=4.4,2.5Hz,1H),4.26–4.13(m,1H),3.88(s,6H),3.78–3.21(m,7H),2.08–1.80(m,4H). MS(ES+):466.3(M+1). MS(ES-):500.2(M+Cl).

[0700] Plan 58

[0701]

[0702] Preparation of (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (58b)

[0703] Step-1: Preparation of 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (58a)

[0704] Compound 58a was prepared from 2,4-dichlorothieno[3,2-d]pyrimidine (12a) (261 mg, 1.27 mmol) in 2-propanol (10 mL) using DIPEA (0.44 mL, 2.54 mmol) and 1-(4-fluorophenyl)-1H-imidazol-4-amine (25a) (225 mg, 1.27 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (58a) (268 mg, 61% yield) as a light pink solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.96 (s, 1H, D2O exchangeable), 8.29-8.18 (m, 2H), 7.91 (d, J = 1.6 Hz, 1H), 7.78-7.65 (m, 2H), 7.48-7.35 (m, 3H); 19 F NMR (282MHz, DMSO-d6) δ-115.27; MS (ES+): 346.3 (M+1), 368.3 (M+Na); (ES-): 344.2 (M-1).

[0705] Step-2: Preparation of (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (58b)

[0706] Compound 58b was prepared from 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (58a) (100 mg, 0.29 mmol), (S)-pyrrolidin-2-ylmethanol (88 mg, 0.86 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-(1-(4-fluorophenyl)-1H-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (58b) (69 mg, 58% yield) was obtained as a brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.14 (s, 1H, D2O exchangeable), 8.15 (d, J = 1.5 Hz, 1H), 8.01-7.88 (m, 2H), 7.77 (s, 2H), 7.36 (t, J = 8.4 Hz, 2H), 7.10 (d, J = 5.3 Hz, 1H), 5.35-4.91 (m, 1H, D2O exchangeable), 4.23 (s, 1H), 3.92-3.69 (m, 1H), 3.69-3.18 (m, 3H), 2.15-1.73 (m, 4H); 19 F NMR (282MHz, DMSO-d6) δ-116.11; MS (ES+): 411.4 (M+1), 433.4 (M+Na); (ES-): 409.4 (M-1).

[0707] Plan 59

[0708]

[0709] Preparation of 3-(4-((2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)cyclobutanecarbonitrile (59c)

[0710] Step-1: Preparation of 3-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)cyclobutanecarbonitrile (59b)

[0711] Compound 59b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (145 mg, 0.77 mmol) in 2-propanol (10 mL) using DIPEA (0.4 mL, 2.31 mmol) and 3-(4-amino-1H-imidazol-1-yl)cyclobutanecarbonitrile (59a) (125 mg, 0.77 mmol) according to the procedure reported in Scheme 1. This afforded 3-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)cyclobutanecarbonitrile (59b) (168 mg, 70% yield) as a yellow solid; 1 HNMR (300MHz, DMSO-d6) δ11.17(s,1H),7.86(d,J=1.5Hz,1H),7.73(dt,J=2.9,1.4Hz,1H),7.57(d,J=1.5Hz,1H),7.35(d,J=4.4Hz,1H),6.77-6.60( m,1H),4.77(p,J=8.6Hz,1H),3.31-3.12(m,1H),2.96-2.81(m,2H),2.79- 2.63 (m, 2H); MS (ES+): 314.3 (M+1); MS (ES-): 312.3 (M-1); HPLC purity: 98.51%.

[0712] Step-2: Preparation of 3-(4-((2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)cyclobutanecarbonitrile (59c)

[0713] Compound 59c was prepared from 3-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)cyclobutanecarbonitrile (59b) (60 mg, 0.19 mmol), 2-(pyrrolidin-2-yl)pyridine (85 mg, 0.57 mmol) and DIPEA (0.1 mL, 0.57 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, 3-(4-((2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)cyclobutanecarbonitrile (59c) (41 mg, 50% yield) was obtained as a white solid; 1H NMR (300 MHz, DMSO-d6) δ 10.31 (s, 1H, D2O exchangeable), 8.62 (d, J = 4.8 Hz, 1H), 7.71 (d, J = 1.5 Hz, 1H), 7.66 (td, J = 7.7, 1.8 Hz, 1H), 7.37 (s, 1H), 7.25–7.19 (m, 1H), 7.17 (d, J = 7.9 Hz, 1H), 7.16–6.97 (m, 2H), 6.36 (dd, J = 4 .4,2.5Hz,1H),5.32(d,J=8.2Hz,1H),4.68–4.40(m,1H),3.96–3.76(m,1H),3.76–3.50(m,1H),3.33–3. 21(m,1H),3.02–2.61(m,4H),2.44–2.26(m,1H),2.16–1.71(m,3H); MS(ES+):426.5(M+1),448.5(M+Na).

[0714] Plan 60

[0715]

[0716] Preparation of (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (60b)

[0717] Step-1: Preparation of 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (60a)

[0718] Compound 60a was prepared from 2,4-dichlorothieno[2,3-d]pyrimidine (31a) (261 mg, 1.27 mmol) in 2-propanol (10 mL) using DIPEA (0.44 mL, 2.54 mmol) and 1-(4-fluorophenyl)-1H-imidazol-4-amine (25a) (225 mg, 1.27 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (60a) (270 mg, 61% yield) as a light pink solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.06 (s, 1H, D2O exchangeable), 8.21 (d, J = 1.6 Hz, 1H), 8.04 (d, J = 5.8 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.76-7.67 (m, 3H), 7.48-7.37 (m, 2H); 19FNMR(282MHz, DMSO-d6)δ-115.31; MS(ES+): 346.3(M+1), 368.3(M+Na); (ES-): 344.3(M-1).

[0719] Step-2: Preparation of (S)-(1-(4-((1-(4-fluorophenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (60b)

[0720] Compound 60b was prepared from 2-chloro-N-(1-(4-fluorophenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (60a) (100 mg, 0.29 mmol), (S)-pyrrolidin-2-ylmethanol (88 mg, 0.86 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-(1-(4-fluorophenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (60b) (25 mg, 22% yield) was obtained as a brown solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.17 (s, 1H, D2O exchangeable), 8.17 (s, 1H), 7.94 (d, J = 1.6 Hz, 1H), 7.91-7.61 (m, 2H), 7.47-7.21 (m, 3H), 7.03 (d, J = 6.0 Hz, 1H), 5.17-4.77 (m, 1H, D2O exchangeable), 4.39-3.99 (m, 1H), 3.89-3.19 (m, 4H), 2.13-1.81 (m, 4H); 19 F NMR (282MHz, DMSO-d6) δ-73.43; MS (ES+) 411.4 (M+1), 433.4 (M+Na).

[0721] Plan 61

[0722]

[0723] Preparation of 3,3-dimethyl-1-(4-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl)butan-1-one (61b)

[0724] Compound 61b was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (31b) (100 mg, 0.31 mmol), tert-3,3-dimethyl-1-(piperazin-1-yl)butan-1-one 2,2,2-trifluoroacetate (61a) (182 mg, 0.61 mmol; prepared according to the procedure described by Bisacchi, Gregory S. et al. in US Pat. 6,335,324) and DIPEA (0.21 mL, 1.22 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, 3,3-dimethyl-1-(4-(4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)piperazin-1-yl)butan-1-one (61b) (95 mg, 66% yield) was obtained as a brown solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.26 (s, 1H, D2O exchangeable), 8.25 (d, J = 1.6 Hz, 1H), 7.86 (d, J = 1.6 Hz, 1H), 7.81 (d, J = 6.0 Hz, 1H), 7.70-7.63 (m, 2H), 7.61-7.52 (m, 2H), 7.45-7.34 (m, 1H), 7.13 (d, J = 6.0 Hz, 1H), 3.87-3.74 (m, 4H), 3.71-3.54 (m, 4H), 2.30 (s, 2H), 1.01 (s, 9H); MS (ES+): 476.6 (M+1), 498.5 (M+Na), (ES-): 474.6 (M-1).

[0725] Plan 62

[0726]

[0727] Preparation of 2-(ethyl(4-(1-phenyl-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)amino)ethanol (62b)

[0728] Compound 62b was prepared from 2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (31b) (100 mg, 0.31 mmol), 2-(ethylamino)ethanol (62a) (82 mg, 0.92 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, 2-(ethyl(4-(1-phenyl-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)amino)ethanol (62b) (43 mg, 37% yield) was obtained as a light brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.16 (s, 1H, D2O exchangeable), 8.23 ​​(d, J = 1.5 Hz, 1H), 7.92 (d, J = 1.5 Hz, 1H), 7.80 (d, J = 6.0 Hz, 1H), 7.75-7.59 (m, 2H), 7.53 (t, J = 7.7 Hz, 2H), 7.42-7.27 (m, 1H), 7.02 (d, J = 6.0 Hz, 1H), 4.82 (s, 1H, D2O exchangeable), 3.82-3.54 (m, 6H), 1.31-1.06 (m, 3H); MS (ES+): 381.4 (M+1), 403.4 (M+Na), (ES-): 379.4 (M-1).

[0729] Plan 63

[0730]

[0731] Preparation of (S)-N-(1-cyclobutyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (63a)

[0732] Compound 63a was prepared from 2-chloro-N-(1-cyclobutyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (37b) (70 mg, 0.24 mmol), (S)-2-phenylpyrrolidine (54 mg, 0.36 mmol) and DIPEA (0.13 mL, 0.73 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-N-(1-cyclobutyl-1H-imidazol-4-yl)-2-(2-phenylpyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (63a) (65 mg, 67% yield) was obtained as a white solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.32 (s, 1H, D2O exchangeable), 7.88–7.79 (m, 1H), 7.42–7.37 (m, 1H), 7.36–7.23 (m, 4H), 7.23–7.15 (m, 1H), 7.09–6.97 (m, 2H), 6.39 (dd, J = 4.4, 2.5 Hz, 1H ),5.41–5.30(m,1H),4.66–4.43(m,1H),3.83–3.69(m,1H),3.67–3.51(m,1H),2.41– 2.08 (m, 6H), 2.02–1.69 (m, 4H); MS (ES+): 400.6 (M+1), 422.5 (M+Na); HPLC purity: 98.69%.

[0733] Plan 64

[0734]

[0735] Preparation of (S)-N-(1-cyclobutyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (64a)

[0736] Compound 64a was prepared from 2-chloro-N-(1-cyclobutyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (37b) (60 mg, 0.21 mmol), (S)-2-(pyrrolidin-2-yl)pyridine dihydrochloride (55 mg, 0.25 mmol) and DIPEA (0.11 mL, 0.62 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-N-(1-cyclobutyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (64a) (10 mg, 12% yield) was obtained as a light yellow solid; 1 HNMR (300 MHz, DMSO-d6) δ10.26 (s, 1H, D2O exchangeable), 8.67–8.48 (m, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.56 (d, J = 1.5 Hz, 1H), 7.38 (s, 1H), 7.30–7.13 (m, 2H), 7.08 (dd, J = 4.4, 1.7 Hz, 1H), 7.05–6.89 (m, 1H), 6. 36(dd,J=4.4,2.5Hz,1H),5.35(d,J=8.1Hz,1H),4.65–4.36(m,1H),3.90–3.72(m,1H),3.68–3.49(m ,1H),2.47–2.25(m,4H),2.26–2.11(m,1H),2.12–1.99(m,1H),2.01–1.90(m,1H),1.90–1.65(m,3H). MS (ES+): 401.5 (M+1), 423.5 (M+Na); HPLC purity: 96.63%.

[0737] Plan 65

[0738]

[0739] Preparation of (S)-(1-(4-((1-(1H-indol-6-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (65c)

[0740] Step-1: Preparation of N-(1-(1H-indol-6-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazin-4-amine (65b)

[0741] Compound 65b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (199 mg, 1.06 mmol) in 2-propanol (20 mL) using DIPEA (0.55 mL, 3.18 mmol) and 1-(1H-indol-6-yl)-1H-imidazol-4-amine (65a) (231 mg, 1.17 mmol) according to the procedure reported in Scheme 1. This afforded N-(1-(1H-indol-6-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazin-4-amine (65b) (271 mg, 73% yield) as a light pink solid; 1 HNMR(300MHz,DMSO-d6)δ11.36(s,2H),8.18(d,J=1.6Hz,1H),7.90(d,J=1.6Hz,1H),7.77 (dd,J=2.6,1.6Hz,1H),7.70(d,J=8.4Hz,1H),7.58(d,J=2.0Hz,1H),7.46(dd,J=3.1,2.4H z,1H),7.41(d,J=4.1Hz,1H),7.27(dd,J=8.4,2.0Hz,1H),6.72(dd,J=4.4,2.6Hz,1H),6.5 2 (ddd, J=3.0, 2.0, 0.9Hz, 1H); MS (ES+): 350.4 (M+1); MS (ES-): 348.3 (M-1), 384.3 (M+Cl).

[0742] Step-2: Preparation of (S)-(1-(4-((1-(1H-indol-6-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (65c)

[0743] Compound 65c was prepared from N-(1-(1H-indol-6-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazin-4-amine (65b) (100 mg, 0.29 mmol), (S)-pyrrolidin-2-ylmethanol (145 mg, 1.43 mmol) and DIPEA (0.15 mL, 0.86 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(1H-indol-6-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (65c) (81 mg, 68% yield) was obtained as a white solid; 1 HNMR (300 MHz, DMSO-d6) δ 11.26 (s, 1H, D2O exchangeable), 10.50 (s, 1H, D2O exchangeable), 8.14 (s, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.70–7.60 (m, 2H), 7.46–7.41 (m, 1H), 7.41–7.37 (m, 1H), 7.33 (dd, J = 8.5, 2.0 Hz, 1H), 7.20–7.11 (m ,1H),6.53–6.46(m,1H),6.40(dd,J=4.4,2.4Hz,1H),5.06–4.37(m,1H),4.30–4.09(m,1H),3.79–3.69( m, 1H), 3.58–3.48 (m, 1H), 3.48–3.23 (m, 2H), 2.15–1.71 (m, 4H); MS (ES+): 415.5 (M+1); HPLC purity: 99.33%.

[0744] Plan 66

[0745]

[0746] Preparation of (S)-(1-(4-((1-(pyridin-2-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (66c)

[0747] Step-1: Preparation of 2-chloro-N-(1-(pyridin-2-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (66b)

[0748] Compound 66b was prepared according to the procedure reported in Scheme 1 from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (112 mg, 0.59 mmol) in 2-propanol (10 mL) using DIPEA (0.31 mL, 1.78 mmol) and 1-(pyridin-2-yl)-1H-imidazol-4-amine (66a) (95 mg, 0.59 mmol; prepared according to the procedure reported by Bleicher, Konrad et al., PCT Int. Appl., 2011089132, Jul. 28, 2011). 2-Chloro-N-(1-(pyridin-2-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (66b) (27 mg, 15% yield) was obtained as a solid after purification by flash column chromatography [silica (24 g), eluted with DMA-80 / DCM from 0 to 40%]; 1 H NMR (300MHz, DMSO-d6) δ11.37(s,1H),8.64-8.49(m,2H),8.25(d,J=1.5Hz,1H),8.11-7.97(m,1H),7.86(d,J=8.2Hz, 1H), 7.80-7.75 (m, 1H), 7.48-7.33 (m, 2H), 6.72 (dd, J = 4.5, 2.6Hz, 1H); MS (ES+): 312.3 (M+1); MS (ES-): 310.3 (M-1).

[0749] Step-2: Preparation of (S)-(1-(4-((1-(pyridin-2-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (66c)

[0750] Compound 66c was prepared from 2-chloro-N-(1-(pyridin-2-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (66b) (27 mg, 0.09 mmol), (S)-pyrrolidin-2-ylmethanol (44 mg, 0.43 mmol) and DIPEA (0.05 mL, 0.26 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(pyridin-2-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (66c) (9 mg, 28% yield) was obtained as a white solid;1 H NMR (300 MHz, DMSO-d6) δ 10.58 (s, 1H, D2O exchangeable), 8.51 (s, 1H), 8.48 (d, J = 4.4 Hz, 1H), 8.19 (s, 1H), 7.98 (t, J = 7.7 Hz, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.47–7.31 (m, 2H), 7.22–7.09 (m, 1H), 6.46–6. 37 (m, 1H), 5.02–4.81 (m, 1H, D2O exchangeable), 4.26–4.11 (m, 1H), 3.90–3.73 (m, 1H), 3.63–3.46 (m, 1H), 3.47–3.15 (m, 2H), 2.19–1.69 (m, 4H); MS (ES+): 377.4 (M+1), 399.4 (M+Na); HPLC purity: 97.04%.

[0751] Plan 67

[0752]

[0753] Preparation of (S)-(1-(4-((1-(1H-indol-5-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (67c)

[0754] Step-1: Preparation of N-(1-(1H-indol-5-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazin-4-amine (67b)

[0755] Compound 67b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (215 mg, 1.14 mmol) in 2-propanol (20 mL) using DIPEA (0.6 mL, 3.43 mmol) and 1-(1H-indol-5-yl)-1H-imidazol-4-amine (67a) (249 mg, 1.26 mmol) according to the procedure reported in Scheme 1. This afforded N-(1-(1H-indol-5-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazin-4-amine (67b) (314 mg, 79% yield) as a light pink solid; 1HNMR(300MHz,DMSO-d6)δ11.36(s,1H),11.33(s,1H),8.16-8.05(m,1H),7.90-7. 84(m,1H),7.80-7.71(m,2H),7.61-7.52(m,1H),7.51-7.45(m,1H),7.46-7.37(m ,1H),7.37-7.25(m,1H),6.72(p,J=3.4,2.9Hz,1H),6.58-6.46(m,1H); MS(ES+): 350.4 (M+1), 372.4 (M+Na); MS (ES-): 348.3 (M-1), 384.3 (M+Cl); HPLC purity: 98.41%.

[0756] Step-2: Preparation of (S)-(1-(4-((1-(1H-indol-5-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (67c)

[0757] Compound 67c was prepared from N-(1-(1H-indol-5-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazin-4-amine (67b) (100 mg, 0.29 mmol), (S)-pyrrolidin-2-ylmethanol (145 mg, 1.43 mmol) and DIPEA (0.15 mL, 0.86 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(1H-indol-5-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (67c) (80 mg, 68% yield) was obtained as a white solid; 1HNMR (300 MHz, DMSO-d6) δ 11.30 (s, 1H, D2O exchangeable), 10.48 (s, 1H, D2O exchangeable), 8.09 (d, J = 1.5 Hz, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.87 (d, J = 2.0 Hz, 1H), 7.55–7.43 (m, 2H), 7.44–7.32 (m, 2H), 7.19–7.11 (m, 1H), 6.53–6.47 (m, 1H), 6.39 (d d, J = 4.4, 2.4 Hz, 1H), 4.87 (t, J = 5.1 Hz, 1H, D2O exchangeable), 4.28–4.06 (m, 1H), 3.86–3.67 (m, 1H), 3.57–3.45 (m, 1H), 3.47–3.25 (m, 2H), 2.11–1.81 (m, 4H); MS (ES+): 415.5 (M+1); MS (ES-): 413.5 (M-1), 449.4 (M+Cl); HPLC purity: 99.37%.

[0758] Plan 68

[0759]

[0760] Preparation of (S)-3-(4-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)cyclobutanecarbonitrile (68a)

[0761] Compound 68a was prepared from 3-(4-((2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)cyclobutanecarbonitrile (59b) (50 mg, 0.16 mmol), (S)-pyrrolidin-2-ylmethanol (81 mg, 0.8 mmol) and DIPEA (0.08 mL, 0.48 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-3-(4-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)amino)-1H-imidazol-1-yl)cyclobutanecarbonitrile (68a) (36 mg, 60% yield) was obtained as a light yellow solid; 1H NMR (300 MHz, DMSO-d6) δ 10.38 (s, 1H, D2O exchangeable), 7.72 (d, J = 1.5 Hz, 1H), 7.65 (d, J = 1.6 Hz, 1H), 7.36 (dd, J = 2.4, 1.6 Hz, 1H), 7.09 (dd, J = 4.5, 1.7 Hz, 1H), 6.36 (dd, J = 4.4, 2.4 Hz, 1H), 4.80 (t, J = 5.2 Hz, 1H, D2O exchangeable), 4.77–4.63 (m, 1H), 4.23–4.04 (m, 1H), 3.81–3.67 (m, 1H), 3.57–3.45 (m, 1H), 3.45–3.33 (m, 2H), 3.27–3.12 (m, 1H), 2.98–2.62 (m, 4H), 2.16–1.75 (m, 4H); MS (ES+): 379.5 (M+1); 401.5 (M+Na).

[0762] Plan 69

[0763]

[0764] Preparation of N-(1-cyclopentyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (69a)

[0765] Compound 69a was prepared from 2-chloro-N-(1-cyclopentyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (50b) (50 mg, 0.17 mmol), 2-(pyrrolidin-2-yl)pyridine (73 mg, 0.5 mmol) and DIPEA (0.09 mL, 0.5 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-cyclopentyl-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (69a) (48 mg, 70% yield) was obtained as a light yellow solid; 1H NMR (300 MHz, DMSO-d6) δ 10.26 (s, 1H, D2O exchangeable), 8.61–8.50 (m, 1H), 7.67 (td, J = 7.7, 1.8 Hz, 1H), 7.51 (d, J = 1.5 Hz, 1H), 7.37 (s, 1H), 7.26–7.13 (m, 2H), 7.13–7.05 (m, 1H), 7.04–6.89 (m, 1H), 6.36 (dd, J = 4.4, 2.4Hz,1H),5.31(d,J=8.1Hz,1H),4.43–4.23(m,1H),3.79(t,J=9.3Hz,1H),3.68–3.50(m,1H),2.41–2 .29 (m, 1H), 2.18–1.87 (m, 5H), 1.89–1.53 (m, 6H); MS (ES+): 415.5 (M+1), 437.5 (M+Na); HPLC purity: 98.48%.

[0766] Plan 70

[0767]

[0768] Preparation of (S)-(1-(6-(hydroxymethyl)-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (70f)

[0769] Step-1: Preparation of 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine (70a)

[0770] To a solution of 2,4-dichlorothieno[2,3-d]pyrimidine (31a) (4 g, 19.51 mmol) in THF (100 mL) was added sodium thiomethoxide (1.418 g, 19.51 mmol) at 0°C and allowed to reach room temperature. The reaction mixture was quenched by the addition of 1N HCl and poured into water (200 mL). The separated solid was collected by filtration and dried under vacuum to give 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine (70a) (3.76 g, 89% yield) as a brown solid; 1 HNMR (300MHz, DMSO-d6) δ7.96 (d, J = 6.0 Hz, 1H), 7.50 (d, J = 6.0 Hz, 1H), 2.68 (s, 3H).

[0771] Step-2: Preparation of 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine-6-carbaldehyde (70b)

[0772] To a solution of 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine (70a) (3.68 g, 17.0 mmol) in dry THF (100 mL) was added n-butyllithium (1.6 M in hexane, 21.25 mL, 34.0 mmol) dropwise at -78 °C under nitrogen. The reaction was stirred at -78 °C for 1.5 h and slowly quenched by the dropwise addition of N,N-dimethylformamide (2.63 mL, 34.0 mmol). The reaction was stirred at -78 °C for 2 h and allowed to warm to room temperature overnight. The reaction mixture was cooled to 0 °C, quenched with 1N HCl, and extracted with ethyl acetate (2 x 100 mL). The organic layer was separated, washed with water (2 x 20 mL); brine (20 mL), dried, filtered, and concentrated in vacuo. The obtained residue was purified by flash column chromatography [silica gel (40 g), eluted with 0-100% ethyl acetate / hexanes] to give 2-chloro-4-(methylsulfanyl)thieno[2,3-d]pyrimidine-6-carbaldehyde (70b) (2.48 g, 60% yield) as a brown solid; 1 H NMR (300MHz, DMSO-d6) δ10.13(s,1H),8.55(s,1H),2.73(s,3H); MS(ES+):277.2(M+Na).

[0773] Step 3: Preparation of 2,4-dichlorothieno[2,3-d]pyrimidine-6-carbaldehyde (70c)

[0774] To a solution of 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine-6-carbaldehyde (70b) (2 g, 8.17 mmol) in acetonitrile (50 mL) and dichloromethane (20 mL) was added sulfuryl chloride (3.32 mL, 40.9 mmol) in dichloromethane (20 mL) at 0°C over 30 minutes. The reaction mixture was stirred at 0°C for 10 minutes and quenched with saturated sodium bicarbonate solution. The reaction mixture was concentrated in vacuo to remove the organic solvent, and the aqueous residue was extracted with ethyl acetate (3x50 mL). The combined organic layers were washed with brine, dried, filtered, and concentrated under reduced pressure to give 2,4-dichlorothieno[2,3-d]pyrimidine-6-carbaldehyde (70c) (1.9 g, 100% yield) as a dark brown solid; 1 H NMR (300MHz, DMSO-d6) δ10.19(s,1H),8.62(s,1H).

[0775] Step 4: Preparation of (2,4-dichlorothieno[2,3-d]pyrimidin-6-yl)methanol (70d)

[0776] To a solution of 2,4-dichlorothieno[2,3-d]pyrimidine-6-carbaldehyde (70c) (1 g, 4.29 mmol) in THF (30 mL) and water (1 mL) was added sodium borohydride (162 mg, 4.29 mmol) and stirred at room temperature for 20 minutes. The reaction mixture was diluted with ethyl acetate (100 mL) and quenched with 1N HCl. The organic layer was separated, washed with brine, dried and concentrated. The obtained residue was purified by flash column chromatography [silica gel (25 g), eluted with 0-100% ethyl acetate / hexane] to give (2,4-dichlorothieno[2,3-d]pyrimidin-6-yl)methanol (70d) (450 mg, 45% yield) as a white solid; 1 H NMR (300 MHz, DMSO-d6) δ 7.43 (t, J = 1.3 Hz, 1H), 6.07 (t, J = 5.7 Hz, 1H, D2O exchangeable), 4.83 (dd, J = 5.8, 1.3 Hz, 2H).

[0777] Step 5: Preparation of (2-chloro-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methanol (70e)

[0778] Compound 70e was prepared from (2,4-dichlorothieno[2,3-d]pyrimidin-6-yl)methanol (70d) (40 mg, 0.17 mmol) in 2-propanol (10 mL) using DIPEA (0.12 mL, 0.68 mmol) and 1-phenyl-1H-imidazol-4-amine hydrochloride (8a) (50 mg, 0.26 mmol) according to the procedure reported in Scheme 1. This afforded (2-chloro-4-(1-phenyl-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-6-yl)methanol (70e) (25 mg, 41% yield) as a light pink solid. 1 H NMR (300 MHz, DMSO-d6) δ 10.95 (s, 1H, D2O exchangeable), 8.25 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.87 (s, 1H), 7.66 (dd, J = 8.4, 1.4 Hz, 2H), 7.57 (t, J = 7.9 Hz, 2H), 7.46-7.35 (m, 1H), 5.83 (t, J = 5.8 Hz, 1H, D2O exchangeable), 4.72 (d, J = 5.6 Hz, 2H); MS (ES+): 380.3 (M+Na), (ES-): 356.2 (M-1).

[0779] Step 6: Preparation of (S)-(1-(6-(hydroxymethyl)-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (70f)

[0780] Compound 70f was prepared from (2-chloro-4-(1-phenyl-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-6-yl)methanol (70e) (24 mg, 0.07 mmol), (S)-pyrrolidin-2-ylmethanol (20 mg, 0.2 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(6-(hydroxymethyl)-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (70f) (10 mg, 35% yield) was obtained as a brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.07 (s, 1H, D2O exchangeable), 8.20 (s, 1H), 7.97 (d, J = 1.7 Hz, 1H), 7.85-7.67 (m, 2H), 7.65 (s, 1H), 7.58-7.42 (m, 2H), 7.39-7.28 (m, 1H), 5.50 (t, J = 5.7 Hz, 1H, D2O exchangeable), 5.05-4.82 (m, 1H, D2O exchangeable), 4.57 (d, J = 5.7 Hz, 2H), 4.42-3.99 (m, 1H), 3.97-3.34 (m, 4H), 2.16-1.76 (m, 4H); MS (ES+): 423.4 (M+1), (ES-): 421.3 (M-1), 457.4 (M+Cl).

[0781] Plan 71

[0782]

[0783] Preparation of (S)-(1-(4-((1-(1H-pyrazol-3-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (71c)

[0784] Step-1: Preparation of N-(1-(1H-pyrazol-3-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazin-4-amine (71b)

[0785] Compound 71b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (357 mg, 1.9 mmol) in 2-propanol (10 mL) using DIPEA (1.0 mL, 5.7 mmol) and 1-(1H-pyrazol-3-yl)-1H-imidazol-4-amine (71a) (340 mg, 2.28 mmol) according to the procedure reported in Scheme 1. This afforded N-(1-(1H-pyrazol-3-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazine-4-amine (71b) (496 mg, 87% yield) as a yellow solid; 1 HNMR(300MHz,DMSO-d6)δ12.92(s,1H),11.34(s,1H),8.35-8.13(m,1H),8.02-7.93(m,1H),7 .93-7.81(m,1H),7.81-7.66(m,1H),7.52-7.26(m,1H),6.83-6.68(m,1H),6.67-6.53(m,1H); 1 HNMR (300MHz, DMSO-d6 / D2O) δ8.14(d,J=1.6Hz,1H),7.92(d,J=1.5Hz,1H),7.82(d,J=2.4Hz,1H),7.72(dd,J=2.6,1.5Hz,1H),7. 33-7.26 (m, 1H), 6.71 (dd, J=4.5, 2.6Hz, 1H), 6.60 (d, J=2.5Hz, 1H); MS (ES+): 301.3 (M+1); MS (ES-): 299.3 (M-1); HPLC purity: 98.56%.

[0786] Step-2: Preparation of (S)-(1-(4-((1-(1H-pyrazol-3-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (71c)

[0787] Compound 71c was prepared from N-(1-(1H-pyrazol-3-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazin-4-amine (71b) (90 mg, 0.3 mmol), (S)-pyrrolidin-2-ylmethanol (151 mg, 1.5 mmol) and DIPEA (0.16 mL, 0.9 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(1H-pyrazol-3-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (71c) (86 mg, 79% yield) was obtained as a white solid; 1 HNMR (300 MHz, DMSO-d6) δ 12.94 (s, 1H, D2O exchangeable), 10.54 (s, 1H, D2O exchangeable), 8.15 (d, J = 1.5 Hz, 1H), 7.97 (d, J = 1.5 Hz, 1H), 7.86 (dd, J = 2.4, 1.1 Hz, 1H), 7.39 (dd, J = 2.4, 1.7 Hz, 1H), 7.13 (dd, J = 4.4, 1.7 Hz, 1H), 6.69 (s, 1 H), 6.39 (dd, J = 4.4, 2.4 Hz, 1H), 4.86 (t, J = 5.6 Hz, 1H, D2O exchangeable), 4.25–4.04 (m, 1H), 3.88–3.71 (m, 1H), 3.58–3.45 (m, 1H), 3.45–3.24 (m, 2H), 2.17–1.70 (m, 4H); MS (ES+): 366.5 (M+1), 388.5 (M+Na); HPLC purity: 99.33%.

[0788] Plan 72

[0789]

[0790] Preparation of (S)-(1-(4-((1-(3,5-dimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (72c)

[0791] Step-1: Preparation of 2-chloro-N-(1-(3,5-dimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (72b)

[0792] Compound 72b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (313 mg, 1.67 mmol) in 2-propanol (20 mL) using DIPEA (0.87 mL, 5.0 mmol) and 1-(3,5-dimethoxyphenyl)-1H-imidazol-4-amine (72a) (365 mg, 1.67 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-N-(1-(3,5-dimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazine-4-amine (72b) (492 mg, 80% yield) as a solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.32 (s, 1H, D2O exchangeable), 8.29 (d, J = 1.6 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.77 (dd, J = 2.6, 1.6 Hz, 1H), 7.39 (d, J = 4.4 Hz, 1H), 6.80 (d, J = 2.2 Hz, 2H), 6.72 (dd, J = 4.5, 2.6 Hz, 1H), 6.54 (t, J = 2.2 Hz, 1H), 3.83 (s, 6H); MS (ES+): 371.4 (M+1); MS (ES-): 369.3 (M-1); HPLC purity: 98.98%.

[0793] Step-2: Preparation of (S)-(1-(4-((1-(3,5-dimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (72c)

[0794] Compound 72c was prepared from 2-chloro-N-(1-(3,5-dimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (72b) (100 mg, 0.27 mmol), (S)-pyrrolidin-2-ylmethanol (136 mg, 1.35 mmol) and DIPEA (0.14 mL, 0.81 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(3,5-dimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (72c) (73 mg, 62% yield) was obtained as a white solid; 1HNMR (300 MHz, DMSO-d6) δ 10.53 (s, 1H, D2O exchangeable), 8.27 (d, J = 1.5 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.39 (dd, J = 2.4, 1.7 Hz, 1H), 7.14 (dd, J = 4.5, 1.7 Hz, 1H), 6.86 (d, J = 2.2 Hz, 2H), 6.47 (t, J = 2.2 Hz, 1H), 6.39 (dd, J = 4.4, 2.4 Hz, 1H), 4.82 (t, J = 5.1 Hz, 1H, D2O exchangeable), 4.27–4.13 (m, 1H), 3.82 (s, 6H), 3.78–3.65 (m, 1H), 3.62–3.48 (m, 1H), 3.49–3.24 (m, 2H), 2.10–1.79 (m, 4H); MS (ES+): 436.5 (M+1), 458.4 (M+Na); MS (ES-): 434.4 (M-1); HPLC purity: 98.94%.

[0795] Plan 73

[0796]

[0797] Preparation of (S)-(1-(4-((1-(3,4-dimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (73c)

[0798] Step-1: Preparation of 2-chloro-N-(1-(3,4-dimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (73b)

[0799] Compound 73b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (313 mg, 1.67 mmol) in 2-propanol (10 mL) using DIPEA (0.87 mL, 5.0 mmol) and 1-(3,4-dimethoxyphenyl)-1H-imidazol-4-amine (73a) (365 mg, 1.67 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-N-(1-(3,4-dimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazine-4-amine (73b) (513 mg, 83% yield) as a solid; 1H NMR (300 MHz, DMSO-d6) δ 11.32 (s, 1H, D2O exchangeable), 8.16 (d, J = 1.6 Hz, 1H), 7.84 (d, J = 1.6 Hz, 1H), 7.76 (dd, J = 2.6, 1.5 Hz, 1H), 7.49-7.34 (m, 1H), 7.25 (t, J = 1.3 Hz, 1H), 7.16-7.06 (m, 2H), 6.72 (dd, J = 4.4, 2.6 Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H); MS (ES+): 371.5 (M+1); MS (ES-): 369.3 (M-1); HPLC purity: 99.51%.

[0800] Step-2: Preparation of (S)-(1-(4-((1-(3,4-dimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (73c)

[0801] Compound 73c was prepared from 2-chloro-N-(1-(3,4-dimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (73b) (100 mg, 0.27 mmol), (S)-pyrrolidin-2-ylmethanol (136 mg, 1.35 mmol) and DIPEA (0.14 mL, 0.81 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(3,4-dimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (73c) (38 mg, 32% yield) was obtained as a light off-white solid; 1H NMR (300 MHz, DMSO-d6) δ 10.51 (s, 1H, D2O exchangeable), 8.16 (d, J = 1.5 Hz, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.42–7.35 (m, 1H), 7.23 (d, J = 8.3 Hz, 2H), 7.14 (dd, J = 4.4, 1.7 Hz, 1H), 7.04 (d, J = 8.3 Hz, 1H), 6.39 (dd, J = 4.4, 2.4Hz,1H),4.85(t,J=5.1Hz,1H,D2O exchangeable),4.19(s,1H),3.87(s,3H),3.80(s,3H),3.80–3.67(m,1H),3.60–3.47(m,1H),3.47–3.25(m,2H),2.09–1.80(m,4H); MS(ES+):436.5(M+1); MS(ES-):434.4(M-1).

[0802] Plan 74

[0803]

[0804] Preparation of N-(1-(1H-pyrazol-3-yl)-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (74a)

[0805] Compound 74a was prepared from N-(1-(1H-pyrazol-3-yl)-1H-imidazol-4-yl)-2-chloropyrrolo[2,1-f][1,2,4]triazin-4-amine (71b) (90 mg, 0.3 mmol), 2-(pyrrolidin-2-yl)pyridine (133 mg, 0.9 mmol) and DIPEA (0.16 mL, 0.9 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1-(1H-pyrazol-3-yl)-1H-imidazol-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (74a) (53 mg, 43% yield) was obtained as a slightly yellow solid; 1HNMR (300 MHz, DMSO-d6) δ 12.93 (s, 1H, D2O exchangeable), 10.43 (s, 1H, D2O exchangeable), 8.40 (d, J = 4.8 Hz, 1H), 8.03 (s, 1H), 7.93 (t, J = 2.0 Hz, 1H), 7.73–7.46 (m, 2H), 7.37 (s, 1H), 7.20 (d, J = 7.9 Hz, 1H), 7.17–7.03 (m, 2H) ,6.69(t,J=2.2Hz,1H),6.38(dd,J=4.4,2.4Hz,1H),5.34(d,J=8.1Hz,1H),3.98–3.78(m,1H),3.78–3. 50 (m, 1H), 2.44–2.27 (m, 1H), 2.11–1.71 (m, 3H); MS (ES+): 413.5 (M+1), 435.5 (M+Na); HPLC purity: 98.54%.

[0806] Plan 75

[0807]

[0808] Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (75b)

[0809] Step-1: Preparation of 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (75a)

[0810] Compound 75a was prepared from 2,4-dichlorothieno[3,2-d]pyrimidine (12a) (304 mg, 1.48 mmol) in 2-propanol (10 mL) using DIPEA (0.52 mL, 2.97 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine (57a) (370 mg, 1.48 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (75a) (403 mg, 65% yield) as a light pink solid; 1H NMR (300 MHz, DMSO-d6) δ 10.86 (s, 1H, D2O exchangeable), 8.24 (d, J = 6.0 Hz, 2H), 7.95 (s, 1H), 7.39 (d, J = 5.4 Hz, 1H), 6.96 (s, 2H), 3.87 (s, 6H), 3.69 (s, 3H); MS (ES+): 440.3 (M+Na), (ES-): 416.3 (M-1).

[0811] Step-2: Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (75b)

[0812] Compound 75b was prepared from 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (75a) (100 mg, 0.24 mmol), (S)-pyrrolidin-2-ylmethanol (73 mg, 0.72 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] followed by conversion to the free base using NaHCO3, (S)-(1-(4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (75b) (93 mg, 81% yield) was obtained as a brown solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.19 (s, 1H, D2O exchangeable), 8.22 (d, J = 1.5 Hz, 1H), 8.09-7.98 (m, 1H), 7.93 (d, J = 5.4 Hz, 1H), 7.10 (d, J = 5.3 Hz, 1H), 6.95 (s, 2H), 5.29-4.79 (m, 1H, D2O exchangeable) ,4.53-4.04(m,1H),3.88(s,6H),3.81-3.55(m,5H),3.46-3.24(m,2H),2.10-1.69(m,4H ); MS(ES+): 483.5(M+1), 505.5(M+Na), 965.8(2M+1), 987.8(2M+Na), (ES-): 481.5(M-1).

[0813] Plan 76

[0814]

[0815] Preparation of (S)-(1-(4-((1-(quinolin-5-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (76c)

[0816] Step-1: Preparation of 2-chloro-N-(1-(quinolin-5-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (76b)

[0817] Compound 76b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (0.5 g, 2.65 mmol) in DCM (20 mL) using DIPEA (1.03 g, 7.97 mmol) and 1-(quinolin-5-yl)-1H-imidazol-4-amine (76a) (0.67 g, 3.19 mmol) according to the procedure reported in Scheme 1. After workup and purification by flash column chromatography (silica gel, eluting with 0-80% ethyl acetate / hexanes), 2-chloro-N-(1-(quinolin-5-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (76b) (300 mg, 31% yield) was obtained as an off-white solid. 1 H NMR (300MHz, DMSO-d6): δ11.45(s,1H),9.04-9.03(s,1H),8.23-8.20(d,1H),8.11-7.96(d,2H),7.93-7.91 (t,1H),7.84-7.82(m,3H),7.77-7.76(m,1H),7.45-7.44(s,1H),6.75-6.74(s,1H); MS(ES+):362.0(M+1).

[0818] Step-2: Preparation of (S)-(1-(4-((1-(quinolin-5-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (76c)

[0819] A stirred solution of 2-chloro-N-(1-(quinolin-5-yl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (76b) (300 mg, 0.83 mmol) and (S)-pyrrolidin-2-ylmethanol (838 mg, 8.29 mmol) in NMP (10 mL) was heated at 150 ° C for 16 h. The reaction mixture was extracted with ethyl acetate (3×100 mL). The combined organic layers were washed with brine solution (100 mL), dried, filtered and concentrated under reduced pressure. The crude product obtained was purified by flash column chromatography (silica gel, eluted with 0-10% ethyl acetate / methanol) to give (S)-(1-(4-((1-(quinolin-5-yl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (76c) (110 mg, 31%) as an off-white solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.63 (s, 1H, D2O exchangeable), 9.03 (dd, J = 4.1, 1.6 Hz, 1H), 8.30-8.10 (m, 2H), 8.02 (d, J = 1.4 Hz, 1H), 7.96-7.86 (m, 2H), 7.80 (dd, J = 7.4, 1.2 Hz, 1H), 7.66 (dd, J = 8.6, 4.2 Hz, 1H), 7.40 (t, J = 2.0 Hz ,1H),7.18(dd,J=4.5,1.7Hz,1H),6.41(dd,J=4.4,2.4Hz,1H),4.51(t,J=5.3Hz,1H,D2O exchangeable),4.10-3.96(m,1H),3.63-3.49(m,1H),3.47-3.20(m,3H),1.98-1.68(m,4H);MS(ES+)449.5(M+Na);HPLC purity:94.15%.

[0820] Plan 77

[0821]

[0822] Preparation of (S)-(1-(7-(4-methoxyphenyl)-4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77d)

[0823] Step-1: Preparation of 7-bromo-2-chloro-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (77b)

[0824] Compound 77b was prepared from 7-bromo-2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (77a) (50 mg, 0.19 mmol; CAS# 1008112-03-5) in 2-propanol (6 mL) using DIPEA (0.67 mL, 3.83 mmol) and 1-phenyl-1H-imidazol-4-amine, HCl (8a) (250 mg, 1.28 mmol) according to the procedure reported in Scheme 1. After workup and purification by flash column chromatography [silica gel, 40 g, eluted with a 9:1 mixture of ethyl acetate and methanol in hexanes (0 to 100%)], 7-bromo-2-chloro-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (77b) (22 mg, 30% yield) was obtained as a white solid. 1 H NMR (300 MHz, DMSO-d6) δ 11.50 (s, 1H, D2O exchangeable), 8.27 (d, J = 1.6 Hz, 1H), 7.92 (d, J = 1.6 Hz, 1H), 7.71-7.63 (m, 2H), 7.57 (dd, J = 8.8, 7.1 Hz, 2H), 7.52 (d, J = 4.7 Hz, 1H), 7.46-7.37 (m, 1H), 6.91 (d, J = 4.7 Hz, 1H). MS (ES+): 389.2, 391.3 (M+2); MS (ES-): 387.2, 389.1 (M+2).

[0825] Step-2: Preparation of (S)-(1-(7-bromo-4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77c)

[0826] Compound 77c was prepared from 7-bromo-2-chloro-N-(1-phenyl-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (77b) (50 mg, 0.13 mmol), (S)-pyrrolidin-2-ylmethanol (0.04 mL, 0.39 mmol) and DIPEA (0.07 mL, 0.39 mmol) in NMP (0.5 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography [silica (4 g), eluting with DMA-80 / CHCl3 from 0 to 20%], (S)-(1-(7-bromo-4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77c) was obtained and used as such in the next step without further purification.

[0827] Step-3: Preparation of (S)-(1-(7-(4-methoxyphenyl)-4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77d)

[0828] A slurry of (S)-(1-(7-bromo-4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77c) (20 mg, 0.04 mmol), 4-methoxyphenylboronic acid (33 mg, 0.22 mmol), Pd(dppf)Cl2 (7 mg, 8.80 μmol), sodium carbonate (12 mg, 0.11 mmol) in dioxane (3 mL) and water (1 mL) was stirred at 90 °C for 2 h in a sealed reactor under a positive flow of nitrogen. The reaction mixture was cooled to room temperature, diluted with EtOAc (50 mL) and filtered through a pad of celite. The reaction mixture was purified by reverse phase flash column chromatography (silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA. The appropriate fractions containing the product were combined and concentrated to remove the acetonitrile. The aqueous solution was basified with saturated sodium bicarbonate, and the resulting solid was collected by filtration and dried under vacuum to give (S)-(1-(7-(4-methoxyphenyl)-4-((1-phenyl-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77d) (6 mg, 28% yield) as a yellow solid; 1 H NMR (300 MHz, DMSO-d6): δ10.53 (s, 1H, D2O exchangeable), 8.29 (d, J = 1.5 Hz, 1H), 8.22–8.13 (m, 2H), 8.01 (d, J = 1.7 Hz, 1H), 7.76 (d, J = 7.9 Hz, 2H), 7.51 (t, J = 7.8 Hz, 2H), 7.36 (t, J = 7.3 Hz, 1H), 7.29 ( d,J=4.6Hz,1H),7.04–6.96(m,2H),6.81(d,J=4.6Hz,1H),4.23(s,1H),3.82(s,1H),3.79(s, 3H), 3.64–3.52 (m, 1H), 3.44 (q, J=10.0, 9.2Hz, 2H), 2.16–1.82 (m, 4H); MS (ES+): 482.6 (M+1).

[0829] Plan 78

[0830]

[0831] Preparation of (S)-(1-(6-(hydroxymethyl)-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (78f)

[0832] Step-1: Preparation of 2-chloro-4-(methylthio)thieno[3,2-d]pyrimidine (78a)

[0833] Compound 78a was prepared from 2,4-dichlorothieno[3,2-d]pyrimidine (12a) (2 g, 9.75 mmol) and sodium thiomethoxide (0.75 g, 10.24 mmol) according to the procedure reported in step-1 of Scheme 70. 2-Chloro-4-(methylsulfanyl)thieno[3,2-d]pyrimidine (78a) (1.85 g, 88% yield) was obtained as a brown solid after work-up; 1 H NMR (300MHz, DMSO-d6) δ8.47 (d, J = 5.4 Hz, 1H), 7.60 (d, J = 5.4 Hz, 1H), 2.75 (s, 3H).

[0834] Step-2: Preparation of 2-chloro-4-(methylthio)thieno[3,2-d]pyrimidine-6-carbaldehyde (78b)

[0835] Compound 78b was prepared from 2-chloro-4-(methylsulfanyl)thieno[3,2-d]pyrimidine (78a) (1 g, 4.61 mmol) according to the procedure reported in step-2 of Scheme 70. 2-Chloro-4-(methylsulfanyl)thieno[3,2-d]pyrimidine-6-carbaldehyde (78b) (1.05 g, 93% yield) was obtained as a red solid after work-up; 1 H NMR (300MHz, DMSO-d6) δ10.25(s,1H),8.50(s,1H),2.77(s,3H).

[0836] Step 3: Preparation of 2,4-dichlorothieno[3,2-d]pyrimidine-6-carbaldehyde (78c)

[0837] Compound 78c was prepared from 2-chloro-4-(methylthio)thieno[3,2-d]pyrimidine-6-carbaldehyde (78b) (200 mg, 0.82 mmol) according to the procedure reported in step-3 of Scheme 70. 2,4-Dichlorothieno[3,2-d]pyrimidine-6-carbaldehyde (78c) (75 mg, 39% yield) was obtained as a white solid after work-up. 1 H NMR (300MHz, DMSO-d6) δ10.29(s,1H),8.63(s,1H).

[0838] Step 4: Preparation of (2,4-dichlorothieno[3,2-d]pyrimidin-6-yl)methanol (78d)

[0839] Compound 78d was prepared from 2,4-dichlorothieno[3,2-d]pyrimidine-6-carbaldehyde (78c) (70 mg, 0.3 mmol) according to the procedure reported in step-4 of Scheme 70. (2,4-Dichlorothieno[3,2-d]pyrimidin-6-yl)methanol (78d) (95 mg) was obtained as a light orange solid after work-up; 1 HNMR (300 MHz, DMSO-d6) δ 7.43 (t, J = 1.3 Hz, 1H), 6.07 (t, J = 5.7 Hz, 1H, D2O exchangeable), 4.83 (dd, J = 5.8, 1.3 Hz, 2H).

[0840] Step 5: Preparation of (2-chloro-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-6-yl)methanol (78e)

[0841] Compound 78e was prepared from (2,4-dichlorothieno[3,2-d]pyrimidin-6-yl)methanol (78d) (90 mg, 0.38 mmol) in 2-propanol (10 mL) using DIPEA (0.1 mL, 0.57 mmol) and 1-phenyl-1H-imidazol-4-amine hydrochloride (8a) (91 mg, 0.57 mmol) according to the procedure reported in Scheme 1. This afforded (2-chloro-4-(1-phenyl-1H-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-6-yl)methanol (78e) (45 mg, 33% yield) as a dark brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.99-10.67 (m, 1H, D2O exchangeable), 8.27 (s, 1H), 7.94 (d, J = 1.7 Hz, 1H), 7.68 (d, J = 7.9 Hz, 2H), 7.57 (t, J = 7.8 Hz, 2H), 7.41 (t, J = 7.3 Hz, 1H), 7.21 (s, 1H), 5.92 (s, 1H, D2O exchangeable), 4.78 (d, J = 5.4 Hz, 2H); MS (ES+): 358.3 (M+1), (ES-): 356.3 (M-1).

[0842] Step 6: Preparation of (S)-(1-(6-(hydroxymethyl)-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (78f)

[0843] Compound 78f was prepared from (2-chloro-4-(1-phenyl-1H-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-6-yl)methanol (78e) (39 mg, 0.11 mmol), (S)-pyrrolidin-2-ylmethanol (33 mg, 0.33 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(6-(hydroxymethyl)-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (78f) (12 mg, 26% yield) was obtained as a brown solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.00 (s, 1H, D2O exchangeable), 8.20 (d, J = 1.7 Hz, 1H), 7.97 (d, J = 1.7 Hz, 1H), 7.81–7.59 (m, 2H), 7.51 (t, J = 7.7 Hz, 2H), 7.34 (t, J = 7.4 Hz, 1H), 6.93 (d, J = 1.1 Hz, 1H), 5.72 (t, J = 5.8 Hz, 1H, D2O exchangeable), 5.04 (s, 1H, D2O exchangeable), 4.70 (dd, J=5.8, 1.2 Hz, 2H), 4.22 (s, 1H), 3.88–3.69 (m, 1H), 3.69–3.49 (m, 2H), 3.44–3.24 (m, 1H), 2.12–1.81 (m, 4H); MS (ES+): 423.4 (M+1); (ES-): 421 (M-1); HPLC purity: 95.50%.

[0844] Plan 79

[0845]

[0846] Preparation of (S)-(1-(7-(pent-1-en-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (79d)

[0847] Step-1: Preparation of 2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde (79b)

[0848] Compound 79b was prepared from 2,4-dichloropyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde (79a) (400 mg, 1.85 mmol) in 2-propanol (20 mL) using DIPEA (0.97 mL, 5.55 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine (57a) (635 mg, 2.22 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde (79b) (564 mg, 71% yield) as a yellow solid; 1 HNMR(300MHz,DMSO-d6)δ11.81(s,1H),10.21(s,1H),9.46(s,0H),8.25(d,J=1.5Hz,1H),7.93(d, J=1.6Hz,1H),7.50(d,J=4.9Hz,1H),7.35(d,J=4.8Hz,1H),6.94(s,2H),3.88(s,6H),3.69(s,3H). MS(ES+): 429.5(M+1); MS(ES-): 427.3(M-1).

[0849] Step 2: Preparation of 1-(2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)pentan-1-ol (79c)

[0850] To a solution of 2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde (79b) (100 mg, 0.23 mmol) in THF (10 mL) was added n-BuLi (1.6 M, 0.32 mL, 0.51 mmol) at -78°C and stirred for 4 h at -78°C. The reaction mixture was quenched with saturated NH4Cl and extracted with ethyl acetate (3 x 30 mL). The combined organic layers were washed with brine, dried, filtered, concentrated in vacuo and purified by flash column chromatography (silica gel 12 g, eluted with MeOH / DCM from 0 to 20%) to give 1-(2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)pentan-1-ol (79c) (65 mg, 57% yield) as a yellow solid; 1H NMR (300MHz, chloroform-d) δ10.51(s,1H),7.94(d,J=1.6Hz,1H),7.65(d,J=1.6Hz ,1H),6.84(d,J=4.5Hz,1H),6.65(s,2H),6.58(d,J=4.4Hz,1H),5.16(dd,J =7.5,6.1Hz,1H),3.92(s,6H),3.88(s,3H),2.14–1.79(m,2H),1.65–1.21( m, 4H), 0.91 (t, J = 7.0Hz, 3H); MS (ES+): 487.5 (M+1); MS (ES-): 485.5 (M-1).

[0851] Step-3: Preparation of (S)-(1-(7-(pent-1-en-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (79d)

[0852] Compound 79d was prepared from 1-(2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)pentan-1-ol (79c) (65 mg, 0.13 mmol), (S)-pyrrolidin-2-ylmethanol (68 mg, 0.67 mmol), DIPEA (0.07 mL, 0.4 mmol) in NMP (2.5 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(7-(pent-1-en-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (79d) (11 mg, 15% yield) was obtained as a white solid; 1HNMR (300 MHz, DMSO-d6) δ 10.47 (s, 1H, D2O exchangeable), 8.24 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.14 (d, J = 4.6 Hz, 1H), 6.95 (s, 2H), 6.70 (d, J = 16.1 Hz, 1H), 6.55 (d, J = 4.6 Hz, 1H), 6.52–6.40 (m, 1H), 4.84 (t, J = 5.1 Hz, 1H, D2O exchangeable), 4.30–4.17 (m, 1H ),3.88(s,6H),3.81–3.68(m,1H),3.68(s,3H),3.66–3.53(m,1H),3.54–3.35(m,2H),2.19(q,J=7.1Hz,2H),2.10–1.81(m, 4H), 1.56–1.39 (m, 2H), 0.93 (t, J=7.2Hz, 3H); MS (ES+): 534.6 (M+1); MS (ES-): 532.7 (M-1), 568.6 (M+Cl); HPLC purity: 94.02%.

[0853] Plan 80

[0854]

[0855] Preparation of (S)-tert-butyl 4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-(1-phenyl-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (80a)

[0856] Compound 80a was prepared from (S)-(1-(7-bromo-4-(1-phenyl-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (77c) (30 mg, 0.07 mmol), 1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-ylboronic acid (30.0 mg, 0.13 mmol), Pd(dppf)Cl2 (9.69 mg, 0.01 mmol), sodium carbonate (17.50 mg, 0.17 mmol) in dioxane (3 mL) and water (1 mL) according to the procedure reported in step-3 of Scheme 77. After purification by reverse phase flash column chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], (S)-tert-butyl 4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-(1-phenyl-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (80a) (7 mg, 19% yield) was obtained as a brown solid; 1 H NMR (300 MHz, DMSO-d6): δ 10.52 (s, 1H, D2O exchangeable), 8.27 (d, J = 1.6 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 7.75 (d, J = 7.9 Hz, 2H), 7.51 (t, J = 7.8 Hz, 2H), 7.35 (t, J = 7.3 Hz, 1H), 7.21 (d,J=4.9Hz,1H),6.50(d,J=4.7Hz,1H),4.19(s,3H),4.06(s,3H),3.78(d,J=9.8Hz ,1H),3.54(s,3H),3.38(s,1H),2.59–2.53(m,1H),2.10–1.91(m,4H),1.43(s,9H). 19 FNMR (282MHz, DMSO-d6) δ-73.99; MS (ES+): 557.6 (M+1); 579.6 (M+Na).

[0857] Plan 81

[0858]

[0859] Preparation of N-(1'-methyl-1'H-[1,4'-biimidazole]-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (81c)

[0860] Step-1: Preparation of 2-chloro-N-(1'-methyl-1'H-[1,4'-biimidazole]-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (81b)

[0861] Compound 81b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (187 mg, 0.99 mmol) in 2-propanol (10 mL) using DIPEA (0.52 mL, 2.98 mmol) and 1'-methyl-1'H-1,4'-biimidazole-4-amine (81a) (162 mg, 0.99 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1'-methyl-1'H-[1,4'-biimidazole]-4-yl)pyrrolo[2,1-f][1,2,4]triazine-4-amine (81b) (205 mg, 66% yield) as a light off-white solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.31 (s, 1H, D2O exchangeable), 8.03 (d, J = 1.5 Hz, 1H), 7.84 (d, J = 1.5 Hz, 1H), 7.76 (dd, J = 2.6, 1.5 Hz, 1H), 7.65 (d, J = 1.4 Hz, 1H), 7.49 (d, J = 1.5 Hz, 1H), 7.39 (dd, J = 4.5, 1.6 Hz, 1H), 6.71 (dd, J = 4.4, 2.6 Hz, 1H), 3.71 (s, 3H); MS (ES+): 315.3 (M+1), 337.3 (M+Na); MS (ES-): 313.3 (M-1); HPLC purity: 99.21%.

[0862] Step-2: Preparation of N-(1'-methyl-1'H-[1,4'-biimidazole]-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (81c)

[0863] Compound 81c was prepared from 2-chloro-N-(1'-methyl-1'H-[1,4'-biimidazole]-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (81b) (70 mg, 0.22 mmol), 2-(pyrrolidin-2-yl)pyridine (99 mg, 0.67 mmol) and DIPEA (0.12 mL, 0.67 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, N-(1'-methyl-1'H-[1,4'-biimidazole]-4-yl)-2-(2-(pyridin-2-yl)pyrrolidin-1-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (81c) (55 mg, 58% yield) was obtained as an off-white solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.40 (s, 1H, D2O exchangeable), 8.44 (d, J = 4.8 Hz, 1H), 7.89 (d, J = 1.5 Hz, 1H), 7.65 (s, 1H), 7.64-7.55 (m, 1H), 7.44 (d, J = 1.5 Hz, 1H), 7.42-7.33 (m, 2H), 7.20 (d, J = 7.9 Hz, 1H), 7.21-7.10 (m, 1H), 7 .12-7.08(m,1H),6.38(dd,J=4.5,2.4Hz,1H),5.34(d,J=8.1Hz,1H),3.92-3.80(m,1H),3.79(s,3H),3.74 -3.57 (m, 1H), 2.53-2.25 (m, 1H), 2.11-1.74 (m, 3H); MS (ES+): 427.5 (M+1), 449.5 (M+Na); HPLC purity: 98.90%.

[0864] Plan 82

[0865]

[0866] Preparation of (S)-(1-(4-((1'-methyl-1'H-[1,4'-biimidazole]-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (82a)

[0867] Compound 82a was prepared from 2-chloro-N-(1'-methyl-1'H-[1,4'-biimidazole]-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (81b) (70 mg, 0.22 mmol), (S)-pyrrolidin-2-ylmethanol (112 mg, 1.11 mmol) and DIPEA (0.12 mL, 0.67 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1'-methyl-1'H-[1,4'-biimidazole]-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (82a) (65 mg, 77% yield) was obtained as an off-white solid; 1 HNMR(300MHz,DMSO-d6)δ10.52(s,1H),8.01(d,J=1.5Hz,1H),7.89(d,J=1.6Hz,1H),7.71-7.5 8(m,1H),7.54(d,J=1.5Hz,1H),7.39(dd,J=2.4,1.6Hz,1H),7.12(dd,J=4.4,1.7Hz,1H),6.39( dd,J=4.4,2.5Hz,1H),5.26-4.98(m,1H),4.31-4.00(m,1H),3.95-3.76(m,1H),3.73-3.65(m,3 H), 3.53-3.25 (m, 3H), 2.16-1.84 (m, 4H); MS (ES+): 380.4 (M+1), 402.4 (M+Na); HPLC purity: 99.92%.

[0868] Plan 83

[0869]

[0870] Preparation of ((S)-1-(4-((1-(3-fluoro-5-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)phenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (83c)

[0871] Step-1: Preparation of 2-chloro-N-(1-(3,5-difluorophenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (83b)

[0872] Compound 83b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (365 mg, 1.94 mmol) in 2-propanol (10 mL) using DIPEA (1.02 mL, 5.83 mmol) and 1-(3,5-difluorophenyl)-1H-imidazol-4-amine (83a) (379 mg, 1.94 mmol) according to the procedure reported in Scheme 1. This gave 2-chloro-N-(1-(3,5-difluorophenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazine-4-amine (83b) (521 mg, 77% yield) as a solid; 1 HNMR (300 MHz, DMSO-d6) δ 11.33 (s, 1H, D2O exchangeable), 8.38 (d, J = 1.6 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.79 (dd, J = 2.6, 1.5 Hz, 1H), 7.65-7.53 (m, 2H), 7.45-7.36 (m, 1H), 7.31 (tt, J = 9.3, 2.2 Hz, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H); 19 F NMR (282 MHz, DMSO-d6) δ -107.50; MS (ES+): 347.3 (M+1); MS (ES-): 345.2 (M-1); HPLC purity: 98.86%.

[0873] Step-2: Preparation of ((S)-1-(4-((1-(3-fluoro-5-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)phenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (83c)

[0874] Compound 83c was prepared from 2-chloro-N-(1-(3,5-difluorophenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (83b) (100 mg, 0.29 mmol), (S)-pyrrolidin-2-ylmethanol (146 mg, 1.44 mmol) and DIPEA (0.15 mL, 0.87 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, ((S)-1-(4-((1-(3-fluoro-5-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)phenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (83c) (66 mg, 47% yield) was obtained as a white solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.55 (s, 1H, D2O exchangeable), 8.24 (d, J = 1.5 Hz, 1H), 7.95 (d, J = 1.6 Hz, 1H), 7.39 (dd, J = 2.5, 1.7 Hz, 1H), 7.14 (dd, J = 4.5, 1.7 Hz, 1H), 6.90–6.77 (m, 1H), 6.60 (s, 1H), 6.46–6.33 (m, 2H), 4.83 (t, J = 6.1 Hz, 2H, D2O exchangeable), 4.27–4.08 (m, 1H), 3.83–3.75 (m, 1H), 3.74–3.64 (m, 1H), 3.61–3.55 (m, 1H), 3.53–3.29 (m, 4H), 3.27–3.21 (m, 1H), 3.18–3.05 (m, 1H), 2.22–1.72 (m, 8H); 19 F NMR(282MHz,DMSO-d6)δ-110.98-111.15(m); 19 FCPD NMR (282MHz, DMSO-d6) δ-111.06; MS (ES+): 493.5 (M+1); MS (ES-): 491.4 (M-1), 527.6 (M+Cl); HPLC purity: 96.03%.

[0875] Plan 84

[0876]

[0877] Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (84b)

[0878] Step-1: Preparation of 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (84a)

[0879] Compound 84a was prepared from 2,4-dichlorothieno[2,3-d]pyrimidine (31a) (0.4 g, 1.95 mmol) in 2-propanol (10 mL) using DIPEA (1.36 mL, 7.8 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine (57a) (669 mg, 2.34 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (84a) (275 mg, 34% yield) as a light tan solid; 1 HNMR (300 MHz, DMSO-d6) δ11.01 (s, 1H, D2O exchangeable), 8.21 (d, J = 1.6 Hz, 1H), 8.02 (s, 1H), 7.91 (d, J = 1.6 Hz, 1H), 7.71 (d, J = 5.9 Hz, 1H), 6.93 (s, 2H), 3.87 (s, 6H), 3.69 (s, 3H); MS (ES+): 440.3 (M+Na), (ES-): 416.2 (M-1).

[0880] Step-2: Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (84b)

[0881] Compound 84b was prepared from 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (84a) (100 mg, 0.24 mmol), (S)-pyrrolidin-2-ylmethanol (73 mg, 0.72 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] followed by conversion to the free base using NaHCO3, (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (84b) (65 mg, 56% yield) was obtained as a brown solid; 1 HNMR (300 MHz, DMSO-d6) δ 10.17 (s, 1H, D2O exchangeable), 8.23 ​​(d, J = 1.7 Hz, 1H), 8.08-7.94 (m, 1H), 7.79 (d, J = 6.0 Hz, 1H), 7.02 (d, J = 6.0 Hz, 1H), 6.95 (s, 2H), 4.90 (s, 1H, D2O exchangeable), 4.47-4.24 (m, 1H), 3.88 (s, 6H ), 3.82-3.51 (m, 5H), 3.46-3.23 (m, 2H), 2.13-1.79 (m, 4H); MS (ES+): 483.4 (M+1), 505.4 (M+Na), (ES-): 481.4 (M-1); The hydrochloride salt of compound 84b was prepared by purification of the crude reaction mixture from the above step-2 by reverse phase flash chromatography [(silica gel C-18, 24 g), eluted with acetonitrile and water containing 0.1% HCl]; 1 HNMR (300MHz, DMSO-d6): δ11.36(s,1H),8.45(s,1H),8.20–7.84(m,2H),7.37(d,J= 5.8Hz,1H),6.99(s,2H),4.68–4.19(m,1H),4.14–3.07(m,13H),2.20–1.76(m,4H). MS (ES+): 483.2 (M+1), 505.3 (M+Na); MS (ES-): 517.2 (M+Cl); HPLC purity; 95.11%.

[0882] Plan 85

[0883]

[0884] Preparation of (S)-(1-(7-bromo-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (85b)

[0885] Step-1: Preparation of 7-bromo-2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (85a)

[0886] Compound 85a was prepared from 7-bromo-2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (77a) (500 mg, 1.87 mmol) in 2-propanol (20 mL) using DIPEA (0.98 mL, 5.62 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine hydrochloride (57a) (0.71 g, 2.47 mmol) according to the procedure reported in Scheme 1. After workup and purification by flash column chromatography [silica gel, 40 g, eluted with DCM and methanol (0 to 30%)], 7-bromo-2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (85a) (480 mg, 53% yield) was obtained as a brown solid. 1 H NMR (300 MHz, DMSO-d6) δ 11.46 (s, 1H, D2O exchangeable), 8.22 (d, J = 1.6 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.51 (d, J = 4.7 Hz, 1H), 6.93 (s, 2H), 6.90 (d, J = 4.6 Hz, 1H), 3.87 (s, 6H), 3.69 (s, 3H). MS (ES+): 481.3 (M+2); MS (ES-): 479.2, 481.2 (M+2).

[0887] Step-2: Preparation of (S)-(1-(7-bromo-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (85b)

[0888] Compound 85b was prepared from 7-bromo-2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (85a) (50 mg, 0.1 mmol), (S)-pyrrolidin-2-ylmethanol (0.03 mL, 0.31 mmol) and DIPEA (0.06 mL, 0.31 mmol) in NMP (3 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash column chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] followed by lyophilization, (S)-(1-(7-bromo-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (85b) (16 mg, 28% yield) was obtained as a white solid; 1 HNMR (300 MHz, DMSO-d6): δ10.68 (s, 1H, D2O exchangeable), 8.26 (d, J = 1.5 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 7.28 (d, J = 4.6 Hz, 1H), 6.96 (s, 2H), 6.55 (d, J = 4.6 Hz, 1H), 4.24 (s, 1H), 3.88 (s, 6H), 3.68 (s, 3H), 3.40–3.34 (m, 2H), 2.07–1.83 (m, 4H). 19 F NMR(282MHz, DMSO-d6)δ-74.03; MS(ES+): 544.4,546.4(M+2); MS(ES-): 542.4,544.3(M+2).

[0889] Plan 86

[0890]

[0891] Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)quinazolin-2-yl)pyrrolidin-2-yl)methanol (86b)

[0892] Step-1: Preparation of 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)quinazolin-4-amine (86a)

[0893] Compound 86a was prepared from 2,4-dichloroquinazoline (21a) (0.4 g, 2.01 mmol) in 2-propanol (10 mL) using DIPEA (1.4 mL, 8.04 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine hydrochloride (57a) (0.69 g, 2.41 mmol) according to the procedure reported in Scheme 1. This afforded 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)quinazolin-4-amine (86a) (1.26 mmol, 63% yield) as a light pink solid; 1 HNMR (300 MHz, DMSO-d6) δ11.12 (s, 1H, D2O exchangeable), 8.75 (d, J = 8.3 Hz, 1H), 8.24 (s, 1H), 8.01 (d, J = 1.7 Hz, 1H), 7.87 (t, J = 7.6 Hz, 1H), 7.72 (d, J = 8.2 Hz, 1H), 7.61 (t, J = 7.7 Hz, 1H), 6.95 (s, 2H), 3.88 (s, 6H), 3.70 (s, 3H); MS (ES+): 412.4 (M+1), 434.3 (M+Na), (ES-): 410.3 (M-1).

[0894] Step-2: Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)quinazolin-2-yl)pyrrolidin-2-yl)methanol (86b)

[0895] Compound 86b was prepared from 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)quinazolin-4-amine (86a) (100 mg, 0.24 mmol), (S)-pyrrolidin-2-ylmethanol (74 mg, 0.73 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-(1-(4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)quinazolin-2-yl)pyrrolidin-2-yl)methanol (86b) (55 mg, 48% yield) was obtained as a cream-colored solid; 1H NMR (300 MHz, DMSO-d6) δ 10.59–10.09 (m, 1H, D2O exchangeable), 8.47 (d, J = 8.1 Hz, 1H), 8.27 (s, 1H), 8.20–7.94 (m, 1H), 7.54 (t, J = 7.7 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.08 (t, J = 7.6 Hz, 1H), 6.98(s, 2H), 5.09–4.67(m, 1H, D2O exchangeable), 4.56–4.14(m, 2H), 3.89(s, 6H), 3.69(s, 5H), 3.57–3.17(m, 1H), 2.18–1.79(m, 4H); MS(ES+): 477.5(M+1), (ES-): 475.5(M-1).

[0896] Plan 87

[0897]

[0898] Preparation of (S)-(1-(7-bromo-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (87c)

[0899] Step-1: Preparation of 7-bromo-2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (87b)

[0900] Compound 87b was prepared from 7-bromo-2,4-dichlorothieno[3,2-d]pyrimidine (87a) (0.2 g, 0.70 mmol; CAS# 41102-25-4) in 2-propanol (6 mL) using DIPEA (0.67 mL, 3.83 mmol) and 1-phenyl-1H-imidazol-4-amine, HCl (8a) (182 mg, 0.93 mmol) according to the procedure reported in Scheme 1. After workup and purification by flash column chromatography [silica gel 12 g, eluted with a 9:1 mixture of ethyl acetate and methanol in hexanes (0 to 100%)], 7-bromo-2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (87b) (122 mg, 43% yield) was obtained as a brown solid. 1 HNMR (300 MHz, DMSO-d6) δ 11.34 (s, 1H, D2O exchangeable), 8.44 (s, 1H), 8.29 (s, 1H), 7.96 (s, 1H), 7.73–7.64 (m, 2H), 7.62–7.52 (m, 2H), 7.46–7.36 (m, 1H). MS (ES-): 404.1, 406.1 (M-2).

[0901] Step-2: Preparation of (S)-(1-(7-bromo-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (87c)

[0902] Compound 87c was prepared from 7-bromo-2-chloro-N-(1-phenyl-1H-imidazol-4-yl)thieno[3,2-d]pyrimidin-4-amine (87b) (50 mg, 0.12 mmol), (S)-pyrrolidin-2-ylmethanol (0.04 mL, 0.39 mmol) and DIPEA (0.06 mL, 0.37 mmol) in NMP (0.5 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash column chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by lyophilization, (S)-(1-(7-bromo-4-((1-phenyl-1H-imidazol-4-yl)amino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (87c) (22 mg, 38% yield) was obtained as a light yellow solid; 1 HNMR (300 MHz, methanol-d4) δ8.78–8.54 (m, 1H), 8.28 (s, 1H), 8.21–8.01 (m, 1H), 7.74–7.54 (m, 4H), 7.54–7.43 (m, 1H), 4.38–4.15 (m, 1H), 4.14–3.93 (m, 2H), 3.93–3.65 (m, 2H), 2.44–2.21 (m, 1H), 2.21–1.99 (m, 2H), 1.99–1.79 (m, 1H); 19 F NMR (282 MHz, methanol-d4) δ-77.25; MS (ES+): 471.3, 473.3 (M+2). HPLC purity: 97.84%.

[0903] Plan 88

[0904]

[0905] Preparation of 2-(4-methoxyphenyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (88a)

[0906] Compound 88a was prepared from 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (57b) (200 mg, 0.5 mmol), 4-methoxyphenylboronic acid (114 mg, 0.75 mmol), PdCl2(dppf) (73 mg, 0.100 mmol) in anhydrous 1,4-dioxane (15 mL) and water (1 mL) using potassium carbonate (207 mg, 1.5 mmol) according to the procedure reported in step-3 of Scheme 77. After workup, 2-(4-methoxyphenyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (88a) (52 mg, 22% yield) was obtained as a white solid; 1 HNMR (300 MHz, DMSO-d6) δ10.89 (s, 1H, D2O exchangeable), 8.33–8.29 (m, 1H), 8.28 (s, 1H), 8.24 (s, 1H), 8.20–8.15 (m, 1H), 7.78 (s, 1H), 7.34 (s, 1H), 7.08–6.97 (m, 4H), 6.73–6.67 (m, 1H), 3.93 (s, 6H), 3.82 (s, 3H), 3.71 (s, 3H); MS (ES+): 473.5 (M+1), 495.4 (M+Na), MS (ES-): 471.4 (M-1), 507.4 (M+Cl).

[0907] Plan 89

[0908]

[0909] Preparation of (S)-(1-(7-(4-methoxyphenyl)-4-(1-phenyl-1H-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (89a)

[0910] Compound 89a was prepared from (S)-(1-(7-bromo-4-(1-phenyl-1H-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (87c) (50 mg, 0.11 mmol), 4-methoxyphenylboronic acid (81 mg, 0.53 mmol), Pd(dppf)Cl2 (4 mg, 5.30 μmol) in anhydrous 1,4-dioxane (3 mL) and water (1 mL) using sodium carbonate (28 mg, 0.27 mmol) according to the procedure reported in step-3 of Scheme 77. After workup, purification by reverse phase flash column chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] and lyophilization, (S)-(1-(7-(4-methoxyphenyl)-4-(1-phenyl-1H-imidazol-4-ylamino)thieno[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (89a) (20 mg, 38% yield) was obtained as a yellow solid; 1 H NMR (300MHz, methanol-d4): δ8.20(s,1H),8.03(d,J=12.4Hz,2H),7.61(dd,J=11.6,7.7Hz,4H),7.53–7.42(m,3H),7.13–7.03(m,2H),4.18(s,1H) ,4.12–3.96(m,1H),3.86(s,3H),3.78(dd,J=10.4,2.4Hz,1H),3.73–3 .63(m,1H),3.60(s,1H),2.34–2.17(m,1H),2.05(s,2H),1.87(s,1H). 19 F NMR (282 MHz, methanol-d4) δ-77.28; MS (ES+): 499.5 (M+1), 521.5 (M+Na); MS (ES-): 497.5 (M-1).

[0911] Plan 90

[0912]

[0913] Preparation of (S)-(1-(7-(4-methoxyphenyl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (90a)

[0914] Compound 90a was prepared from (S)-(1-(7-bromo-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (85b) (70 mg, 0.13 mmol), 4-methoxyphenylboronic acid (98 mg, 0.64 mmol), Pd(dppf)Cl2 (5 mg, 6.43 μmol) in anhydrous 1,4-dioxane (3 mL) and water (1 mL) using sodium carbonate (34 mg, 0.32 mmol) according to the procedure reported in step-3 of Scheme 77. After workup, purification by reverse phase flash column chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] and lyophilization, (S)-(1-(7-(4-methoxyphenyl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (90a) (31 mg, 42% yield) was obtained as a yellow solid; 1 H NMR (300 MHz, DMSO-d6): δ10.57 (s, 1H, D2O exchangeable), 8.33 (s, 1H), 8.17 (d, J=8.7 Hz, 2H), 8.01 (s, 1H), 7.27 (s, 1H), 7.06–6.92 (m, 4H), 6.81 (s, 1H), 4.57 (s, 1H), 4.36–4.16 (m, 1H), 4.04 (s, 1H), 3.92–3.87 (m, 6H), 3.83–3.75 (m, 3H), 3.73–3.64 (m, 3H), 3.57–3.31 (m, 2H), 2.12–1.85 (m, 4H). 19 F NMR (282MHz, DMSO-d6) δ-74.45; MS (ES+): 572.6, 594.6 (M+Na), 610.4 (M+K).

[0915] Plan 91

[0916]

[0917] Preparation of (S)-1-(4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidine-2-carboxamide (91a)

[0918] Compound 91a was prepared from a stirred suspension of 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (57b) (0.2 g, 0.5 mmol), (S)-pyrrolidine-2-carboxamide (0.17 g, 1.5 mmol) and DIPEA (0.26 mL, 1.5 mmol) in NMP (2 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash column chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] followed by lyophilization, (S)-1-(4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidine-2-carboxamide (91a) (50 mg, 19% yield) was obtained as a white solid; 1 H NMR (300 MHz, DMSO-d6): δ 10.50 (s, 1H, D2O exchangeable), 8.22 (d, J = 5.6 Hz, 1H), 7.92 (d, J = 5.4 Hz, 1H), 7.42 (d, J = 5.4 Hz, 1H), 7.23 (s, 1H, D2O exchangeable), 7.17 (s, 1H), 7.12-7.05 (m, 2H), 7. 02(s,1H,D2O exchangeable),6.41(d,J=5.6Hz,1H),4.41(s,1H),3.93(t,J=4.2Hz,6H),3.68(t,J=4.2Hz,3H),3.35(s,1H),2.19(s,1H),1.95(d,J=13.6Hz,4H); MS(ES+):479.5(M+1).

[0919] Plan 92

[0920]

[0921] Preparation of isobutyl (S)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidine-6-carboxylate (92d)

[0922] Step-1: Preparation of isobutyl 2-chloro-4-(methylthio)thieno[2,3-d]pyrimidine-6-carboxylate (92a)

[0923] Compound 92a was prepared from 2-chloro-4-(methylsulfanyl)thieno[2,3-d]pyrimidine (70a) (0.5 g, 2.31 mmol) in THF (20 mL) using n-butyllithium (1.6 M in hexanes, 3.03 mL, 4.85 mmol) and quenched with isobutyl chloroformate (0.6 mL, 4.61 mmol) according to the procedure reported in step-2 of Scheme 70. After workup and purification by flash column chromatography [silica gel, (25 g), eluted with 0-100% ethyl acetate / hexanes], isobutyl 2-chloro-4-(methylsulfanyl)thieno[2,3-d]pyrimidine-6-carboxylate (92a) (403 mg, 55% yield) was obtained as a brown solid; 1 HNMR (300MHz, DMSO-d6) δ 8.09 (s, 1H), 4.14 (d, J = 6.6Hz, 2H), 2.70 (s, 3H), 2.04 (hept, J = 6.6Hz, 1H), 0.97 (d, J = 6.7Hz, 6H); MS (ES+): 339.2 (M + Na).

[0924] Step-2: Preparation of isobutyl 2,4-dichlorothieno[2,3-d]pyrimidine-6-carboxylate (92b)

[0925] Compound 92b was prepared from isobutyl 2-chloro-4-(methylsulfanyl)thieno[2,3-d]pyrimidine-6-carboxylate (92a) (375 mg, 1.18 mmol) using sulfuryl chloride (0.48 mL, 5.92 mmol) in acetonitrile (30 mL) and DCM (5 mL) according to the procedure reported in step-3 of Scheme 70. After work-up and purification by flash column chromatography [silica gel, (12 g), eluted with 0-100% ethyl acetate / hexane], isobutyl 2,4-dichlorothieno[2,3-d]pyrimidine-6-carboxylate (92b) (174 mg, 48% yield) was obtained as a syrup; 1 H NMR (300MHz, DMSO-d6) δ8.21 (s, 1H), 4.17 (d, J = 6.6Hz, 2H), 2.06 (dt, J = 13.4, 6.7Hz, 1H), 0.99 (d, J = 6.8Hz, 6H).

[0926] Step 3: Preparation of isobutyl 2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidine-6-carboxylate (92c)

[0927] Compound 92c was prepared from isobutyl 2,4-dichlorothieno[2,3-d]pyrimidine-6-carboxylate (92b) (160 mg, 0.52 mmol) in 2-propanol (5 mL) using DIPEA (0.27 mL, 1.57 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine hydrochloride (57a) (0.22 g, 0.78 mmol) according to the procedure reported in Scheme 1. This afforded isobutyl 2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidine-6-carboxylate (92c) (160 mg, 59% yield) as a brown solid; 1 HNMR (300 MHz, DMSO-d6) δ11.43 (s, 1H, D2O exchangeable), 8.87 (s, 1H), 8.22 (d, J = 1.6 Hz, 1H), 7.91 (d, J = 1.6 Hz, 1H), 6.94 (s, 2H), 4.12 (d, J = 6.5 Hz, 2H), 3.88 (s, 6H), 3.70 (s, 3H), 2.09-1.96 (m, 1H), 1.01 (d, J = 6.7 Hz, 6H); MS (ES+): 540.5 (M+Na), (ES-): 516.5 (M-1).

[0928] Step 4: Preparation of (S)-2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidine-6-carboxylic acid isobutyl ester (92d)

[0929] Compound 92d was prepared from 2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidine-6-carboxylate (92c) (80 mg, 0.15 mmol), (S)-pyrrolidin-2-ylmethanol (46.9 mg, 0.46 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup by pouring the reaction mixture into water and collecting the precipitated solid by filtration followed by drying in vacuo, (S)-isobutyl 2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidine-6-carboxylate (92d) (65 mg, 72% yield) was obtained as a brown solid; 1H NMR (300 MHz, DMSO-d6) δ 10.32 (s, 1H, D2O exchangeable), 8.63 (s, 1H), 8.12 (d, J = 1.7 Hz, 1H), 7.95 (s, 1H), 6.92 (s, 1H), 4.61 (s, 1H), 4.31 (s, 1H), 4.08-3.99 (m, 2H), 3.87 (s, 6H), 3.84-3.58 (m, 5H), 3.52-3.36 (m, 2H), 2.13-1.76 (m, 5H), 1.00 (dd, J = 6.6, 1.6 Hz, 6H); MS (ES+): 583.6 (M+1).

[0930] Plan 93

[0931]

[0932] Preparation of (S)-4-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (93c)

[0933] Step-1: Preparation of 4-(4-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (93b)

[0934] Compound 93b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (180 mg, 0.97 mmol) in 2-propanol (20 mL) using DIPEA (0.51 mL, 2.92 mmol) and 4-(4-amino-1H-imidazol-1-yl)benzamide hydrochloride (93a) (0.26 g, 1.29 mmol) according to the procedure reported in Scheme 1. After workup and purification by flash column chromatography [silica gel, (40 g) eluted with DCM and methanol (0 to 30%)], 4-(4-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (93b) (0.26 g, 76% yield) was obtained as a brown solid; 1H NMR (300 MHz, DMSO-d6): δ 11.37 (s, 1H, D2O exchangeable), 8.38 (d, J = 1.7 Hz, 1H), 8.09 (s, 1H, D2O exchangeable), 8.08-8.01 (m, 2H), 7.98 (d, J = 1.7 Hz, 1H), 7.78 (d, J = 2.3 Hz, 2H), 7.75 (s, 1H), 7.50 (s, 1H, D2O exchangeable), 7.40 (d, J = 4.4 Hz, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H). MS (ES+): 354.4; MS (ES-): 352.3.

[0935] Step-2: Preparation of (S)-4-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (93c)

[0936] Compound 93c was prepared from 4-(4-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (93b) (160 mg, 0.45 mmol), (S)-pyrrolidin-2-ylmethanol (0.13 mL, 1.34 mmol) and DIPEA (0.23 mL, 1.34 mmol) in NMP (1.5 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-4-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (93c) (102 mg, 55% yield) was obtained as a brown solid; 1HNMR (300 MHz, DMSO-d6): δ10.57 (s, 1H, D2O exchangeable), 8.37 (d, J = 1.5 Hz, 1H), 8.08 (s, 1H, D2O exchangeable), 8.05-8.01 (m, 2H), 7.99 (s, 1H), 7.86 (d, J = 8.4 Hz, 2H), 7.44 (s, 1H, D2O exchangeable), 7.40 (t, J = 2.0 Hz, 1H ),7.16(dd,J=4.4,1.7Hz,1H),6.40(dd,J=4.5,2.4Hz,1H),4.99(s,1H,D2O exchangeable),4.21(s,2H),3.89-3.70(m,1H),3.50(s,2H),2.17-1.75(m,4H); MS(ES+):419.4(M+1); MS(ES-):453.4(M+Cl).

[0937] Plan 94

[0938]

[0939] Preparation of (S)-3-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (94c)

[0940] Step-1: Preparation of 3-(4-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (94b)

[0941] Compound 94b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (240 mg, 1.29 mmol) in 2-propanol (20 mL) using DIPEA (0.68 mL, 3.87 mmol) and 3-(4-amino-1H-imidazol-1-yl)benzamide hydrochloride (94a) (0.4 g, 1.68 mmol) according to the procedure reported in Scheme 1. After workup and purification by flash column chromatography [silica gel, (40 g) eluted with DCM and methanol (0 to 30%)], 3-(4-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (94b) (0.27 g, 60% yield) was obtained as a brown solid; 1H NMR (300 MHz, DMSO-d6): δ 11.36 (s, 1H, D2O exchangeable), 8.31 (d, J = 1.6 Hz, 1H), 8.18 (s, 1H), 8.11 (t, J = 1.9 Hz, 1H), 7.96 (d, J = 1.6 Hz, 1H), 7.89 (dt, J = 7.6, 1.3 Hz, 1H), 7.86–7.80 (m, 1H), 7.78 (dd, J = 2.6, 1.5 Hz, 1H), 7.65 (t, J = 7.9 Hz, 1H), 7.60 (s, 1H), 7.41 (d, J = 4.4 Hz, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H). MS(ES+):354.3(M+1); MS(ES-):352.3(M-1).

[0942] Step-2: Preparation of (S)-3-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (94c)

[0943] Compound 94c was prepared from 3-(4-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (94b) (150 mg, 0.42 mmol), (S)-pyrrolidin-2-ylmethanol (0.13 mL, 1.34 mmol) and DIPEA (0.22 mL, 1.27 mmol) in NMP (1.5 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-3-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)benzamide (94c) (0.12 g, 69% yield) was obtained as a brown solid; 1HNMR (300 MHz, DMSO-d6): δ10.57 (s, 1H, D2O exchangeable), 8.30 (d, J = 1.5 Hz, 1H), 8.15–8.08 (m, 2H), 8.04 (d, J = 1.6 Hz, 1H), 7.92 (dd, J = 8.0, 2.1 Hz, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.69–7.53 (m, 2H), 7.39 (t, J=2.0 Hz, 1H), 7.14 (dd, J=4.4, 1.6 Hz, 1H), 6.40 (dd, J=4.5, 2.4 Hz, 1H), 4.97 (s, 1H, D2O exchangeable), 4.21 (s, 1H), 3.78 (dd, J=10.0, 3.5 Hz, 1H), 3.51 (d, J=18.1 Hz, 2H), 3.35 (s, 1H), 2.11–1.82 (m, 4H). 19 F NMR (282MHz, DMSO-d6) δ-73.49; MS (ES+): 419.5 (M+1); MS (ES-): 453.4 (M+Cl).

[0944] Plan 95

[0945]

[0946] Preparation of (S)-1-(4-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)phenyl)ethanone (95c)

[0947] Step-1: Preparation of 1-(4-(4-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)phenyl)ethanone (95b)

[0948] Compound 95b was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (240 mg, 1.3 mmol) in 2-propanol (20 mL) using DIPEA (0.51 mL, 2.92 mmol) and 1-(4-(4-amino-1H-imidazol-1-yl)phenyl)ethanone hydrochloride (95a) (0.4 g, 1.68 mmol) according to the procedure reported in Scheme 1. After workup and purification by flash column chromatography [silica gel, (40 g) eluted with DCM and methanol (0 to 30%)], 1-(4-(4-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)phenyl)ethanone (95b) (0.26 g, 57% yield) was obtained as a brown solid; 1H NMR (300 MHz, DMSO-d6): δ 11.40 (s, 1H, D2O exchangeable), 8.45 (d, J = 1.6 Hz, 1H), 8.18-8.09 (m, 2H), 8.01 (d, J = 1.6 Hz, 1H), 7.86-7.80 (m, 2H), 7.79 (dd, J = 2.6, 1.5 Hz, 1H), 7.41 (d, J = 4.4 Hz, 1H), 6.73 (dd, J = 4.5, 2.6 Hz, 1H), 2.62 (s, 3H). MS (ES-): 351.3, 353.3 (M-1).

[0949] Step-2: Preparation of (S)-1-(4-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)phenyl)ethanone (95c)

[0950] Compound 95c was prepared from 1-(4-(4-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)phenyl)ethanone (95b) (150 mg, 0.43 mmol), (S)-pyrrolidin-2-ylmethanol (0.13 mL, 1.34 mmol) and DIPEA (0.22 mL, 1.28 mmol) in NMP (1.5 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by conversion to the free base using NaHCO3, (S)-1-(4-(4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)pyrrolo[1,2-f][1,2,4]triazin-4-ylamino)-1H-imidazol-1-yl)phenyl)ethanone (95c) (30 mg, 14% yield) was obtained as a brown solid; 1H NMR (300 MHz, DMSO-d6): δ 10.79 (s, 1H, D2O exchangeable), 8.64 (s, 1H), 8.13-8.05 (m, 3H), 7.95 (d, J = 8.5 Hz, 2H), 7.44 (t, J = 2.0 Hz, 1H), 7.16 (dd, J = 4.5, 1.6 Hz, 1H), 6.43 (dd, J = 4.4, 2.4 Hz, 1H), 4.19 (s, 1H), 3.76 (dd, J = 10.0, 3.6 Hz, 1H), 3.58-3.42 (m, 1H), 3.36 (dd, J = 11.7, 7.1 Hz, 2H), 2.62 (s, 3H), 2.11-1.83 (m, 4H). MS(ES+): 418.5(M+1); MS(ES-): 452.5(M+Cl).

[0951] Plan 96

[0952]

[0953] Preparation of (S)-(1-(2-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96b)

[0954] Step-1: Preparation of (S)-(1-(2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96a)

[0955] To a solution of 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine (4a) (0.5 g, 2.7 mmol) in 2-propanol (6 mL) was added (S)-pyrrolidin-2-ylmethanol (0.39 mL, 4.0 mmol), DIPEA (1.39 mL, 8.0 mmol) and heated at 90°C for 1 hour. The reaction was cooled to room temperature and the resulting solid was collected by filtration to give (S)-(1-(2-chloropyrrolo[2,1-f][1,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96a) (0.49 g, 73% yield) as a white solid; 1H NMR (300 MHz, DMSO-d6): δ 7.70 (dd, J = 2.6, 1.4 Hz, 1H), 6.97 (dd, J = 4.7, 1.6 Hz, 1H), 6.80-6.57 (m, 1H), 5.15 (t, J = 5.7 Hz, 1H, D2O exchangeable), 4.87 (t, J = 5.7 Hz, 1H), 4.44 (d, J = 17.8 Hz, 1H), 4.05-3.82 (m, 1H), 3.72-3.39 (m, 2H), 2.22-1.84 (m, 4H). MS (ES+): 253.3, 255.3 (M+2); MS (ES-): 287.2, 289.2 (M+Cl).

[0956] Step-2: Preparation of (S)-(1-(2-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96b)

[0957] A slurry of (S)-(1-(2-chloropyrrolo[1,2-f][1,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96a) (0.1 g, 0.4 mmol), 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine hydrochloride (57a) (0.11 g, 0.4 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (30 mg, 0.04 mmol), sodium 2-methylpropan-2-ol (80 mg, 0.79 mmol), and Pd2(dba)3 (40 mg, 0.04 mmol) in anhydrous dioxane (4 mL) was heated at 90° C. for 18 h in a sealed reactor under a positive flow of nitrogen. The reaction mixture was diluted with EtOAc (100 mL) and the organic layer was separated. The organic layer was washed with water (3×s), brine, dried, filtered, and concentrated to dryness in vacuo. The residue was purified by reverse phase flash column chromatography [(silica gel C-18, 24 g), eluting with acetonitrile and water containing 0.1% HCl] and lyophilized to give (S)-(1-(2-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-4-yl)pyrrolidin-2-yl)methanol (96b) (21 mg, 11% yield) hydrochloride as a yellow solid; 1H NMR (300 MHz, DMSO-d6): δ9.72 (s, 1H, D2O exchangeable), 9.63 (s, 1H, D2O exchangeable), 9.38 (s, 1H), 7.92 (s, 1H), 7.66 (s, 1H), 7.15 (s, 2H), 6.90 (d, J=4.5 Hz, 1H), 6.56 (s, 1H), 4.54 (s, 1H), 4.07-3.93 (m, 1H), 3.89 (s, 6H), 3.77 (s, 1H), 3.71 (s, 3H), 3.68-3.62 (m, 1H), 3.60-3.47 (m, 1H), 2.23-1.88 (m, 4H). MS(ES+): 466.5(M+1), 688.5(M+Na); MS(ES-): 464.6(M-1).

[0958] Plan 97

[0959]

[0960] Preparation of (S)-(1-(6-(morpholinomethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (97d)

[0961] Step-1: Preparation of (2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methanol (97a)

[0962] Compound 97a was prepared from (2,4-dichlorothieno[2,3-d]pyrimidin-6-yl)methanol (70d) (1.2 g, 5.1 mmol) in 2-propanol (15 mL) using DIPEA (2.67 mL, 15.31 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine hydrochloride (57a) (1.89 g, 6.64 mmol) according to the procedure reported in Scheme 1. This afforded (2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-6-yl)methanol (97a) (1.48 g, 65% yield) as a light brown solid; 1H NMR (300 MHz, DMSO-d6) δ 10.90 (s, 1H, D2O exchangeable), 8.19 (d, J = 1.6 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.84 (s, 1H), 6.93 (s, 2H), 5.82 (t, J = 5.8 Hz, 1H, D2O exchangeable), 4.72 (dd, J = 5.8, 1.2 Hz, 2H), 3.87 (s, 6H), 3.69 (s, 3H); MS (ES+): 448.3 (M+1), 470.3 (M+Na), (ES-): 446.3 (M-1).

[0963] Step-2: Preparation of 2-chloro-6-(chloromethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b)

[0964] To a stirred suspension of (2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-6-yl)methanol (97a) (0.5 g, 1.12 mmol) in DCM (50 mL) was added N,N-dimethylformamide (5 mL) and thionyl chloride (0.2 mL, 2.79 mmol) at 0°C. The reaction mixture was allowed to warm to room temperature overnight, concentrated to dryness in vacuo, triturated with hexanes and filtered to afford 2-chloro-6-(chloromethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b) (520 mg, 100% yield) as a solid, which was used as is in the next step; 1 H NMR (300 MHz, DMSO-d6 / D2O) δ 11.26 (s, 1H, D2O exchangeable), 8.07 (s, 1H), 8.00 (s, 1H), 7.96 (s, 1H), 7.01 (s, 2H), 5.17 (s, 2H), 3.88 (s, 6H), 3.70 (s, 3H); MS (ES+): 466.4, 468.4 (M+1), (ES-): 464.3, 466.4 (M-1).

[0965] Step 3: Preparation of 2-chloro-6-(morpholinomethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97c)

[0966] To a solution of 2-chloro-6-(chloromethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b) (100 mg, 0.21 mmol) in THF (3 mL) was added morpholine (0.04 mL, 0.43 mmol) and DIPEA (0.15 mL, 0.86 mmol) and heated at 50° C. overnight. The reaction mixture was concentrated in vacuo and purified by flash column chromatography to give 2-chloro-6-(morpholinomethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97c); 1 H NMR(300MHz,DMSO-d6)δ10.89(s,1H),8.19(d,J=1.6Hz,1H),7.88(d,J=1.6Hz,1H),6.93(s,2H), 3.87(s,6H),3.75(s,2H),3.60(m,6H),2.47(m,6H); MS(ES+):539.4(M+Na),(ES-):515.4(M-1).

[0967] Step 4: Preparation of (S)-(1-(6-(morpholinomethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (97d)

[0968] Compound 97d was prepared from 2-chloro-6-(morpholinomethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97c) (50 mg, 0.09 mmol), (S)-pyrrolidin-2-ylmethanol (0.03 mL, 0.26 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile and water containing 0.1% HCl] followed by lyophilization, (S)-(1-(6-(morpholinomethyl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (97d) (21 mg, 42% yield) HCl salt was obtained as a yellow solid; 1HNMR (300 MHz, DMSO-d6): δ11.70 (s, 1H, D2O exchangeable), 11.49 (s, 1H, D2O exchangeable), 8.52 (s, 1H), 8.11 (s, 1H), 8.07 (s, 1H), 8.02 (s, 1H, D2O exchangeable), 7.01 (s, 2H), 4.60 (s, 2H), 4.50 (s, 1H), 4.34 (s, 1H), 3.96 (s, 1H), 3.88 (s, 6H), 3.81 (s, 2H), 3.68 (s, 3H), 3.60-3.41 (m, 4H), 3.40-3.07 (m, 4H), 2.15-1.86 (m, 4H). MS(ES+): 582.6(M+1); MS(ES-): 616.6(M+Cl).

[0969] Plan 98

[0970]

[0971] Preparation of (S)-tert-butyl 4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (98a)

[0972] Compound 98a was prepared from (S)-(1-(7-bromo-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (85b) (150 mg, 0.28 mmol), 1-(tert-butoxycarbonyl)-1,2,3,6-tetrahydropyridin-4-ylboronic acid (188 mg, 0.83 mmol), Pd(dppf)Cl2 (10 mg, 0.01 mmol), sodium carbonate (73 mg, 0.69 mmol) in dioxane (3 mL) and water (1 mL) according to the procedure reported in step-3 of Scheme 77. After purification by reverse phase flash column chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] and subsequent conversion to the free base using NaHCO3, (S)-tert-butyl 4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (98a) (70 mg, 38% yield) was obtained as a white solid; 1H NMR (300 MHz, DMSO-d6): δ10.53 (s, 1H, D2O exchangeable), 8.24 (d, J = 1.5 Hz, 1H), 7.98 (d, J = 1.6 Hz, 1H), 7.20 (d, J = 4.6 Hz, 2H), 6.96 (s, 2H), 6.50 (d, J = 4.6 Hz, 1H), 4.85 (s, 1H, D2O exchangeable) (replaced),4.21(s,2H),4.06(s,2H),3.88(s,6H),3.79-3.71(m,1H),3.68(s,3H),3.54(s, 2H), 3.42 (d, J = 6.9Hz, 1H), 3.28 (s, 1H), 2.54 (s, 2H), 2.09-1.86 (m, 4H), 1.43 (s, 9H). MS(ES+):669.7(M+Na).

[0973] Plan 99

[0974]

[0975] Preparation of 1-(2-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)ethanol (99b)

[0976] Step-1: Preparation of 1-(2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)ethanol (99a)

[0977] Compound 99a was prepared from 2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde (79b) (200 mg, 0.47 mmol) in THF (10 mL) using MeLi (3M in THF, 0.33 mL, 1.03 mmol) according to the procedure reported in step-2 of Scheme 79. After work-up and purification by flash column chromatography (silica gel 12 g, eluted with MeOH / DCM from 0 to 10%), 1-(2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)ethanol (99a) (103 mg, 50% yield) was obtained as a light yellow solid; 1H NMR (300MHz, DMSO-d6) δ11.21(s,1H),8.20(d,J=1.6Hz,1H),7.88(d,J=1.6Hz,1H),7.36(d,J=4.5Hz,1H),6.93(s,2H),6.68(d,J=4.5Hz ,1H),5.31(d,J=5.0Hz,1H),5.16(p,J=6.4Hz,1H),3.87(s,6H),3.69(s,3H),1.45(d,J=6.5Hz,3H); MS(ES+):445.5(M+1),467.4(M+Na).

[0978] Step 2: Preparation of 1-(2-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)ethanol (99b)

[0979] Compound 99b was prepared from 1-(2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)ethanol (99a) (35 mg, 0.08 mmol), (S)-pyrrolidin-2-ylmethanol (80 mg, 0.79 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA] followed by lyophilization, 1-(2-((S)-2-(hydroxymethyl)pyrrolidin-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)ethanol (99b) (25 mg, 51% yield) TFA salt was obtained as a yellow solid; 1HNMR (300 MHz, DMSO-d6) δ 10.79 (s, 1H, D2O exchangeable), 9.32 (s, 1H, D2O exchangeable), 9.20 (s, 1H, D2O exchangeable), 8.37-8.15 (m, 1H), 8.07-7.90 (m, 1H), 7.25 (dd, J = 10.5, 4.6 Hz, 1H), 6.96 (s, 2H), 6.77 (dd, J=16.6,4.6Hz,1H),5.45-5.21(m,1H),4.37-4.14(m,1H),3.88(s,6H),3.68(s,3H),3.67-3 .49(m,2H),3.47-3.18(m,3H),2.17-1.76(m,4H),1.76-1.65(m,3H); MS(ES+):492.5(M-OH); 19 FNMR (282 MHz, DMSO-d6) δ-74.28; HPLC purity: 92.61%; elemental analysis: C 25 H 31 Calculated values ​​for N7O5.2CF3COOH.3H2O: C, 42.29; H, 4.77; N, 11.90; found: C, 42.02; H, 4.79; N, 12.08.

[0980] Plan 100

[0981]

[0982] Preparation of (S)-(1-(6-bromo-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (100e)

[0983] Step 1: Preparation of 2-chlorothieno[2,3-d]pyrimidin-4-ol (100a)

[0984] Compound 100a was prepared from 2,4-dichlorothieno[2,3-d]pyrimidine (31a) (4 g, 19.51 mmol) using the procedure reported by Deng, Jifeng et al., European Journal of Medicinal Chemistry, 46(1), 71-76; 2010. This gave 2-chlorothieno[2,3-d]pyrimidin-4-ol (100a) (2.45 g, 13.13 mmol, 67.3% yield) as a white solid; 1HNMR (300 MHz, DMSO-d6) δ 13.54 (s, 1H, D2O exchangeable), 7.61 (d, J = 5.8 Hz, 1H), 7.39 (d, J = 5.8 Hz, 1H); MS (ES-): 185.1 (M-1).

[0985] Step 2: Preparation of 6-bromo-2-chlorothieno[2,3-d]pyrimidin-4-ol (100b)

[0986] To a solution of 2-chlorothieno[2,3-d]pyrimidin-4-ol (100a) (2.43 g, 13.02 mmol) in acetic acid (30 mL) was added bromine (2.01 mL, 39.1 mmol) and stirred at room temperature for 10 h. The resulting solid was collected by filtration, washed with water, and dried under vacuum to afford 6-bromo-2-chlorothieno[2,3-d]pyrimidin-4-ol (100b) (2.85 g, 82% yield) as a tan solid. 1 H NMR (300MHz, DMSO-d6) δ7.94 (s, 1H).

[0987] Step 3: Preparation of 6-bromo-2,4-dichlorothieno[2,3-d]pyrimidine (100c)

[0988] A mixture of 6-bromo-2-chlorothieno[2,3-d]pyrimidin-4-ol (100b) (2.84 g, 10.70 mmol) and phosphorus oxychloride (9.97 mL, 107 mmol) was heated under reflux for 30 hours. The mixture was concentrated to remove excess phosphorus oxychloride, diluted with ice-cold water, and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water (20 mL), brine (30 mL), dried, filtered, and concentrated in vacuo to afford 6-bromo-2,4-dichlorothieno[2,3-d]pyrimidine (100c) (1.4 g, 46% yield) as a white solid. 1 H NMR (300MHz, DMSO-d6) δ7.94 (s, 1H).

[0989] Step 4: Preparation of 6-bromo-2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (100d)

[0990] Compound 100d was prepared from 6-bromo-2,4-dichlorothieno[2,3-d]pyrimidine (100c) (0.5 g, 1.76 mmol) in 2-propanol (10 mL) using DIPEA (0.92 mL, 5.28 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine hydrochloride (57a) (654 mg, 2.29 mmol) according to the procedure reported in Scheme 1. This afforded 6-bromo-2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (100d) (718 mg, 82% yield) as a pale purple solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.04 (s, 1H, D2O exchangeable), 8.21 (d, J = 1.6 Hz, 2H), 7.88 (d, J = 1.6 Hz, 1H), 6.93 (s, 2H), 3.87 (s, 6H), 3.70 (s, 3H); MS (ES-): 494.2, 496.3 (M-1).

[0991] Step 5: Preparation of (S)-(1-(6-bromo-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (100e)

[0992] Compound 100e was prepared from 6-bromo-2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (100d) (300 mg, 0.6 mmol) and (S)-pyrrolidin-2-ylmethanol (18 mg, 1.81 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup by pouring into water and collecting the precipitated solid by filtration, followed by drying in vacuo, (S)-(1-(6-bromo-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (100e) (35 mg, 10% yield) was obtained as a white solid; 1H NMR (300 MHz, DMSO-d6): δ 11.08 (s, 1H, D2O exchangeable), 8.57 (s, 1H), 8.04 (d, J = 15.7 Hz, 2H), 7.01 (s, 2H), 4.42 (s, 1H), 4.20 (s, 1H), 3.94 (s, 1H), 3.88 (s, 6H), 3.81 (s, 1H), 3.68 (s, 3H), 3.44 (d, J = 9.3 Hz, 1H), 2.12-1.85 (m, 4H). MS (ES+): 561.3, 564.3 (M+1), (ES-) 595.3 597.4 (M+Cl).

[0993] Plan 101

[0994]

[0995] Preparation of (S)-(1-(7-(hydroxymethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (101c) Step-1: Preparation of (2,4-dichloropyrrolo[2,1-f][1,2,4]triazin-7-yl)methanol (101a)

[0996] Compound 101a was prepared from 2,4-dichloropyrrolo[1,2-f][1,2,4]triazine-7-carbaldehyde (79a) (100 mg, 0.46 mmol) according to the procedure reported in Step-4 of Scheme 70. After workup, (2,4-dichloropyrrolo[1,2-f][1,2,4]triazin-7-yl)methanol (101a) (100 mg, 99% yield) was obtained as an oil, which was used in the next reaction without further purification. MS (ES+): 218.1 (M+1).

[0997] Step 2: Preparation of (2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-7-yl)methanol (101b)

[0998] Compound 101b was prepared from (2,4-dichloropyrrolo[2,1-f][1,2,4]triazin-7-yl)methanol (101a) (100 mg, 0.46 mmol) in 2-propanol (10 mL) using DIPEA (0.24 mL, 1.38 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-amine hydrochloride (57a) (157 mg, 0.55 mmol) according to the procedure reported in Scheme 1. This afforded (2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)methanol (101b) (85 mg, 43% yield) as a light off-white solid; 1 HNMR (300 MHz, DMSO-d6) δ11.24 (s, 1H, D2O exchangeable), 8.20 (d, J = 1.6 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.37 (d, J = 4.3 Hz, 1H), 6.93 (s, 2H), 6.69 (d, J = 4.4 Hz, 1H), 5.24 (t, J = 5.6 Hz, 1H, D2O exchangeable), 4.70 (d, J = 5.5 Hz, 2H), 3.87 (s, 6H), 3.69 (s, 3H); MS (ES+): 431.4 (M+1), 453.4 (M+Na); MS (ES-): 429.3 (M-1); HPLC: 98.24%.

[0999] Step 3: Preparation of (S)-(1-(7-(hydroxymethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (101c)

[1000] A slurry of (2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)methanol (101b) (97 mg, 0.23 mmol), (S)-pyrrolidin-2-ylmethanol (171 mg, 1.69 mmol), di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (di-t-Bu-XPhos, 14 mg, 0.034 mmol), Pd2(dba)3 (14 mg, 0.016 mmol), and sodium tert-butoxide (162 mg, 1.69 mmol) in PhMe (5 mL) was degassed and placed in a sealed reactor. The reaction was heated at 100°C for 48 hours, cooled to room temperature, quenched with saturated aqueous NH4Cl, and extracted with ethyl acetate (3 x 20 mL). The organic layers were combined, washed with water and brine, dried, filtered, and concentrated to dryness in vacuo. The resulting residue was purified by flash column chromatography (12 g silica gel, eluted with MeOH / DCM from 0 to 40%) to give (S)-(1-(7-(hydroxymethyl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (101c) (12 mg, 11% yield) as a white solid. 1 H NMR (300 MHz, DMSO-d6) δ 10.47 (s, 1H, D2O exchangeable), 8.24 (d, J = 1.5 Hz, 1H), 7.97 (s, 1H), 7.10 (d, J = 4.4 Hz, 1H), 6.96 (s, 2H), 6.37 (d, J = 4.4 Hz, 1H), 4.67 (s, 2H), 4.32–4.09 (m ,1H),3.88(s,6H),3.79–3.70(m,1H),3.68(s,3H),3.67–3.52(m,1H),3.53–3.20(m ,2H),2.14–1.75(m,4H); MS(ES+):496.5(M+1),518.5(M+Na); MS(ES-):494.4(M-1).

[1001] Plan 102

[1002]

[1003] Preparation of (S)-1-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-ol (102b)

[1004] Step-1: Preparation of 1-((2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-ol (102a)

[1005] Compound 102a was prepared from 2-chloro-6-(chloromethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b) (100 mg, 0.21 mmol), DIPEA (0.15 mL, 0.86 mmol) and piperidin-4-ol (43 mg, 0.43 mmol) in THF (3 mL) according to the procedure reported in step-3 of scheme 97. This afforded 1-((2-chloro-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-ol (102a) (32 mg 28% yield); MS (ES+): 531.5, 533.5 (M+1), (ES-): 529.4, 531.4 (M-1).

[1006] Step-2: Preparation of (S)-1-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-ol (102b)

[1007] Compound 102b was prepared from 1-((2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-ol (102a) (0.03 g, 0.06 mmol), (S)-pyrrolidin-2-ylmethanol (0.02 mL, 0.18 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile and water containing 0.1% HCl] followed by lyophilization, (S)-1-((2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-6-yl)methyl)piperidin-4-ol (102b) (13 mg, 36% yield) HCl salt was obtained as a solid; 1H NMR (300MHz, DMSO-d6): δ11.40(s,1H),10.97(s,1H),8.49(s,1H),8.19–7.88(m,2H),7.00(s,2H),4.65–4.41 (m,2H),4.40–3.91(m,6H),3.88(s,6H),3.68(s,3H),3.64–2.87(m,4H),2.15–1.86(m,7H),1.85–1.60(m,1H). MS(ES+): 596.6(M+1); MS(ES-): 630.6(M+Cl).

[1008] Plan 103

[1009]

[1010] Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (103b)

[1011] Step-1: Preparation of (2-chloro-furo[3,2-d]pyrimidin-4-yl)-[1-(3,4,5-trimethoxy-phenyl)-1H-imidazol-4-yl]-amine (103a)

[1012] Compound 103a was prepared from 2,4-dichloro-furo[3,2-d]pyrimidine (1a) (1.0 g, 5.29 mmol) in IPA (30 mL) using DIPEA (2.06 mL, 15.87 mmol) and 1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamine hydrochloride (57a) (1.81 g, 6.34 mmol) according to the procedure reported in Scheme 1. After workup, (2-chloro-furo[3,2-d]pyrimidin-4-yl)-[1-(3,4,5-trimethoxy-phenyl)-1H-imidazol-4-yl]-amine (103a) (1.0 g, 47%) was obtained as an off-white solid; MS (ES+): 402.0 (M+1); MS (ES-): 400.0 (M+1).

[1013] Step-2: Preparation of (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (103b)

[1014] Compound 103b was prepared from (2-chloro-furo[3,2-d]pyrimidin-4-yl)-[1-(3,4,5-trimethoxy-phenyl)-1H-imidazol-4-yl]-amine (103a) (300 mg, 0.75 mmol) and (S)-pyrrolidin-2-ylmethanol (0.76 g, 7.5 mmol) in NMP (20 mL) according to the procedure reported in step-2 of Scheme 76. (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (103b) (100 mg, 29%) free base was obtained as a white solid after work-up and purification by flash chromatography (silica gel, eluted with 0-10% methanol / ethyl acetate). The free base was purified again by reverse phase flash column chromatography (silica gel C-18 column, 24 g), eluting with acetonitrile and 0.1% HCl in water (0-50%), followed by lyophilization to afford (S)-(1-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (103b) (25 mg) HCl salt as a light yellow solid; 1 H NMR (300MHz, DMSO-d6): δ13.40(s,1H),11.91(s,1H),8.54(s,1H),8.35(s,1H),8.04(s,1H),7.01(d,J=10.6H z,3H),4.44(s,1H),3.87(d,J=3.8Hz,6H),3.75(s,1H),3.68(d,J=3.7Hz,3H),3.58–3.34(m,3H),2.02(s,4H). MS (ES+): 467.5 (M+1), 489.5 (M+Na); MS (ES-): 501.5 (M+Cl); HPLC purity: 98.60%.

[1015] Plan 104

[1016]

[1017] Preparation of (S)-(1-(6-((4-methylpiperazin-1-yl)methyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (104b)

[1018] Step-1: Preparation of 2-chloro-6-((4-methylpiperazin-1-yl)methyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (104a)

[1019] Compound 104a was prepared from 2-chloro-6-(chloromethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b) (100 mg, 0.21 mmol), DIPEA (0.15 mL, 0.86 mmol) and 1-methylpiperazine (0.048 mL, 0.43 mmol) in THF (3 mL) according to the procedure reported in step-3 of scheme 97. This afforded 2-chloro-6-((4-methylpiperazin-1-yl)methyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (104a) (32 mg, 28% yield); MS (ES+): 530.5, 532.5 (M+1), (ES-): 528.4 (M-1), 564.4, 566.4 (M+Cl).

[1020] Step-2: Preparation of (S)-(1-(6-((4-methylpiperazin-1-yl)methyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (104b)

[1021] Compound 104b was prepared from 2-chloro-6-((4-methylpiperazin-1-yl)methyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (104a) (0.05 g, 0.09 mmol), (S)-pyrrolidin-2-ylmethanol (0.03 mL, 0.26 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile and water containing 0.1% HCl] followed by lyophilization, (S)-(1-(6-((4-methylpiperazin-1-yl)methyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (104b) (10 mg, 24% yield) HCl salt was obtained as a tan solid; 1HNMR (300MHz, DMSO-d6): δ11.14(s,1H),8.43(s,1H),8.07–7.85(m,2H),6.98(d,J=4.6Hz,2H),4.48(s,1H),4.27(s,2H),3.94(s ,1H),3.88(s,6H),3.86(s,2H),3.81(s,1H),3.68(s,3H),3.61–3.40(m,4H),3.40–3.12(m,4H),2.79(s,3H),2.11–1.85(m,4H). MS(ES+):595.6(M+1).

[1022] Plan 105

[1023]

[1024] Preparation of (S)-(1-(7-(piperidin-1-ylmethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (105b)

[1025] Step-1: Preparation of 2-chloro-7-(piperidin-1-ylmethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (105a)

[1026] To a solution of 2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazine-7-carbaldehyde (79b) (100 mg, 0.23 mmol) in dichloroethane (5 mL) was added piperidine (0.025 mL, 0.26 mmol) and acetic acid (0.03 mL). To the suspension was added NaBH(OAc)3 (64 mg, 0.3 mmol) and the reaction was stirred for 8 hours. An additional amount of NaBH(OAc)3 (64 mg, 0.3) was added and the reaction was stirred for 8 hours. The reaction was quenched with 1N NaOH (2 mL), the organic layer was separated, and the aqueous layer was extracted with CHCl (3×10 mL). The combined organic layers were dried, filtered, and concentrated in vacuo. The crude product was purified by flash column chromatography (silica gel 12 g, eluted with MeOH / DCM from 0% to 10%) to give 2-chloro-7-(piperidin-1-ylmethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (105a) (43 mg, 37% yield) as a light off-white solid; 1H NMR (300MHz, chloroform-d) δ10.56(s,1H),7.95(s,1H),7.66(s,1H),7.07–6.81(m,1H),6.84–6.40(m,3H),4.10–3.73( m,11H),2.61–2.41(m,4H),1.67–1.49(m,4H),1.48–1.33(m,2H); MS(ES+):498.5(M+1); MS(ES-):496.5(M-1).

[1027] Step 2: Preparation of (S)-(1-(7-(piperidin-1-ylmethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (105b)

[1028] Compound 105b was prepared from 2-chloro-7-(piperidin-1-ylmethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (105a) (43 mg, 0.09 mmol), (S)-pyrrolidin-2-ylmethanol (87 mg, 0.86 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by flash chromatography (silica gel 4 g, eluting with MeOH / DCM from 0% to 10%), (S)-(1-(7-(piperidin-1-ylmethyl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (105b) (6 mg, 13% yield) was obtained as a white solid; 1H NMR (300MHz, methanol-d4) δ7.98(d,J=1.6Hz,1H),7.93(d,J=1.6Hz,1H),6.88–6.83(m,3H ),6.45(d,J=4.5Hz,1H),4.33–4.16(m,1H),3.91(s,6H),3.87(s,2H),3.88–3.78(m, 1H), 3.79 (s, 3H), 3.75–3.50 (m, 2H), 3.40–3.25 (m, 1H), 2.64–2.45 (m, 4H), 2.14–1.86 (m, 4H), 1.72–1.53 (m, 4H), 1.49–1.36 (m, 2H); MS (ES+): 563.6 (M+1), 585.6 (M+Na). The crude reaction mixture from Step 2 above was purified by reverse phase flash chromatography [(silica gel C-18, 24 g), eluted with acetonitrile and water containing 0.1% HCl] and then lyophilized to give the hydrochloride salt of Compound 105b as a yellow solid. 1 HNMR (300MHz, DMSO-d6): δ10.90(s,1H),10.36(s,1H),8.46(s,1H),8.01(s,1H),7.23(d,J=4.6Hz,1H),6.99(s,2H),6.72(d ,J=4.5Hz,1H),4.49(s,2H),4.29–4.14(m,1H),3.88(s,6H),3.84–3.26(m,9H),2.86(d,J=11.4Hz,2H),2.13–1.16(m,10H). MS(ES+): 563.3(M+1); MS(ES-): 597.4(M+Cl). HPLC purity: 95.10%.

[1029] Plan 106

[1030]

[1031] Preparation of (S)-(1-(7-((4-cyclopropylpiperazin-1-yl)methyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (106b)

[1032] Step-1: Preparation of 2-chloro-7-((4-cyclopropylpiperazin-1-yl)methyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (106a)

[1033] Compound 106a was prepared from 2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazine-7-carbaldehyde (79b) (100 mg, 0.23 mmol) in dichloroethane (3 mL) using 1-cyclopropylpiperazine (44 mg, 0.35 mmol), acetic acid (0.03 mL) and NaBH(OAc)3 (74 mg, 0.35 mmol) according to the procedure reported for the reductive amination in step-1 of Scheme 105. After workup and purification by flash column chromatography (silica gel 12 g, eluted with DMA-80 / DCM from 0% to 10%), 2-chloro-7-((4-cyclopropylpiperazin-1-yl)methyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (106a) (46 mg, 37% yield) was obtained as a solid; 1 HNMR (300MHz, chloroform-d) δ10.64(s,1H),7.95(s,1H),7.65(s,1H),6.91(d,J=4.5Hz,1H),6.66(s,2H),6.61(d,J=4.5Hz,1H),4.18-3. 61(m,11H),3.36-2.11(m,8H),1.68-1.47(m,1H),0.62-0.15(m,4H); MS(ES+):539.5(M+1),561.5(M+Na); MS(ES-):537.5(M-1).

[1034] Step 2: Preparation of (S)-(1-(7-((4-cyclopropylpiperazin-1-yl)methyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (106b)

[1035] Compound 106b was prepared from 2-chloro-7-((4-cyclopropylpiperazin-1-yl)methyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (106a) (46 mg, 0.09 mmol), (S)-pyrrolidin-2-ylmethanol (86 mg, 0.85 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel C-18, 24 g), eluting with acetonitrile containing 0.1% TFA and water containing 0.1% TFA], followed by lyophilization, (S)-(1-(7-((4-cyclopropylpiperazin-1-yl)methyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (106b) (14 mg, 27% yield) was obtained as a solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.47 (s, 1H, D2O exchangeable), 8.24 (d, J = 1.5 Hz, 1H), 7.97 (d, J = 1.6 Hz, 1H), 7.13 (d, J = 4.4 Hz, 1H), 6.95 (s, 2H), 6.33 (d, J = 4.5 Hz, 1H), 4.89-4.79 (m, 1H, D2O exchangeable), 4.26-4.08 (m, 1H), 3.87 (s, 6H), 3.85-3.66 (m, 3H), 3.68 (s, 3H), 3.64-3.5 4 (m, 1H), 3.52-3.38 (m, 2H), 2.67-2.25 (m, 8H), 2.11-1.81 (m, 4H), 1.65-1.49 (m, 1H), 0.37 (s, 2H), 0.28-0.18 (m, 2H); MS (ES+): 604.7 (M+1), 626.6 (M+Na); The crude reaction mixture from the above step-2 was purified by reverse phase flash chromatography [(silica gel C-18, 24 g), eluted with acetonitrile and water containing 0.1% HCl] and then lyophilized to give the hydrochloride salt of compound 106b as a yellow solid. 1HNMR (300MHz, DMSO-d6): δ10.49(s,1H),8.23(s,1H),7.97(s,1H),7.13(d ,J=4.4Hz,1H),6.95(s,2H),6.34(d,J=4.2Hz,1H),4.83(s,1H),4.19(s,1H ),3.87(s,6H),3.79(s,2H),3.68(s,3H),3.58(s,1H),3.52–3.42(m,2H),3 .42–3.20(m,9H),2.11–1.71(m,4H),1.67–1.40(m,1H),0.44–0.13(m,4H). MS(ES-):602.6(M-1). HPLC purity: 93.61%.

[1036] Plan 107

[1037]

[1038] Preparation of (S)-(1-(7-(1,2,3,6-tetrahydropyridin-4-yl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (107a)

[1039] To a solution of (S)-tert-butyl 4-(2-(2-(hydroxymethyl)pyrrolidin-1-yl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (98a) (0.06 g, 0.05 mmol) in DCM (5 mL) was added 2,2,2-trifluoroacetic acid (0.04 mL, 0.54 mmol) and stirred at room temperature overnight. The reaction mixture was diluted with EtOAc (50 mL), washed with water (3x), brine, dried, filtered, and concentrated in vacuo. The residue was purified by reverse phase flash column chromatography [(silica gel C-18, 24 g), eluting with acetonitrile and water containing 0.1% HCl] and lyophilized to give (S)-(1-(7-(1,2,3,6-tetrahydropyridin-4-yl)-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (107a) (8 mg, 27% yield) as the HCl salt; 1H NMR (300MHz, DMSO-d6) δ10.68(s,1H),9.16(s,2H),8.37(s,1H),8.01(s,1H),7.29(s,1H),7.22(d,J=4.6Hz,1H),6.98 (s,2H),6.58(d,J=4.7Hz,1H),4.20(s,1H),4.00–3.25(m,17H),2.83–2.68(m,2H),2.11–1.83(m,4H); MS(ES+):547.6. HPLC purity: 96.94%.

[1040] Plan 108

[1041]

[1042] Preparation of (S)-(1-(6-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (108b)

[1043] Step-1: Preparation of 2-chloro-6-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (108a)

[1044] Compound 108a was prepared from 2-chloro-6-(chloromethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (97b) (100 mg, 0.21 mmol), DIPEA (0.15 mL, 0.86 mmol) and 1-(pyridin-2-yl)piperazine (0.065 mL, 0.43 mmol) in THF (3 mL) according to the procedure reported in step-3 of scheme 97. This afforded 2-chloro-6-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (108a) (60 mg, 47%) as a solid. MS(ES+):593.5(M+1),(ES-):591.4(M-1),627.5,629.5(M+Cl).

[1045] Step-2: Preparation of (S)-(1-(6-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (108b)

[1046] Compound 108b was prepared from 2-chloro-6-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)thieno[2,3-d]pyrimidin-4-amine (108a) (0.06 g, 0.1 mmol), (S)-pyrrolidin-2-ylmethanol (0.03 mL, 0.3 mmol) in NMP (1 mL) according to the procedure reported in Scheme 2. After workup and purification by reverse phase flash chromatography [(silica gel 18, 24 g), eluting with acetonitrile and water containing 0.1% HCl] followed by lyophilization, (S)-(1-(6-((4-(pyridin-2-yl)piperazin-1-yl)methyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (108b) (10 mg, 15% yield) HCl salt was obtained as a white solid; 1 HNMR (300MHz, DMSO-d6) δ12.16(s,1H),11.60(s,1H),8.58(s,1H),8.19–7.93(m,5H),7.37(d,J=8.9Hz,1H),7.00(d,J=8. 5Hz, 2H), 4.74–4.30 (m, 4H), 3.88 (s, 6H), 3.81–3.19 (m, 13H), 2.16–1.89 (m, 4H); .MS (ES+): 658.5; MS (ES-): 692.5 (M+Cl). HPLC purity: 97.78%.

[1047] Plan 109

[1048]

[1049] Preparation of 3-(6-(hydroxymethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)benzaldehyde (109a)

[1050] Compound 109a was prepared from (2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)thieno[2,3-d]pyrimidin-6-yl)methanol (97a) (0.2 g, 0.44 mmol) using 3-formylphenylboronic acid (0.1 g, 0.67 mmol), PdCl2(dppf) (65 mg, 0.09 mmol), potassium carbonate (185 mg, 1.34 mmol) in 1,4-dioxane (10 mL) and water (1 mL) according to the procedure reported in step-3 of Scheme 77. After workup and purification by flash column chromatography [(silica gel, 12 g), eluting with DMA 80 / dichloromethane], 3-(6-(hydroxymethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)thieno[2,3-d]pyrimidin-2-yl)benzaldehyde (109a) (134 mg, 58% yield) was obtained as a yellow solid; 1 H NMR (300 MHz, DMSO-d6) δ 10.63 (s, 1H, D2O exchangeable), 10.14 (s, 1H), 8.95 (d, J = 1.9 Hz, 1H), 8.76 (d, J = 7.8 Hz, 1H), 8.28 (d, J = 1.6 Hz, 1H), 8.18 (d, J = 1.6 Hz, 1H), 8.03 (d, J = 7.6 Hz, 1 H), 7.94 (s, 1H), 7.73 (t, J = 7.7 Hz, 1H), 7.03 (s, 2H), 5.84 (s, 1H, D2O exchangeable), 4.76 (s, 2H), 3.90 (s, 6H), 3.71 (s, 3H); MS (ES+): 518.5 (M+1), 540.3 (M+Na), (ES-): 516.5 (M-1).

[1051] Plan 110

[1052]

[1053] Preparation of 3-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)benzaldehyde (110a)

[1054] Compound 110a was prepared from 2-chloro-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (57b) (0.2 g, 0.5 mmol) using 3-formylphenylboronic acid (112 mg, 0.75 mmol), PdCl2(dppf) (73 mg, 0.1 mmol), potassium carbonate (207 mg, 1.5 mmol) in 1,4-dioxane (10 mL) and water (1 mL) according to the procedure reported in step-3 of Scheme 77. After workup and purification by flash column chromatography [(silica gel, 12 g), eluting with DMA 80 / dichloromethane], 3-(4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)benzaldehyde (110a) (45 mg, 19% yield) was obtained as a white solid; 1 H NMR (300 MHz, DMSO-d6) δ 11.02 (s, 1H, D2O exchangeable), 10.13 (s, 1H), 8.82 (t, J = 1.7 Hz, 1H), 8.64 (dt, J = 7.8, 1.5 Hz, 1H), 8.30 (d, J = 1.6 Hz, 1H), 8.18 (d, J = 1.7 Hz, 1H), 8.04 (dt, J = 7.7, 1.4 Hz, 1 H),7.88(dd,J=2.6,1.6Hz,1H),7.73(t,J=7.7Hz,1H),7.51-7.25(m,1H),7.03(s,2H),6.77 (dd, J=4.4, 2.6Hz, 1H), 3.90 (s, 6H), 3.71 (s, 3H); MS (ES+): 471.4 (M+1), (ES-): 469.4 (M-1).

[1055] Plan 111

[1056]

[1057] Preparation of (S)-(1-(7-(morpholinomethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (111b)

[1058] Step-1: Preparation of 2-chloro-7-(morpholinomethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (111a)

[1059] Compound 111a was prepared from 2-chloro-4-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-ylamino)pyrrolo[1,2-f][1,2,4]triazine-7-carbaldehyde (79b) (200 mg, 0.47 mmol) in dichloroethane (3 mL) using 1-morpholine (0.045 mL, 0.51 mmol), acetic acid (0.05 mL) and NaBH(OAc)3 (129 mg, 0.61 mmol) according to the procedure reported for the reductive amination in step-1 of Scheme 105. After workup and purification by flash column chromatography (silica gel 12 g, eluting with MeOH / DCM from 0% to 10%), 2-chloro-7-(morpholinomethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine (111a) (131 mg, 56% yield) was obtained as a slightly pink solid; 1 HNMR (300 MHz, DMSO-d6) δ11.24 (s, 1H, D2O exchangeable), 8.20 (d, J = 1.6 Hz, 1H), 7.88 (d, J = 1.6 Hz, 1H), 7.40 (d, J = 4.4 Hz, 1H), 6.93 (s, 2H), 6.67 (d, J = 4.5 Hz, 1H), 3.87 (s, 6H), 3.78 (s, 2H), 3.69 (s, 3H), 3.56 (t, J = 4.6 Hz, 4H), 2.47–2.37 (m, 4H); MS (ES+): 500.4 (M+1), 522.4 (M+Na); HPLC purity: 95.21%.

[1060] Step 2: Preparation of (S)-(1-(7-(morpholinomethyl)-4-((1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidin-2-yl)methanol (111b)

[1061] Compound 111b was prepared from 2-chloro-7-(morpholinomethyl)-N-(1-(3,4,5-trimethoxyphenyl)-1H-imidazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (111a) (106 mg, 0.21 mmol), (S)-pyrrolidin-2-ylmethanol (161 mg, 1.59 mmol), di-tert-butyl(2',4',6'-triisopropylbiphenyl-2-yl)phosphine (di-t-Bu-XPhos) (14 mg, 0.032 mmol), Pd2(dba)3 (14 mg, 0.015 mmol) and sodium tert-butoxide (153 mg, 1.59 mmol) in toluene (5 mL) according to the procedure reported in step-3 of Scheme 101. After workup and purification by flash chromatography (silica gel...

Claims

1. A compound represented by formula (Ia), formula (IIa), formula (Ij) or formula (IIj): or a pharmaceutically acceptable salt thereof; in: If valence permits, Q, T, U and V each independently represent CH, CH2, N, NH, O or SO2, wherein any hydrogen of a CH, CH2 or NH group is optionally replaced by an R 4 Replacement; W is C or N; If valence permits, X, Y and Z each independently represent CH, CH2, CO, N, NH, O, S or SO2, wherein any hydrogen in a CH, CH2 or NH group is optionally replaced by an R 4 Replacement; R a represents H or (C1-C6) alkyl; -R 1 -R 1a express Where R 1a represents an optionally substituted -C(O)(C1-C6)alkyl, -C(O)aryl, -C(O)heteroaryl, -C(O)O((C1-C6)alkyl), -C(O)(heterocyclyl), -C(O)NR x R y , cycloalkyl, heterocycloalkyl, aryl or heteroaryl; J stands for -OR 2 、-NR 2 R 3 , -C(O)O((C1-C6)alkyl) or -C(O)OH; R 2 represents optionally substituted (C1-C6)alkyl, aralkyl, heteroaryl(C1-C6)alkyl, cycloalkyl, heterocycloalkyl, (cycloalkyl)(C1-C6)alkyl, (heterocycloalkyl)(C1-C6)alkyl or hydroxy(C1-C6)alkyl; R 3 represents H or (C1-C6)alkyl; or R 2 and R 3 together form a heterocycloalkyl ring, which is optionally replaced by one or more occurrences of R 2a replace; R 2a Each occurrence independently represents halogen, hydroxy, -C(O)H, oxo, -NH2, -C(O)NH2, -C(O)OH, -C(O)R 5 、-C(O)OR 5 , or optionally substituted (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, aryl(C1-C6)alkyloxy, heteroaryl(C1-C6)alkyloxy or -N((C1-C6)alkyl)2; or any two Rs in a geminal or vicinal position 2a Together they may form a spiro or fused (C3-C7)cycloalkyl ring; R 4 wherein each occurrence independently represents halogen, cyano or optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, halo(C1-C6)alkyl, hydroxy(C1-C6)alkyl, amino(C1-C6)alkyl, (C1-C6)alkoxy, aryl, aryl(C1-C6)alkyl, heteroaryl, heteroaryl(C1-C6)alkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)(C1-C6)alkyl, cycloalkyl, (cycloalkyl)(C1-C6)alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, aryl(C1-C6)alkyloxy, heteroaryl(C1-C6)alkyloxy, -CH2C(O)NH2, -C(O)R 5 、-C(O)OR 5 or -S(O)2R 5 ; m is an integer from 0 to 4, as allowed by the valence; n is an integer from 0 to 4, as permitted by valence; and R 5 represents independently at each occurrence optionally substituted (C1-C6)alkyl, aryl(C1-C6)alkyl, aryl, heteroaryl(C1-C6)alkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)(C1-C6)alkyl or (heterocycloalkyl)C1-C6alkyl; wherein the optional substituents, when present, are selected from halogen, halo(C-C)alkyl, hydroxy, carbonyl, thiocarbonyl, (C-C)alkoxy, (C-C)alkenyloxy, (C-C)alkynyloxy, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, silyl, silyloxy, heterocycloalkyl, cycloalkyl, (C-C)alkyl, (C-C)alkenyl, (C-C)alkynyl, aryl, heteroaryl, aryl(C-C)alkyl and heteroaryl(C-C)alkyl; "Aryl" refers to C6-C 10 Aryl; "Heteroaromatic ring" or "heteroaryl" refers to monocyclic, bicyclic and polycyclic aromatic groups having a total of 3 to 12 atoms in the ring structure including one or more heteroatoms selected from nitrogen, oxygen and sulfur; "Cycloalkyl" refers to a monocyclic or bicyclic or bridged saturated carbocyclic ring, each having 3 to 12 carbon atoms; "Heterocycloalkyl" refers to a monocyclic, bicyclic or tricyclic non-aromatic ring having from 3 to 12 atoms including one or more heteroatoms selected from nitrogen, oxygen and sulfur; and "Heterocycloalkenyl" refers to a monocyclic, bicyclic or tricyclic non-aromatic ring having from 3 to 12 atoms, including one or more heteroatoms selected from nitrogen, oxygen and sulfur, and having at least one unit of unsaturation.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following table:

3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following table:

4. A compound represented by formula (Ia), formula (IIa), formula (Ij) or formula (IIj): or a pharmaceutically acceptable salt thereof; in: If valence permits, Q, T, U and V each independently represent CH, CH2, N, NH, O or SO2, wherein any hydrogen of a CH, CH2 or NH group is optionally replaced by an R 4 Replacement; W is C or N; If valence permits, X, Y and Z each independently represent CH, CH2, CO, N, NH, O, S or SO2, wherein any hydrogen in a CH, CH2 or NH group is optionally replaced by an R 4 Replacement; R a represents H or (C1-C6) alkyl; -R 1 -R 1a express Where R 1a represents a heteroaryl group; J represents halogen, -OR 2 、-NR 2 R 3 , -C(O)O((C1-C6)alkyl), -C(O)OH or aryl, wherein aryl is optionally replaced by one or more occurrences of R 2a replace; R 2 represents optionally substituted (C1-C6)alkyl, aryl(C1-C6)alkyl, heteroaryl(C1-C6)alkyl, cycloalkyl, heterocycloalkyl, (cycloalkyl)(C1-C6)alkyl, (heterocycloalkyl)(C1-C6)alkyl or hydroxy(C1-C6)alkyl; R 3 represents H or (C1-C6)alkyl; or R 2 and R 3 together form a heterocycloalkyl ring, which is optionally replaced by one or more occurrences of R 2a replace; R 2a Each occurrence independently represents halogen, hydroxy, -C(O)H, oxo, -NH2, -C(O)NH2, -C(O)OH, -C(O)R 5 、-C(O)OR 5 、-C(O)NH(R 5 ), or optionally substituted (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, heteroaryl, aryl, aryloxy, heteroaryloxy, aryl(C1-C6)alkyloxy, heteroaryl(C1-C6)alkyloxy, or -N((C1-C6)alkyl)2; or any two Rs in a geminal or vicinal position 2a Together they may form a spiro or fused (C3-C7)cycloalkyl ring; R 4 Each occurrence independently represents halogen, cyano or optionally substituted (C1-C6)alkyl, (C2-C6)alkenyl, halo(C1-C6)alkyl, hydroxy(C1-C6)alkyl, amino(C1-C6)alkyl, (C1-C6)alkoxy, aryl, aryl(C1-C6)alkyl, heteroaryl, heteroaryl(C1-C6)alkyl, heterocycloalkyl, heterocycloalkenyl, (heterocycloalkyl)C1-C6alkyl, cycloalkyl, (cycloalkyl)C1-C6alkyl, halocycloalkyl, hydroxycycloalkyl, aminocycloalkyl, aryloxy, heteroaryloxy, aryl(C1-C6)alkyloxy, heteroaryl(C1-C6)alkyloxy, -CH2C(O)NH2, -C(O)R 5 、-C(O)OR 5 or -S(O)2R 5 ; m is an integer from 0 to 4, as allowed by the valence; n is an integer from 0 to 4, as permitted by valence; and R 5 represents independently at each occurrence optionally substituted (C1-C6)alkyl, aryl(C1-C6)alkyl, aryl, heteroaryl(C1-C6)alkyl, heteroaryl, cycloalkyl, heterocycloalkyl, (cycloalkyl)(C1-C6)alkyl or (heterocycloalkyl)C1-C6alkyl; wherein the optional substituents, when present, are selected from halogen, halo(C-C)alkyl, hydroxy, carbonyl, thiocarbonyl, (C-C)alkoxy, (C-C)alkenyloxy, (C-C)alkynyloxy, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, silyl, silyloxy, heterocycloalkyl, cycloalkyl, (C-C)alkyl, (C-C)alkenyl, (C-C)alkynyl, aryl, heteroaryl, aryl(C-C)alkyl and heteroaryl(C-C)alkyl; "Aryl" refers to C6-C 10 Aryl; "Heteroaromatic ring" or "heteroaryl" refers to monocyclic, bicyclic and polycyclic aromatic groups having a total of 3 to 12 atoms in the ring structure including one or more heteroatoms selected from nitrogen, oxygen and sulfur; "Cycloalkyl" refers to a monocyclic or bicyclic or bridged saturated carbocyclic ring, each having 3 to 12 carbon atoms; "Heterocycloalkyl" refers to a monocyclic, bicyclic or tricyclic non-aromatic ring having from 3 to 12 atoms including one or more heteroatoms selected from nitrogen, oxygen and sulfur; and "Heterocycloalkenyl" refers to a monocyclic, bicyclic or tricyclic non-aromatic ring having from 3 to 12 atoms, including one or more heteroatoms selected from nitrogen, oxygen and sulfur, and having at least one unit of unsaturation.

5. The compound of claim 1 or claim 4, wherein the compound is represented by formula (Ia) or (IIa):

6. The compound of claim 5, wherein the compound is represented by formula (Ib) or (IIb): wherein Q represents CH or N; and V represents CH or N.

7. The compound of claim 5, wherein the compound is represented by formula (Ic) or (IIc):

8. The compound of claim 5, wherein the compound is represented by formula (Id) or (IId): wherein T represents CH2, NH, O or SO2; and U represents CH2, NH, O or SO2.

9. The compound of claim 5, wherein the compound is represented by formula (Ie) or (IIe):

10. The compound of claim 6, wherein Q is N and V is CH; or wherein Q is CH and V is N.

11. The compound of claim 8, wherein T is NH and U is CH2; or wherein T is CH2 and U is NH.

12. The compound of any one of claims 1 and 4-11, wherein m is 0 or 1.

13. The compound of claim 1 or claim 4, wherein the compound is represented by formula (Ij) or formula (IIj):

14. The compound of claim 13, wherein the compound is represented by formula (Ik) or (IIk): wherein X, Y and Z each independently represent CH, N, NH, O, S or SO2.

15. The compound of claim 14, wherein the compound is represented by formula (Ik') or (IIk'):

16. The compound of claim 14, wherein the compound is represented by formula (Ik") or (IIk"): wherein at least one of X and Z is selected from O, N, NH and S.

17. The compound of claim 16, wherein: (a) one of X and Z is selected from O, NH and S; and the other of X and Z is CH; (b) X is selected from O, NH and S; (c) Z is selected from O, NH and S; (d) X and Z are independently selected from O, N, NH and S; or (e) One of X and Z is N and the other of X and Z is NH.

18. The compound of claim 14, wherein the compound is represented by formula (In) or (IIn): wherein Y and Z are independently selected from O, N, NH and S.

19. The compound of claim 18, wherein Y is N and Z is NH.

20. The compound of claim 13, wherein the compound is represented by formula (Im) or (IIm): wherein X, Y and Z each independently represent CH2, CO, NH, O, S or SO2.

21. The compound of claim 20, wherein: (a) X, Y and Z are each CH2; or (b) One of X, Y and Z is NH or O.

22. The compound of any one of claims 13-21, wherein n is 0 or 1.

23. The compound according to any one of claims 1 and 4 to 22, wherein If present, R 4 Selected from optionally substituted (C1-C6)alkyl, hydroxy(C1-C6)alkyl, amino(C1-C6)alkyl, (C1-C6)alkoxy, aryl, aryl(C1-C6)alkyl and (heterocycloalkyl)C1-C6alkyl.

24. The compound of any one of claims 1 and 4-23, wherein R a It's H.

25. The compound of any one of claims 1 and 4-24, wherein -R 1 -R 1a express 26. The compound of any one of claims 1 and 4-25, wherein R 1a It is 3,4,5-trimethoxyphenyl.

27. The compound of any one of claims 1 and 4-25, wherein R 1a It's quinoline.

28. The compound of any one of claims 4-25 and 27, wherein J is aryl, optionally replaced by one or more occurrences of R 2a replace.

29. The compound of any one of claims 1 and 4-28, wherein J is -NR 2 R 3 .

30. The compound of claim 29, wherein R 2 and R 3 together form a heterocycloalkyl ring, which is optionally replaced by one or more occurrences of R 2a replace.

31. The compound of claim 30, wherein R 2 and R 3 together form a pyrrolidine ring, which is optionally replaced by one or more occurrences of R 2a replace.

32. The compound of any one of claims 28 to 31, wherein R 2a Each occurrence independently represents -C(O)NH2, -C(O)R 5 , hydroxy(C1-C6)alkyl, heteroaryl or aryl.

33. The compound of any one of claims 28 to 32, wherein R 2a It is -C(O)NH2.

34. The compound of any one of claims 28 to 32, wherein R 2a It is hydroxy(C1-C6)alkyl.

35. The compound of claim 4 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following table:

36. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the following table:

37. A pharmaceutical composition comprising a compound according to any one of claims 1 to 36 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.

38. Use of the compound according to any one of claims 1 to 36 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating fibrodysplasia ossificans progressiva.

39. Use of the compound according to any one of claims 1 to 36 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer.

40. The use of claim 39, wherein the cancer is glioma.

41. The use of claim 40, wherein the glioma is a diffuse intrinsic pontine glioma.

Citation Information

Patent Citations

  • Coated implantable medical device

    US20040243225A1

  • Cosmetic applicator useful for skin moisturizing

    US4559157A

  • Method for producing a non greasy protective and emollient film on the skin

    US4608392A

  • Electric massage appliance

    US4733655A

  • Endovascular stent and delivery system

    US4800882A